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1 Introduction 
In this work pharmacometric analyses were performed to investigate the pharmacokinetics 
and the pharmacokinetic/pharmacodynamic relationship of the novel dipeptidyl-
peptidase 4 (DPP-4) inhibitor linagliptin, which is undergoing clinical development for the 
treatment of type 2 diabetes. 
1.1 Type 2 diabetes mellitus 
1.1.1 Epidemiology and pathology 
Recent estimates revealed that in the year 2007, 246 million people suffered from diabetes 
worldwide (1). This number is projected to rise to 366 million people affected in the year 
2030 (2). Diabetes mellitus is defined by the current World Health Organization (WHO) 
(3,4) and American Diabetes Association (5) diagnostic criteria based on plasma glucose 
levels. If a venous fasting plasma glucose (FPG) ≥7.00 mmol/L or a venous plasma 
glucose ≥11.1 mmol/L, 2 h after ingestion of a 75 g oral glucose load is diagnosed, a 
patient is considered to be diabetic. The WHO classifies diabetes mellitus based on 
aetiology in four types: type 1, type 2, other specific types and gestational diabetes (4). 
Type 2 diabetes is the common major type, affecting 85–95% of diabetic patients in 
developed countries and an even higher percentage in developing countries (1). It is caused 
by impaired pancreatic insulin secretion, almost always with a major contribution of 
insulin resistance (4,6,7), the reduced susceptibility of muscle, liver, and adipose tissue to 
insulin.  
Insulin resistance plays a central role in the pathogenesis of type 2 diabetes mellitus. It is 
influenced by genetic (e.g. mutations in the PPARγ gene) (8,9) and environmental (e.g. 
obesity) factors (10,11). Initially, insulin resistance in muscle leads to reduced insulin-
dependent glucose uptake compensated by increases in pancreatic insulin secretion to 
maintain normal blood glucose levels (12). However, as the disease progresses, insulin 
secretion decreases (11). Lower levels of insulin diminish the insulin-dependent uptake of 
glucose in muscle and thus lead to higher post-prandial glucose levels. In addition, hepatic 
glucose production, which is normally inhibited by insulin, is augmented. This in turn 
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leads to an increase of fasting plasma glucose levels. Increasing hyperglycemia on the 
other hand deteriorates both insulin sensitivity and insulin secretion – a phenomenon 
known as ‘glucose toxicity’(13). Insulin resistance also affects adipose tissue, leading to an 
increase in free fatty acids from enhanced lipolysis, which further diminishes the insulin 
response in skeletal muscle and liver and may in addition further impair pancreatic insulin 
secretion (‘lipotoxicity’) (14). An overview of factors contributing to hyperglycemia is 
provided in Figure 1-1. 
Pancreatic ß-cells
Insulin Secretion
Decreased
Impaired Insulin Secretion
Liver
Glucose Production
Increased
Skeletal Muscle
 Glucose Uptake
Decreased
Adipose Tissue
Lipolysis Increased
Insulin Resistance in Insulin Target Tissues
Small Intestine
Carbohydrate
Absorption
Free Fatty
Acids
Increased
Glucotoxicity
Lipotoxicity
Sulfonylureas
Glinides
GLP-1 Agonists
DPP-4 Inhibitors
                 
Increase Insulin
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DPP-4 Inhibitors
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Hyperglycemia
Micro- and
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Delay Carbohydrate
Absorption
GLP-1 Agonists
Slow Gastric Emptying
 
Figure 1-1  Major metabolic defects and treatment options of type 2 diabetes, adapted from (12). 
Hyperglycaemia resulting from type 2 diabetes leads to a diminished life expectancy and 
quality of life (3). It is associated with risk of microvascular complications, e.g. retinopa-
thy, nephropathy, and neuropathy, as well as macrovasular complications, e.g. ischaemic 
heart disease, stroke, and peripheral vascular disease. Cardiovascular disease accounts for 
approximately 70% of the mortality in diabetic patients (15). Controlled clinical studies 
demonstrated that intensive glycaemic control slows down the progression of microvascu-
lar complications in patients with type 2 diabetes (16-18). A positive effect of intensive 
diabetes therapy on macrovasular complications like cardiovascular disease however could 
so far only clearly be shown in type 1 diabetes (19,20) and is controversial for type 2 
diabetes (21-23).  
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1.1.2 Treatment 
For type 2 diabetic patients, several treatment options are available (12,24). While the 
major focus of diabetes treatment is glycaemic control, other strategies target coincident 
features of the disease such as insulin resistance or obesity. The current consensus 
treatment of type 2 diabetes follows a stepwise manner, starting with lifestyle interventions 
(e.g. diet and exercise) and pharmacotherapy with metformin. Eventually, combination 
therapy with lifestyle interventions, oral agents, and/or insulin is generally indicated for 
many type 2 diabetic patients (24). The success of the antidiabetic therapy is controlled by 
measuring blood glucose, as an index of acute glycaemia and HbA1c, i.e. glycosylated 
haemoglobin, as an index of chronic glycaemia (24). 
Lifestyle interventions to promote weight loss and increase exercise should, if possible, 
always be included in the treatment of diabetes (24). While weight loss can effectively 
ameliorate hyperglycaemia (25), the long-term success of incorporating such intervention 
programs into the usual lifestyle and maintaining them is limited. For pharmacotherapy, 
several classes of antidiabetic medications are currently available, targeting different 
angles of the disease (Figure 1-1). Hepatic glucose production is decreased by metformin, 
resulting in decreased fasting glycaemia. Sulfonylureas and glinides act by enhancing 
insulin secretion. α-Glucosidase inhibitors reduce the rate of digestion of polysaccharides, 
thereby lowering postprandial glucose levels (26). Glitazones increase the sensitivity of 
muscle, fat, and liver to insulin (27). Finally, insulin is the oldest and most effective 
treatment for lowering glycaemia, and over time, as β-cell function decreases, many 
diabetics require intensive insulin therapy. Metformin, sulfonylureas and glinides lower 
HbA1c by ~1.5% (12,24), more than the other oral antidiabetics, but not as much as 
insulin. Metformin is indicated at every stage of the disease (24). In the United Kingdom 
Prospective Diabetes Study it was shown not to affect body weight (28) and to decrease 
mortality compared to other antidiabetic treatments (17).  
These currently available therapies for type 2 diabetes have several disadvantages includ-
ing increased risk of hypoglycaemia (sulphonylureas, insulin), gastrointestinal side effects 
(metformin, α-glucosidase inhibitors, amylin agonists), weight gain (sulphonylureas, 
glitazones, glinides, insulin), fluid retention and congestive heart failure (glitazones) (29), 
as well as myocardial infarction (rosiglitazone) (30,31). One new approach yielding 
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promising results is the use of agents that mimic or enhance the effect of incretin hor-
mones. This new approach is discussed in detail in section 1.2.3. 
1.2 New treatment options based on incretins 
1.2.1 Incretins 
An oral glucose load leads to a greater insulin secretion compared to an intravenous (i.v.) 
glucose load matched to produce a similar glycaemic profile (32,33). This phenomenon is 
called ‘incretin effect’. The incretin hormones mainly responsible for this effect are 
glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) 
(34,35). Incretin hormones are secreted from intestinal endocrine cells in response to oral 
but not intravenous glucose administration. GLP-1 is secreted from L-cells, GIP from 
K-cells (34). Secretion occurs in response to oral intake of carbohydrates, lipids and, in the 
case of GLP-1, also proteins (36). GLP-1 and GIP both enhance the insulin secretion in 
pancreatic ß-cells (35,37-39). In addition, GLP-1 acts on glucose homeostasis by inhibiting 
the glucagon secretion of pancreatic α-cells, thereby further decreasing the hepatic glucose 
production (40-42). Both mechanisms directly lower the plasma glucose levels in a 
glucose-dependent manner. For rodents, GLP-1 and GIP have been shown to have 
protective effects on pancreatic ß-cells by enhancing their proliferation and increasing their 
resistance to apoptosis (43-47). Moreover, the survival of isolated human islets of Langer-
hans was prolonged in the presence of GLP-1 (48). Other beneficial aspects of GLP-1 are 
the prolongation of gastric emptying (49,50) and the induction of satiety, both supporting 
dietary goals in diabetes treatment.  
In type 2 diabetic patients, incretin levels (mainly GLP-1) are reduced (51) and the incretin 
effect is markedly decreased compared to healthy volunteers (52). In line with these 
studies, patients with impaired glucose tolerance show a reduced suppression of glucagon 
following an oral glucose load compared to healthy volunteers (53). In type 2 diabetic 
patients, the insulinotropic activity of GLP-1, in contrast to GIP, remains relatively intact 
(54). Pharmacotherapy therefore mainly focuses on GLP-1. Continuous subcutaneous 
infusion of GLP-1 over six weeks normalised blood glucose levels, decreased HbA1c and 
body weight and greatly improved the first-phase insulin response in type 2 diabetic 
patients (55). 
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1.2.2 Dipeptidyl-peptidase 4 
DPP-4 rapidly inactivates the incretins, making the long-term diabetes treatment with 
GLP-1 itself difficult. The hydrolytic activity of DPP-4 results in half-lives of 1–2 min for 
GLP-1 and 7 min for GIP (36). In fact, more than 50% of secreted GLP-1 is degraded by 
DPP-4 immediately following release into intestinal capillaries, i.e. before reaching the 
general circulation (56).  
DPP-4 (EC 3.4.14.5) is an ubiquitous serine-type peptidase that cleaves dipeptide frag-
ments from the N-terminus of polypeptides with either proline or alanine as their second 
residue most effectively (57). Furthermore, DPP-4 acts as regulatory peptidase on a large 
number of bioactive peptides. Substrates that have been identified for DPP-4 (58) include, 
besides gastrointestinal hormones like GLP-1 and GIP (59), the neuropeptides (58) 
endomorphin, neuropeptide Y (60), substance P (61) and bradykinin, as well as growth 
hormone-releasing hormone (59,62) and several chemokines (63). Apart from its catalytic 
activity, it interacts with a number of other proteins, e.g. collagen (64), the chemokine 
receptor CXCR4 (65), adenosine deaminase (66), and the human immunodeficiency virus 
gp120 surface protein (65,67). In the immune system, DPP-4, also known as CD26, acts as 
a co-stimulatory molecule in T cell activation (57). It also plays a role in malignant 
transformation, cancer progression (68-70), and possibly human immunodeficiency virus 
entry (71). 
DPP-4 is expressed in a variety of tissues, primarily on the apical membrane of epithelial 
and endothelial cells (57,72-75). The distribution of DPP-4 when determined with a 
polyclonal antibody corresponds to the distribution of DPP-4 activity determined histo-
chemically (74). In blood vessels, lung, myocardium and striated muscles, almost the total 
DPP-4 activity is located endothelially (75). In kidney, intestine, and liver however, where 
DPP-4 is abundantly expressed (58,72,76), endothelial DPP-4 activity accounts for only a 
small part of the total DPP-4 activity (75). The membrane-bound form of DPP-4 is also 
found on fibroblasts (76), T-cells (77) and other cell types (57). In addition to the mem-
brane-bound form, DPP-4 exists as a soluble form lacking the intracellular part and the 
transmembrane region (78). Soluble DPP-4 is present in low nanomolar concentrations in 
plasma (79,80) and other body fluids (57). The origin of soluble DPP-4 in human plasma is 
not completely understood, but several lines of evidence suggest that soluble DPP-4 may 
originate from endothelial or epithelial cells or from circulating leukocytes. 
   6 1 Introduction 
A substrain of Fischer rats (F344/DuCrlCrlJ) bred by Charles River, Japan exhibits a 
mutation resulting in the complete loss of DPP-4 activity (81). In these animals, most of 
the immature protein is retained and degraded in the endoplasmic reticulum (82). A DPP-4 
knockout mouse model has also been developed (83). Despite its ubiquitous localisation 
and its multiple functions, DPP-4-deficient rats and DPP-4 knockout mice are viable and 
show no evident pathology. In both animal models, the lack of DPP-4 interferes with blood 
glucose regulation. After a glucose challenge, intact GLP-1 levels rise higher than in the 
respective wildtype animals leading to elevated insulin levels accompanied by lower blood 
glucose levels (83,84). For DPP-4-deficient rats it was also demonstrated that the devel-
opment of diabetes under a high fat diet is less frequent compared to wildtype rats (85,86). 
1.2.3 GLP-1 agonists and DPP-4 inhibitors 
With the aim of obtaining clinical benefit from the positive effects of incretins despite their 
short half-life, GLP-1 analogues resistant to DPP-4 degradation and compounds inhibiting 
DPP-4 have been developed. GLP-1 agonists such as exenatide or liraglutide bind to the 
GLP-1 receptor on pancreatic ß-cells and augment glucose-mediated insulin secretion. 
They also suppress glucagon secretion, resulting in a decreased hepatic glucose production, 
and they slow down gastric emptying (87). GLP-1 agonists mainly reduce post-prandial 
glucose levels and do not cause hypoglycaemia (24). Clinical studies have indicated that 
the administration of GLP-1 agonists lowers body weight by ~2–3 kg over 30 weeks (88-
91), and by ~4 kg after 80 weeks (92). The main adverse effects are nausea, vomiting, and 
diarrhoea, but these apparently abate over time (87-91). Some patients were shown to 
develop antibodies against GLP-1 agonists, albeit with weak binding affinity and low titres 
(88-91). Being peptide molecules, GLP-1 agonists require subcutaneous injection. In April 
2005, the U.S. Food and Drug Administration (FDA) approved the first GLP-1 agonist, 
synthetic exendin-4, exenatide. Exenatide needs to be administered twice daily due to its 
short half-life. Liraglutide is a new GLP-1 agonist with a longer half-life, submitted to the 
FDA in 2008, that can be given once daily. 
While GLP-1 agonists mimic the biologic function of GLP-1, DPP-4 inhibitors prevent the 
degradation of incretins by DPP-4, prolonging the beneficial effects of these regulatory 
peptides for type 2 diabetic patients. They stimulate insulin secretion and inhibit glucagon 
secretion, but unlike GLP-1 agonists they are not associated with the prolongation of 
gastric emptying (87) and clinical studies demonstrated that DPP-4 inhibitors do not affect 
body weight (87,93,94). In general, they are well tolerated and, like GLP-1 agonists, do not 
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cause hypoglycaemia (24,94). As DPP-4 is involved in the immune system, DPP-4 
inhibitors carry the potential risk of interfering with immune function. In fact, an increase 
in infections, e.g. of the upper respiratory tract was reported for sitagliptin, but not for 
vildagliptin (94). In October 2006, the FDA approved the first DPP-4 inhibitor sitagliptin. 
The second DPP-4 inhibitor vildagliptin is so far only approved in Europe, since February 
2008. Alogliptin and saxagliptin were submitted to the FDA in 2007 and 2008, respec-
tively. 
In general, GLP-1 agonists and DPP-4 inhibitors are well tolerated and lower HbA1c by 
0.5–1%, comparable to α-glucosidase inhibitors (24). Both classes have the potential 
advantage of preserving the ß-cell mass through stimulation of cell proliferation and 
inhibition of apoptosis, as demonstrated in animal models (95-98). However, these effects 
need yet to be confirmed in human. In addition, apart from surrogate endpoints like 
reduction in fasting plasma glucose and HbA1c, clinically important endpoints like 
reduction of the incidence of cardiovascular events have to be examined in order to prove 
the long-term efficacy of these new compounds. 
1.3 Linagliptin 
Linagliptin is a novel competitive DPP-4 inhibitor under clinical development for the 
treatment of type II diabetes. Its chemical structure is depicted in Figure 1-2 (99). It binds 
to the active site of the DPP-4 enzyme, as shown by the crystal structure of human DPP-4 
in complex with linagliptin (100). 
 
Figure 1-2  Chemical structure of linagliptin 
Linagliptin is highly soluble in water at the physiological pH of 7.4 (>5 g/L) (100), at 
acidic pH linagliptin solubility is increased (107). It displays a log D value of 0.4 at pH 7.4 
indicating that its solubility in the lipophilic octanol phase is greater compared to the 
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aqueous phase (100). The linagliptin pKa values of 1.9 and 8.6 correspond to the protona-
tion of the nitrogen of the quinazoline group and the primary amino group, respectively 
(100). 
1.3.1 Pharmacodynamic properties 
1.3.1.1 In Vitro investigations and preclinical pharmacodynamics 
In vitro studies revealed linagliptin to be a highly potent, competitive DPP-4 inhibitor. The 
concentration leading to half-maximal inhibition (IC50) of DPP-4 in vitro was approxi-
mately 1 nM, and thus linagliptin was more potent compared to sitagliptin (IC50: 19 nM), 
alogliptin (IC50: 24 nM), saxagliptin (IC50: 50 nM), and vildagliptin (IC50: 62 nM). 
Linagliptin binding to DPP-4 exhibits a slow off-rate (3.0·10−5 s−1) (101). 
The potent DPP-4 inhibition of linagliptin was confirmed in vivo in various species 
including male Wistar rats, Beagle dogs, and Rhesus monkeys. In all three species, 
linagliptin was highly efficacious and resulted in long-lasting and potent DPP-4 inhibition 
of >70% for >7 h after oral administration of 1 mg/kg (100). After a single oral dose of 
3 mg/kg, linagliptin increased active GLP-1 and insulin levels, and reduced the glucose 
levels compared to the control group after an oral glucose tolerance test (OGTT) in Zucker 
fatty rats (101). The effect on glucose tolerance was long-lasting. Glucose excursion was 
significantly reduced 16 h after a single administration in C57/BL6 mice, or 24 h in Zucker 
fatty (fa/fa) rats (101). Glucose excursion was measured by an OGTT, as the increment of 
the area under the plasma concentration-time curve (AUC) of glucose. In addition, basal 
active GLP-1, but not basal insulin levels, were elevated in Zucker fatty rats and in the 
postprandial phase, plasma glucagon values tended to be lower (101). The effects of 
linagliptin after a single dose were confirmed for multiple dosing in two animal models for 
diabetes, high-fat diet/streptozotocin-induced diabetic mice and Zucker diabetic fatty rats 
(102). In addition, HbA1c was decreased after 4–5 weeks of treatment. In both animal 
models, body weight was unaffected compared to placebo treatment. 
1.3.1.2 Clinical pharmacodynamics 
Linagliptin treatment resulted in a rapid, potent and long-lasting inhibition of plasma 
DPP-4 in clinical studies. Already after a single dose of linagliptin, DPP-4 was effectively 
inhibited as shown by maximum DPP-4 inhibitions of 72.7 and 86.1% for 2.5 and 5 mg, 
and >95% for doses ≥25 mg (103). At steady-state, plasma DPP-4 activity was inhibited 
1 Introduction   9 
 
 
over 24 h by >80% in most patients receiving 5 or 10 mg linagliptin once daily (104). 
Generally, DPP-4 inhibition ≥80% over 24 h is aimed for, as this was shown to be related 
to maximum effects in incretin response and glucose reduction (105,106). 
The effects of linagliptin on the incretins and the glucose levels in type 2 diabetic patients 
were investigated during an OGTT after twelve days of treatment. Treatment with 2.5, 5, 
and 10 mg, but not 1 mg linagliptin, considerably elevated the increase of GLP-1 levels 
during the OGTT on day 13 compared with baseline. In line with this, 2.5, 5, and 10 mg 
linagliptin, but not 1 mg, significantly reduced glucose excursion during the OGTT on 
days 1 and 13 compared to placebo (104). 
1.3.2 Pharmacokinetic properties 
1.3.2.1 Preclinical pharmacokinetics and in vitro investigations 
The pharmacokinetics of linagliptin was mainly investigated in rats and cynomolgus 
monkeys. The pharmacokinetics of linagliptin was nonlinear in both species (107) 
accompanied by a dose-dependency of pharmacokinetic parameters like clearance and 
volume of distribution. After intravenous administration of 5 mg/kg linagliptin to rats and 
1.5 mg/kg to cynomolgus monkeys, an apparent clearance (CL) of 37.3 mL/min/kg in rats 
and 15.8 mL/min/kg in monkeys was determined (100). The volumes of distribution at 
steady-state (VSS) were 5.4 L/kg in rats and 15.8 L/kg in cynomolgus monkeys (100), both 
exceeding the total body volume indicating that linagliptin is extensively distributed in the 
tissues. The gastrointestinal absorption of linagliptin was moderate with an oral bioavail-
ability (F) of ~50% in rats and cynomolgus monkeys. This absolute bioavailability 
estimate was determined by a comparison of the area under the plasma concentration-time 
curve of oral 5 mg/kg linagliptin to intravenous 5 mg/kg (rats) and 1.5 mg/kg (monkey) 
(100). Despite the moderate bioavailability, only a minor first-pass metabolism was 
observed (107). The mean residence times after oral administration of 5 mg/kg linagliptin 
were 14.3 h and 17.4 h in rats and cynomolgus monkeys, respectively (100). The terminal 
half-lives (t1/2) of linagliptin after oral administration were long in both species (35.9 h in 
rats and 41.4 h in cynomolgus monkeys) (100).  
Plasma protein binding of linagliptin was investigated for various species including rats, 
cynomolgus monkeys and humans, by equilibrium dialysis. At plasma concentrations 
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>30 nM, the fraction bound ranged from 75–89% (107). At lower concentrations, the 
fraction bound increased to 99%. 
In human liver microsomes linagliptin only weakly inhibited cytochrome P450 (CYP) 3A4 
and no other CYP isoforms. These findings were confirmed in rats, mice, rabbits, and 
cynomolgus monkeys. In these animals, metabolism was only a minor elimination pathway 
(107). Excretion mainly occurred via faeces with a prominent biliary fraction, whereas 
renal excretion was only of minor importance. After intravenous administration of 1 mg/kg 
[14C]linagliptin to rats and 1.5 mg/kg to cynomolgus monkeys, the fraction of 
[14C]linagliptin-related radioactivity excreted in urine was 21.7 and 15.3%, respectively.  
1.3.2.2 Clinical pharmacokinetics 
The pharmacokinetics of linagliptin after oral administration was investigated in healthy 
volunteers (103) and type 2 diabetic patients (104). Basic pharmacokinetics was compara-
ble between both groups. 
Linagliptin was rapidly absorbed, with a median time of maximum plasma concentration 
(tmax) of ~1.5 h (range: 0.5–6.0 h) after single and multiple dosing (104). Linagliptin 
exhibited nonlinear pharmacokinetics after single and multiple dosing, in contrast to other 
DPP-4 inhibitors including sitagliptin, vildagliptin, saxagliptin and alogliptin (108-111). At 
supratherapeutic doses (25–600 mg), the exposure after a single dose of linagliptin 
increased more than dose-proportionally (103). In contrast, in the therapeutic dose range 
(1–10 mg linagliptin once daily), the nonlinearity was characterised by a less than dose-
proportional increase in the maximum linagliptin plasma concentration (Cmax) and the 
AUC (103). The pharmacokinetic parameters for this dose range, as determined by 
noncompartmental analysis, are presented in Table 1-1. Both the CL/F and VSS/F were 
increasing with increasing dose. In general, a low clearance was estimated as well as a high 
volume of distribution, suggesting an extensive tissue distribution of linagliptin in humans. 
The terminal half-life of linagliptin was between 113 and 131 h and nearly constant 
between the therapeutic dose groups. Despite the long terminal half-life, steady-state was 
reached after few days and only moderate accumulation was observed after once daily 
treatment. Both the time to reach steady-state and the accumulation ratio decreased with 
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Table 1-1   Non-compartmental pharmacokinetic parameters of linagliptin (adapted from (104,107)) 
Parameter 1 mg 
gMean (gCV [%]) 
2.5 mg 
gMean (gCV [%]) 
5 mg 
gMean (gCV [%]) 
10 mg 
gMean (gCV [%]) 
AUC0-24h [nmol·h/L]  40.2 (39.7) 85.3 (22.7) 118 (16.0) 161 (15.7) 
AUCτ,ss [nmol·h/L]  81.7 (28.3) 117 (16.3) 158 (10.1) 190 (17.4) 
Cmax [nM]  3.13 (43.2) 5.25 (24.5) 8.32 (42.4) 9.69 (29.8) 
Cmax,SS [nM]  4.53 (29.0) 6.58 (23.0) 11.1 (21.7) 13.6 (29.6) 
tmax1) [h] 1.50 [1.00–3.00] 2.00 [1.00–3.00] 1.75 [0.92–6.02] 2.00 [1.50–6.00] 
tmax,SS1) [h] 1.48 [1.00–3.00] 1.42 [1.00–3.00] 1.53 [1.00–3.00] 1.34 [0.50–3.00] 
(Vz/F)SS [L] 4,510 (32.1) 7,400 (13.1) 12,700 (17.7) 20,800 (22.7) 
(CL/F)SS [mL/min] 431 (28.3) 757 (16.3) 1,120 (10.1) 1,850 (17.4) 
CLR,SS [mL/min] 14.0 (24.2) 23.1 (39.3) 70.0 (35.0) 59.5 (22.5) 
fe0-24h [%] Not calculated2) 0.139 (51.2) 0.453 (125) 0.919 (115) 
feτ,SS [%] 3.34 (38.3) 3.06 (45.1) 6.27 (42.2) 3.22 (34.2) 
t½,SS [h]  121 (21.3) 113 (10.2) 131 (17.4) 130 (11.7) 
Accumulation t½ [h] 23.9 (44.0) 12.5 (18.2) 11.4 (37.4) 8.59 (81.2) 
RA,AUC  2.03 (30.7) 1.37 (8.2) 1.33 (15.0) 1.18 (23.4) 
1)
 Median and range [minimum–maximum] 
2) not calculated as most values were below the lower limit of quantification 
 
increasing dose. Steady-state was achieved after 4–6 days for dose groups 1–5 mg and 
after two days in case of the 10 mg dose. The accumulation ratio was 2.0-fold for the 1 mg 
dose group and 1.2-fold for the 10 mg dose group. The accumulation half-life1 decreased 
accordingly with dose from 24 h for the 1 mg dose group to 8.6 h for the 10 mg dose 
group. The contribution of renal clearance to overall clearance was small. In the therapeu-
tic dose range of 1–10 mg, the cumulative amount of linagliptin excreted in urine was 
                                                 
1
 calculcated as τ·ln2/ln(RA,AUC/(RA,AUC-1)) 
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below 1% of the administered dose on day 1 and 3–6% on day 12. With higher single 
doses, the fraction of dose excreted increased up to 33% in the 600 mg dose group (103). 
Further studies revealed that linagliptin is predominantly excreted unchanged via the 
faeces (107). Metabolism was only of subordinate importance for the elimination of 
linagliptin. Linagliptin had one main metabolite, CD1790, representing 17% of the drug-
related radioactivity in plasma. This metabolite was formed by oxidation of the amino 
group of the piperidine moiety to a hydroxyl group. CD1790 is pharmacologically inactive 
and was found in all investigated species (107). 
1.3.3 Safety 
Binding of linagliptin to DPP-4 is highly selective. The in vitro selectivity of binding to 
DPP-4 is ≥10,000-fold higher compared to dipeptidyl-peptidase 8 (DPP-8) and dipeptidyl-
peptidase 9 (DPP-9), and a number of other proteases tested (101). A low inhibition of 
DPP-8 and DPP-9 is of great importance, as inhibition of these enzymes is assumed to be 
associated with severe immunotoxic side effects (112). In addition, linagliptin has a low 
affinity for the hERG channel (100), indicating that the risk for a prolongation of the QT 
interval is small. In preclinical toxicity studies linagliptin exhibited a very low toxicity 
with a high safety margin to clinical use (107). No genotoxic or teratogenic effects were 
observed.  
In healthy volunteers, single oral doses of linagliptin up to 600 mg were well tolerated. The 
incidence of adverse events was not dose-dependent and was not different between 
subjects treated with linagliptin or placebo (103). This positive safety and tolerability 
profile after single doses in healthy volunteers was confirmed by a multiple dose study in 
type 2 diabetic patients. In this study, 1–10 mg oral doses of linagliptin were administered 
once daily over twelve days (104). Again linagliptin was well tolerated in all dose groups, 
and no patient discontinued the treatment due to adverse events. In addition, there were no 
clinically relevant changes in laboratory or electrocardiogram (ECG) parameters and no 
signs of hypoglycaemia were reported during the study.  
1 Introduction   13 
 
 
1.4 Pharmacometrics in drug development 
1.4.1 Pharmacometrics 
Pharmacometrics is the development and application of mathematical and statistical 
methods in order to characterise, understand, and predict the pharmacokinetic and pharma-
codynamic properties of a given drug. It allows the differentiation of variability into 
interindividual, intraindividual, and residual variability (η, κ, and ε, respectively), as well 
as their quantification, aiding rational drug development and pharmacotherapy (113). 
Pharmacometric analyses involve the development of a pharmacokinetic and/or pharmaco-
dynamic model. A pharmacokinetic model describes the relationship between the adminis-
tered drug and the concentration of the drug in plasma or other body fluids. This relation-
ship is often described using compartmental models. A pharmacodynamic model describes 
the relationship between the observed exposure of the drug and the observed pharmacody-
namic response (e.g. biomarker). A commonly used pharmacodynamic model is for 
example the Emax model. Depending on the availability of data, the knowledge about the 
drug and the objective of the analysis, pharmacometric models can be empirical, i.e. purely 
descriptive, or mechanism-based, i.e. reflecting the underlying physiological system as 
much as possible (114). In pharmacometric analyses, semi-mechanistic models are often 
used incorporating only the key elements of a physiological system. 
Pharmacometric models not only provide estimates for pharmacokinetic and/or pharmaco-
dynamic parameters, but they can also be used for simulations (113). By illustrating the 
implications of a pharmacometric model, e.g. the amount of drug in the peripheral 
compartment, simulations can help to understand the pharmacokinetics or pharmacody-
namics. Furthermore, clinical trial simulations are a useful tool to answer ‘what if’ 
scenarios and thereby optimise and evaluate the design of subsequent studies. 
1.4.2 Population approach 
The models applied in pharmacometrics are often population models using the nonlinear 
mixed-effect modelling technique. Population analysis is the characterisation of the typical 
pharmacokinetic and/or pharmacodynamic behaviour of a drug together with the study of 
sources and correlates of the variability in the drug concentration and/or the pharmacologi-
cal effect (113,115,116). This includes explorations on the impact of certain patient 
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characteristics like age or weight (called covariates) on the pharmacokinetic and/or 
pharmacodynamic behaviour of a drug. A population analysis typically investigates the 
pharmacokinetics and/or pharmacodynamics of clinically relevant doses of a drug in the 
patient population (116).  
The population approach using the nonlinear mixed-effect modelling technique has several 
advantages compared to the two-stage approach that has traditionally been used for 
population analyses (117). In the two-stage approach, the individual parameters are 
estimated first and then their distribution statistics are calculated. In contrast, in the 
population approach based on nonlinear mixed-effect modelling the data of all individuals 
are analysed together, and different kinds of variabilities are directly taken into account. 
Thereby, the individuality of each subject is maintained and accounted for. In conse-
quence, the population approach based on nonlinear mixed-effect modelling is the more 
versatile approach (117). It can be applied to different types of data and can be used to 
analyse extensively as well as sparsely sampled data. The analysis of sparse data is 
important in situations in which dense sampling is not possible for ethical reasons, e.g. 
studies in children or severely ill patients. A balanced study design is not required, thus 
irregular sampling or the combination of data from different studies is possible (115). As 
the data are analysed together, information can be ‘borrowed’ between individuals, this is 
also important for the investigation of nonlinear processes in which every dose group 
contains different kinds of information (118). Furthermore, the population approach based 
on nonlinear mixed-effect modelling provides considerably more accurate estimates of the 
variability compared to the two-stage approach (119,120).  
To perform population analyses using nonlinear mixed-effect modelling different software 
programs are available including NONMEM, NLME in Splus, NLMIX in SAS, and 
Monolix (121-123). The population analyses presented in this thesis were performed with 
the NONMEM software (Version V, level 1.1, GloboMax LLC, Hanover MD, USA) 
(124). NONMEM was the first software for nonlinear mixed-effect modelling, introduced 
in its first version in the early 1980s by Sheiner, Beal, and Brockman (125) and is still the 
most widely used software for nonlinear mixed-effect modelling (120,123,126).  
1.4.3 Regulatory perspective on pharmacometrics 
Pharmacometrics is widely accepted and recommended by authorities to contribute to a 
better understanding of the pharmacokinetic and pharmacodynamic behaviour of a drug in 
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order to allow a safe and efficacious therapy. The FDA and the European Medicines 
Agency (EMEA) have both issued guidances on population analysis. The FDA’s Guidance 
for industry: Population Pharmacokinetics (115) elaborates when and how to perform a 
population analysis while the EMEA guidance (127) focuses on documentation and 
reporting. In their white paper Challenge and Opportunity on the Critical Path to New 
Medical Products (128), the FDA urges, amongst other approaches, the use of computer-
based predictive models to optimise the time-consuming and expensive development of 
new products. Furthermore, the FDA has published two summaries illustrating the impact 
of pharmacometrics on new drug approval or labelling (129,130).  
1.4.4 Impact of  pharmacometrics in different phases of  clinical drug 
development 
Pharmacometrics can be applied throughout different phases of drug development 
(114,117,131,132). Early clinical development includes phase I studies, typically con-
ducted in healthy volunteers as well as phase IIa studies, typically performed in the patient 
population. The objectives of phase I and IIa studies are to investigate safety and tolerabil-
ity of a compound, as well as pharmacokinetics and pharmacodynamics. In these studies 
proof-of-mechanism biomarkers are usually determined to provide evidence of target 
engagement. Due to the short study period or when the study population is composed of 
healthy volunteers, disease-related biomarkers are often not meaningful. Usually, in phase 
I and IIa studies many pharmacokinetic and pharmacodynamic observations are available 
per subject, but the number of subjects is lower compared to phase IIb and III studies. In 
pharmacometric analyses, the dense data of phase I and IIa studies can be used to charac-
terise and understand the pharmacokinetics and the relationship between pharmacokinetics 
and pharmacodynamics of the compound. Due to strict inclusion and exclusion criteria, the 
variability in the subject-specific characteristics is usually small, and thus the data will 
only provide limited information about the impact of subject-specific characteristics on the 
pharmacokinetic or pharmacodynamic model parameters.  
In contrast, phase IIb and phase III trials include a larger and more diverse patient popula-
tion, but the number of pharmacokinetic and pharmacodynamic observations per patient is 
lower than in early clinical development. The objective of phase IIb trials is to investigate 
safety and provide the ‘proof of concept’, i.e. demonstrating positive effects on disease-
related biomarkers/surrogate endpoints. The objective of phase III studies is to assess 
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safety and efficacy in a large patient population. The sparse data of phase IIb and III trials 
can be analysed by nonlinear mixed-effect modelling techniques to understand and confirm 
the dose-exposure-response relationship in the target population. Investigations about the 
relationship between patient characteristics and model parameters may partially explain the 
variability observed in the drug concentration or effect. By this approach, one may identify 
subgroups of patients exhibiting a deviant exposure or pharmacological effect. For these 
patients, safety or efficacy may be compromised, necessitating a dose adjustment.  
Throughout all phases of drug development, pharmacometrics is a valuable tool to predict 
untested scenarios, support dosing recommendations and design future clinical trials. 
Simulations are of special interest for compounds with nonlinear pharmacokinetics, as for 
these the pharmacokinetic and pharmacodynamic drug behaviour is difficult to predict. 
1.5 Aim of  the work 
Prior to this thesis, it was known that linagliptin exhibits nonlinear pharmacokinetics with 
a less than dose-proportional increase in the exposure in various animal species and 
humans in the therapeutic dose range. The reason for the nonlinearity was unknown. Due 
to the dependence of the free fraction in plasma on the concentration of linagliptin in the 
low nanomolar range, it was speculated that the less than dose-proportional increase in the 
exposure was due to concentration-dependent binding of linagliptin to its target protein 
DPP-4. 
The aim of this work was to characterise the nonlinear pharmacokinetics of linagliptin and 
the relationship between linagliptin pharmacokinetics and its plasma DPP-4 activity using 
nonlinear mixed-effect modelling. The developed models were to be applied to support the 
clinical drug development of linagliptin. This was conducted in a total of five projects. 
The aim of Project 1 was to characterise the nonlinear pharmacokinetics and the pharma-
cokinetic/pharmacodynamic relationship of linagliptin in type 2 diabetic patients. The 
hypothesis that concentration-dependent binding of linagliptin to DPP-4 is the reason for 
the nonlinear pharmacokinetics of linagliptin in humans was to be tested.  
In Project 2, the population pharmacokinetic/pharmacodynamic model developed in 
Project 1 was used for clinical trial simulations to support the clinical development of 
linagliptin.  
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In Project 2a, simulations were performed to evaluate the adequate dose of linagliptin for a 
twice-daily dosing strategy. This dosing scheme was required for the fixed dose combina-
tion of linagliptin with metformin.  
In Project 2b, the impact of a reduced clearance on the exposure of linagliptin was 
simulated in order to support the definition of the inclusion and exclusion criteria with 
regard to renal function for Phase IIb studies.  
In Project 2c, simulations were performed to investigate the optimal duration of a treatment 
period in a change-over design, i.e. a cross-over design without a washout between the 
periods, to adequately test the dose-proportionality of linagliptin at steady-state.  
In Project 2d, the model was adapted to describe the single dose plasma concentration-time 
profiles of a drug-drug interaction trial investigating the influence of ritonavir comedica-
tion on linagliptin pharmacokinetics and to simulate the steady-state exposure of linagliptin 
under ritonavir comedication. 
The aim of Project 3 was to characterise the variability in the pharmacokinetics (Pro-
ject 3a) and the pharmacodynamics (Project 3b) of linagliptin and to identify clinically 
relevant covariates affecting either drug concentration or DPP-4 inhibition. 
In Project 4 a modelling approach was used to determine the absolute bioavailability of 
linagliptin taking into account its nonlinear pharmacokinetics.  
The aim of Project 5 was to test the hypothesis that concentration-dependent binding to 
DPP-4 is the reason for the nonlinear pharmacokinetics of linagliptin by comparing the 
plasma concentration-time profiles of wildtype and DPP-4-deficient Fischer rats using a 
model-based analysis.  
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2 Methods and studies 
2.1 Data acquisition 
In this thesis pharmacokinetic and/or pharmacodynamic observations of the DPP-4 
inhibitor linagliptin from one nonclinical and six clinical studies were analysed. Table 2-1 
provides an overview of these studies. The analytical methods used to quantify the 
linagliptin plasma concentration and DPP-4 activity are described in the following 
sections. 
Table 2-1  Overview of clinical and nonclinical studies analysed 
Study Pro-
ject 
Phase Popu-
lation 
No. of 
subjects 
Dose Route Design Treatment 
duration 
Obser-
vation 
I 1+3 IIa T2D 35 1, 2.5, 5, 10 mg p.o. parallel 12 days PK, PD 
II 1+3 IIa T2D 61 2.5, 5, 10 mg p.o. parallel 28 days PK, PD 
III 3 IIb T2D 170 0.5, 2.5, 5 mg p.o. parallel 12 weeks PK, PD 
IV 3 IIb T2D 196 1, 5, 10 mg p.o. parallel 12 weeks PK, PD 
V 2d I HV 12 5 mg p.o. cross-over 
(± ritonavir) 
SD PK 
0.5, 2.5, 5, 10 mg i.v. parallel SD PK VI 4 I HV 28 
10 mg p.o. cross-over  
vs. 5 mg iv 
SD PK 
VII 5 nc Rats 28 0.01, 0.1, 0.3, 
1.0 mg/kg 
i.v. parallel SD PK 
nc, nonclinical; T2D, type 2 diabetic patients; HV, healthy volunteers; p.o., peroral; i.v., intravenous; SD, single 
dose; PK, pharmacokinetic; PD, pharmacodynamic (i.e. DPP-4 activity) 
 
2.1.1 Quantification of  linagliptin in plasma  
For quantification of linagliptin plasma concentrations in the clinical studies, blood was 
taken from a cubital or forearm vein in potassium ethylendiaminetetraacetic acid (EDTA)-
anticoagulant blood drawing tubes. The EDTA-anticoagulated blood samples were 
centrifuged immediately after collection or within 30 min after collection and stored in an 
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ice bath prior to centrifugation. The samples were centrifuged for ~10 min at 2,000–
4,000 × g at 4–8°C. The plasma samples were stored at about −20°C until analysis. In the 
nonclinical study of Project 5, blood was taken under isoflurane anaesthesia from the 
sublingual vein in potassium EDTA-coated tubes. Until centrifugation, the collected blood 
was stored in an ice bath. Plasma was separated by centrifugation (5 min at 4,000 × g at 
4°C) and stored at about −20°C until analysis. 
Total (bound plus unbound) linagliptin concentrations in plasma of humans and rats were 
determined by a set of validated assays based on high performance liquid chromatography 
coupled to tandem mass spectrometry (HPLC-MS/MS) methods as described (103). 
Validation of the assays was performed according to the current international guidance on 
bioanalytical methods (133). The assays comprised sample clean-up by solid-phase 
extraction in the 96-well plate format. Chromatography was performed on an analytical 
phenyl-hexyl reversed phase high performance liquid chromatography column with 
gradient elution. The substance was detected and quantified by HPLC-MS/MS using 
electrospray ionisation in the positive ion mode with [13C3]-linagliptin as an internal 
standard.  
The validated concentration ranges of linagliptin in undiluted plasma samples varied 
slightly among the assays applied in the different studies (Appendix, Table 1). The lower 
limit of quantification of linagliptin was either 0.106 or 0.100 nM, dependent on the study. 
In the preclinical study (Project 5) [14C]-linagliptin was administered to rats. Since only the 
unlabelled analyte was directly measured, the resulting concentrations were multiplied 
with a correction factor of 2.71 for the dose groups 0.01–1 mg/kg to calculate the total 
concentration. The correction factor was determined from the ratio of total to unlabelled 
compound in the respective formulation. The analytical range was adjusted accordingly to 
a lower limit of quantification of 0.271 nM and an upper limit of quantification of 271 nM 
in the investigated dose groups. Linagliptin plasma concentrations were either measured at 
the bioanalytical laboratories at the Department of Drug Metabolism and Pharmacokinet-
ics, Boehringer Ingelheim, Biberach, Germany, or at Covance Laboratories Ltd., Harro-
gate, UK (Appendix, Table 1). 
Assay performance during the studies was assessed by back-calculation of calibration 
standards, tabulation of the standard curve fit function parameters and measurement of 
quality control samples. Inaccuracy and imprecision data of the plasma quality control 
samples for linagliptin of the different studies are listed in Appendix, Table 2. An inaccu-
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racy value of up to ±15% and an imprecision value of up to 15% was accepted according 
to the Guidance for Industry: Bioanalytical method validation issued by the FDA (133). 
No relevant interference of endogenous compounds with linagliptin was observed in blank 
human plasma and blank Fischer rat plasma. The data document the accuracy, precision, 
and specificity of the HPLC-MS/MS assays employed for the studies. It was therefore 
concluded that the linagliptin plasma concentration determined in the study samples were 
reliable within the given inaccuracy and imprecision ranges. 
2.1.2 Quantification of  DPP-4 activity in plasma 
For quantification of plasma DPP-4 activity, blood was collected in potassium EDTA-
anticoagulant blood drawing tubes. The EDTA-anticoagulated blood samples were 
centrifuged immediately or within 30 min after collection. The samples were centrifuged 
for ~10 min at 1,000 × g or 2,500 × g at 2–8°C or 4–8°C. The plasma samples were stored 
at about −20°C until analysis.  
DPP-4 activity in plasma was analysed by a validated method using a semi-quantitative 
enzyme activity assay with fluorescence detection as previously described (103). The 
DPP-4 present in the human plasma samples cleaves the assay substrate alanine-proline-7-
amido-4-trifluoro-methylcoumarine yielding the fluorescent product 7-amino-4-trifluoro-
methylcoumarine. The higher the DPP-4 activity in the sample, the higher the fluorescence 
measured as relative fluorescence units (RFU). The fluorescence was detected at 535 nm 
(emission) using 405 nm excitation wavelength after 10 min of incubation. The assay 
performance was evaluated during the study by co-analysis of six in-house standards as 
quality control samples in each run/plate. The plasma DPP-4 activity was measured at the 
Institut für Klinische Forschung und Entwicklung Mainz (ikfe), Germany.  
In Project 1 DPP-4 activity was calculated as percentage of pre-dose DPP-4 activity, thus 
the individual DPP-4 activities under treatment were normalised to the respective pre-dose 
measurement of the individual patient. In Project 3 DPP-4 activity as measured in RFU 
was used in the analysis. 
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2.2 Datasets 
2.2.1 Dataset building 
2.2.1.1 General dataset building 
The structure of NONMEM datasets is predetermined by the program (124). In general, 
NONMEM data files contain an identifier for the individual subjects, one or more depend-
ent variables (e.g. linagliptin plasma concentration, plasma DPP-4 activity), independent 
variables such as dosing information, actual sampling and dosing time and possibly 
information about subject-specific covariates.  
The raw data used to build the NONMEM datasets were provided by Medical Data 
Services, Boehringer Ingelheim. The NONMEM datasets of Projects 2d, 4, and 5 were 
prepared manually using Excel (Version 2002, Microsoft, Redmond, WA, USA). The data 
quality was assured by double data entry, i.e. a dataset was prepared in two independent 
versions which were then compared. The initial NONMEM datasets of studies I to IV used 
in Projects 1 and 3 were provided by Medical Data Services, Boehringer Ingelheim. These 
datasets were created by a well documented SAS (Version 8.02, SAS Institute Inc., Cary, 
NC, USA) program based on a comprehensive dataset specification document. Problems 
during the dataset creation were discussed and resolved by both parties to ensure a 
complete, consistent and accurate reporting database. Subsequently, an intensive data 
checkout analysis was carried out and documented to assure the quality of the datasets.  
Changes of the initial datasets like combination of different datasets, division or modifica-
tion were performed either manually using Excel or by user-written Splus (Version 7 
and 8, Insightful Corporation, Seattle, WA, USA) scripts. All changes of the datasets were 
checked and documented to allow traceability. 
2.2.1.2 Handling of covariates 
Information on the following covariates was included in the datasets of studies I–IV:  
1. Demographic information: age (years), weight (kg), height (cm), body mass index 
(kg/m2), body surface area (m2), sex, ethnic origin, smoking and alcohol status 
2. Laboratory values: serum creatinine (mg/dL), creatinine clearance (ml/min), urea 
(mM), alanine transaminase (U/L), aspartate transaminase (U/L), alkaline phos-
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phatase (U/L), gamma-glutamyl transferase (U/L), total bilirubin (mg/dL), creatine 
kinase (U/L), cholesterol (mg/dL), C-reactive protein (mg/dL), triglyceride 
(mg/dL), fasting plasma glucose (mM) 
3. Others: study number, randomisation group, formulation, metformin co-treatment, 
pre-dose DPP-4 activity (RFU) 
The derived covariates body mass index, body surface area and creatinine clearance were 
calculated as follows. The body mass index was calculated according to equation 2-1:  
 2(m)height 
(kg)weight index massBody =      (Equation 2-1) 
Body surface area was derived based on the equation described by DuBois and DuBois 
(134) as shown in equation 2-2:  
0.4250.725 (kg)weight (cm)height 0.007184area surfaceBody ⋅⋅=   (Equation 2-2) 
Creatinine clearance was calculated according to the Cockroft-Gault equation (135) as 
presented in equations 2-3a and 2-3b: 
 (mg/dL)ion concentratcreatinine72
(kg)weight (years)) age(140
 clearance Creatinine
 male
⋅
⋅−
=   (Equation 2-3a) 
0.85(mg/dL)ion concentratcreatinine72
(kg)weight (years)) age(140
  clearance Creatinine
 female ⋅
⋅
⋅−
=   (Equation 2-3b) 
2.2.1.3 Handling of missing observations 
If observations of the dependent variables were missing, these values were omitted in the 
dataset. If date and/or time were missing for an observation, the respective observation was 
not included into the dataset. Plasma linagliptin concentrations below the limit of quantifi-
cation were removed a priori from the dataset, except when measured during the lag time 
in which case they were implemented and set to zero. Patients randomised to placebo were 
excluded from the pharmacokinetic analysis. 
2.2.1.4 Handling of missing dosing records 
If both date and time of a dosing record were missing, it was assumed that the dose was not 
taken and the dose was not included in the dataset. If only either date or time of a dosing 
record was missing, it was assumed that the dose was taken and the dose was implemented 
2 Methods and studies   23 
 
 
with protocol date or time. If date and/or time of the last dose before an observation was 
missing, this observation was not included in the dataset. 
2.2.1.5 Handling of missing covariates 
A covariate completely missing for a particular subject was replaced by the population 
median of the baseline values for continuous covariates and by the mode for a categorical 
covariate. If a covariate that was measured more than once within a subject was missing, 
the last measurement was carried forward until a new measurement was available. 
2.2.1.6 Handling of outliers 
All data, i.e. dependent variables and covariates, were included in the analysis whenever 
possible. Data were only exluded if they were not plausible. Whenever possible, outliers 
which were excluded from the analysis were tested on their impact on the analysis. All 
outliers are reported in the respective results sections of the projects. 
2.2.2 Dataset description 
Before start of the actual population pharmacokinetic or pharmacodynamic analysis, the 
data were extensively explored graphically to further assure the data quality and to allow a 
comprehensive overview of the investigated data. In general, the distribution of subjects 
and observations per dose group, visit and time after dose was investigated. Pharmacoki-
netic and pharmacodynamic observations were plotted versus time and versus each other. 
Furthermore, frequency distributions of covariates and correlations between covariates 
were examined. The main results of the dataset description are presented in the respective 
section of each project. 
   24 2 Methods and studies 
2.3 Population analysis 
The population pharmacokinetic or pharmacodynamic analyses presented within this thesis 
were performed using the nonlinear mixed-effects modelling software package 
NONMEM V (124).  
2.3.1 Nonlinear mixed-effect modelling 
The name of the software NONMEM is derived from NONlinear Mixed-Effects Modelling. 
In a population analysis using nonlinear mixed-effect modelling techniques, data from all 
individuals are analysed together, but the individuality of the subjects is maintained. This 
is achieved by simultaneously estimating typical model parameters (so-called fixed effects) 
together with different levels of variability (so-called random effects). As pharmacokinetic 
or pharmacodynamic models are nonlinear and comprise both fixed effects and random 
effects the method was termed nonlinear mixed-effect modelling.  
A nonlinear mixed-effect model, referred to as population model in this thesis, consists of 
the following submodels: 
1. Structural model 
2. Stochastic model 
3. Covariate model (optional) 
2.3.1.1 Structural model 
The structural model describes the plasma concentration-time profile or the effect-time 
profile of a typical subject as a function of dose, time and parameters of the underlying 
model as presented in equation 2-4: 
)= θ,( ijij xfy        (Equation 2-4) 
The jth response y (concentration or effect) of the ith individual can be described by a 
function f that depends on measurable variables xij like dose or time, as well as estimated 
typical model parameters θ. Structural models for pharmacokinetic analyses are often 
compartmental models, while for pharmacokinetic/pharmacodynamic analyses  Emax 
models are frequently applied. 
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2.3.1.2 Stochastic model 
Even when subjects receive identical doses and the concentration or response is measured 
at the same time, they do not exhibit identical concentrations or responses. This is also true 
for the case when the same dose is given twice to the same subject. To account for this, the 
stochastic model allows for different levels of variability, called random effects: 
1. interindividual variability 
2. intraindividual variability 
3. residual variability 
All variability levels have in common that they are random and thus cannot be predicted in 
advance. Although it can be expected that all parameters vary between individuals and 
often also within the single individuum, the data might not allow to account for variability 
in all parameters. 
2.3.1.2.1 Interindividual variability 
Interindividual variability accounts for unexplained differences in the model parameters 
between individuals, as illustrated in equation 2-5: 
iTVi PP η+=        (Equation 2-5) 
Pi is the model parameter in the ith individual. It is dependent on the typical model parame-
ter of the population PTV and the difference ηi between the individual parameter Pi and the 
typical parameter PTV. It is assumed that the individual ηi values are independent and 
normally distributed with a mean of zero and a variance ω2. The variance ω2 is estimated 
by NONMEM and reflects the extent of interindividual variability in the respective model 
parameter. Most pharmacokinetic parameters follow a log-normal distribution rather than a 
normal distribution. A log-normal distribution has the advantage that it constrains the 
individual parameters to be greater than zero and thus avoids the estimation of negative 
clearance or volume of distribution values. To account for this, interindividual variability 
was implemented for the model parameters by an exponential model as presented in 
equation 2-6: 
)exp( iTVi PP η⋅=        (Equation 2-6) 
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2.3.1.2.2 Intraindividual variability 
Intraindividual variability accounts for the unexplainable differences in the model parame-
ters of a single individual between different study occasions (136). The occasion intervals 
can be set arbitrarily. Most often, time intervals are chosen based on the available data. For 
example, in a cross-over study, the occasion intervals may correspond to the different 
periods. The only constrain in setting the intervals is that more than 1 measurement has to 
be available per time interval to differentiate between intraindividual variability and 
residual variability. 
Intraindividual variability was implemented like interindividual variability. Exponential 
models were again chosen to account for intraindividual variability for the same reason as 
discussed above. Equation 2-7 shows how intraindividual variability was implemented: 
)exp( ioiTVio PP κη +⋅=       (Equation 2-7) 
Pio is the model parameter in the ith individual for the occasion interval o. Pio is not only 
dependent on PTV and ηi, but also on the difference between the individual parameter Pi on 
different occasions. It is assumed that the individual κio values are independent and 
normally distributed with a mean of zero and a variance pi2. The variance pi 2 was estimated 
by NONMEM and reflects the extent of intraindividual variability in the respective model 
parameter. 
2.3.1.2.3 Residual variability 
Residual variability accounts for the unexplainable deviation between an observed value 
and the corresponding model-predicted value, considering inter- and intraindividual 
variability. Residual variability might be due to errors in the analytical assay, errors in the 
amount of the administered dose, errors in the recording of the sampling or administration 
time, model misspecifications, and others. The residual variability can be accounted for by 
different types of models. Within this work, residual variability was investigated using an 
additive model, a proportional model, and the combination of both.  
An additive residual variability model assumes that errors are additive regardless of the 
magnitude of the individual prediction. The corresponding mathematical equation is given 
in equation 2-8: 
iojiojioj yy ε+= ˆ         (Equation 2-8) 
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In this equation, yioj is the jth measured response y (concentration or effect) of the ith 
individual at the oth occasion. ŷioj is the corresponding response predicted by the model 
taking into account inter- and intraindividual variability. The random variability εioj is the 
difference of the observed and the predicted response. The individual εioj values are 
assumed to be normally distributed with a mean of zero and a variance σ2. The variance 
characterises the extent of residual variability. An additive model is the simplest model, 
but it often does not reflect the residual variability which increases most often with 
increasing response. For these cases a proportional residual variability model is more 
appropriate, as in this model the residual variability is proportional to the magnitude of the 
individual prediction. The mathematical equation for a proportional variability model is 
given in equation 2-9: 
)1(ˆ iojiojioj yy ε+⋅=       (Equation 2-9) 
A third model which was investigated was a combined additive and proportional model, as 
presented in equation 2-10: 
iojiojiojioj yy 21 )1(ˆ εε ++⋅=       (Equation 2-10) 
During the analysis, concentrations were log-transformed to increase the stability of the 
parameter estimation process (137). In consequence, the residual variability models needed 
to be adapted accordingly. An additive residual variability model used for log-transformed 
data (equation 2-11) corresponds to an exponential residual variability model for untrans-
formed data (equation 2-12). An exponential model in turn approximately corresponds to a 
proportional model (equation 2-9), as exp(ε) = 1+ε for small ε.  
iojiojioj yy ε+= )ˆln()ln(              (Equation 2-11) 
)exp(ˆ iojiojioj yy ε⋅=          (Equation 2-12) 
Furthermore, the model presented in equation 2-13 used for log-transformed data approxi-
mately corresponds an additive model for untransformed data (138), assuming that 
exp(θ) = 1+θ for small values of θ. 
( ) ioj
ioj
iojioj y
yy εθ ⋅+= 2
2
ˆ
ˆln)ln(          (Equation 2-13) 
Using this coding, θ was estimated whereas εioj was fixed to 1. θ2 corresponds approxi-
mately to the variance σ2.  
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2.3.1.3 Covariate model 
A covariate model accounts for the impact of a covariate on a model parameter. Parameters 
of a covariate model are fixed effects. A covariate model should explain the variability of 
the model parameter, thereby reducing its random, unexplained interindividual (sometimes 
also intraindividual) variability. Covariates are subject-specific factors. They can be 
classified in intrinsic factors such as demographics (e.g. age, sex) or laboratory values (e.g. 
liver enzymes) as well as extrinsic factors (e.g. formulation). Covariates can either be 
continuous like age or weight, or categorical like sex.  
2.3.1.3.1 Continuous covariates 
Continuous covariates were implemented into the model based on the graphical relation-
ship between the individual covariate values and the individual model parameters. Most 
often the correlations were sufficiently described by a linear model, as presented in 
equation 2-14. The individual covariates covi were centered around their median covmedian 
leading to an easier interpretation of the estimates and to a higher numerical stability of the 
model: 
)
mediancovi(cov2θ1θP −⋅+=             (Equation 2-14) 
The parameter P is equal to θ1 if an individual’s covariate value equals the median 
covariate value. If an individual’s covariate changes by 1 unit from the median covariate 
value, P changes by θ2 from θ1. If more than one covariate was implemented per parameter, 
the different covariates were incorporated in a multiplicative way. 
2.3.1.3.2 Categorical covariates 
Categorical covariates were implemented in two different ways. The first possibility was to 
estimate separate typical parameters θn for each category, as demonstrated in equa-
tion 2-15.  





=
ncategory for  
n
θ 
1category for  1θ
P M            (Equation 2-15) 
2 Methods and studies   29 
 
 
If only two categories existed the following coding could be applied (equation 2-16). 
icov2θ1θP ⋅+=          (Equation 2-16) 
θ1 is the typical parameter of a subject belonging to category 1, whereas the sum of θ1 and 
θ2 is the typical parameter for subjects of category 2. covi is the identifier for the catego-
ries; it is 0 for subjects of category 1 and 1 for subjects of category 2. Separate categories 
were only tested if one category contained at least 10% of the subjects in the dataset. 
2.3.2 Estimation of  population parameters 
NONMEM adapts the model function parameters in an iterative process so that they fit the 
observed data, in order to obtain parameters which describe the observations best (139-
141). By using the maximum-likelihood method, NONMEM estimates the fixed (θ) and 
random effects (ω2, κ2, and σ2) simultaneously. Likelihood is a measure of how likely it is, 
if the model were true with its current parameters, that the present observations would have 
been observed. The overall likelihood L is the product of the likelihoods of the individual 
observations. In order to maximise the likelihood L, NONMEM minimises −2 log likeli-
hood. Maximizing likelihood and minimizing −2 log likelihood are essentially the same 
thing. However, mathematically, it is easier to take the log of a series of factors, which 
reduces the problem from one of multiplication to one of sums. The −2 log likelihood 
function that is minimised by NONMEM is presented in equation 2-17: 
( ) ( )∑
=








−
++⋅=−
n
1i
2
i
2
ii2
i σ
YˆY)log(σ2pilogn2log(L)      (Equation 2-17) 
Equation 2-17 consists of a constant term (n×log(2л)) that is dependent on the number n of 
observations, and of a variable term that is minimised. The squared difference between the 
individual observed (Yi) and predicted (Ŷi) observation is weighted by the variance (σi2). A 
penalty term (log σi2) is introduced to prevent minimisation by high variances. The 
variable term is called extended least square objective function and represents the ‘objec-
tive function value’ in NONMEM. 
The −2 log likelihood equation is often difficult to solve as for most population pharma-
cokinetic/pharmacodynamic models no closed-form solution for Ŷi and σi2 exists 
(113,140). Thus, approximation methods are used. The most common ones are the first-
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order estimation method (FO), first-order conditional estimation method (FOCE), and 
FOCE with interaction (FOCE-I). All three use a first-order Taylor series expansion with 
respect to the random effects ηi, κio, and εij, assuming that they are normally distributed 
with a mean of zero. The simplest estimation method, FO, expands the nonlinear mixed-
effects model as a first-order Taylor series about η = 0 and then uses a linear approxima-
tion to estimate the parameters of the nonlinear model. With FO, estimates for the fixed 
and random effects, but no individual model parameter estimates are obtained. These are 
then calculated using the maximum Bayesian estimation method as implemented in the 
NONMEM ‘post-hoc’ option (124). FOCE provides estimates of the population parameters 
as well as the individual random effects during each iteration step. Here, the model is 
expanded about the conditional estimates of the η’s by a first-order Taylor series. When 
this algorithm is used, estimates of the population parameters as well as the random-effects 
parameters are obtained during each iteration step. Finally, FOCE-I calculates the objective 
function allowing for an interaction of ε on η. This is especially useful when a proportional 
residual variability model is estimated. 
In general, the precision of the estimation method increases in the order 
FO < FOCE < FOCE-I, whereas the calculation speed decreases in that order (126,140). 
FO was the first method available in NONMEM (139). It performs adequately for sparse 
data, but it is not recommended for dense data. Today, with the increase in processing 
power, it is less and less used. FOCE-I was the preferred estimation method in this thesis. 
In Project 3a, FOCE was used instead to reduce the exceptionally long run times.  
2.3.3 Model development 
Model development followed a bottom up approach, starting with a simple model and 
expanding this model in order to allow an adequate description of the data. Whenever 
possible, this expansion was done in a mechanistic way, reflecting the current knowledge 
on linagliptin in the model. A separate modelling and simulation strategy was developed 
for each project, based on the objective of the project, the available data, and the a priori 
information. These individual strategies are outlined in detail in the sections of the 
respective projects (cf. section 2.5). An analysis plan describing the planned analysis was 
written prior to the analysis in Projects 1 and 3. At first, a base model was developed 
consisting of a structural and a stochastic model. This base model was expanded by a 
covariate model in Projects 1 and 3. Throughout the complete model development, log-
transformed linagliptin plasma concentrations were used.  
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2.3.3.1  Model selection 
Model selection was guided by different graphical and statistical methods. For nested 
models, the likelihood ratio test, a common test for statistical significance, was considered 
for model selection. Two models are nested if a full model can be reduced to a simpler 
model by setting one or more parameters to a fixed value. The difference between the 
objective functions (corresponding to −2·log of the ratio of likelihoods) of a full and a 
reduced model are approximately χ2-distributed, with n degrees of freedom, where n is the 
number of parameters set to a fixed value in the reduced model. Unless stated otherwise, 
the full model was accepted if the drop in the objective function was >3.84 after addition 
of one single model parameter, corresponding to a significance level of p < 0.05. For the 
backward elimination procedure during a covariate analysis, a stricter significance level of 
p < 0.001 was applied.  
Furthermore, graphical goodness-of-fit analysis (127) was performed utilizing user-written 
Splus scripts or Xpose (Version 3.104, Uppsala University, Uppsala, Sweden) (142). Plots 
showing population and individual predictions versus measured observations, as well as 
weighted residuals versus population predictions and versus time, amongst others, were 
routinely investigated. To accept a model, the data points were required to be randomly 
distributed around the line of identity for plots showing predictions versus observations or 
randomly distributed around zero for residual plots. 
Another criterion was the precision of parameter estimates as reported by the relative 
standard error obtained from NONMEM. A relative standard error of a parameter higher 
than 50% indicates that this parameter might be redundant. Further selection criteria were 
the absence of a correlation >0.95 between model parameters, numerical stability of the 
model, and the plausibility of the parameter estimates.  
2.3.3.2 Development of the base model 
2.3.3.2.1 Structural model 
The aim of the structural model development was to find the model that best described the 
typical pharmacokinetic or pharmacodynamic profile of linagliptin. If possible, the 
structural model was to be mechanistic, reflecting the known characteristics of linagliptin. 
The model selection was based on the criteria described in section 2.3.3.1. The structural 
pharmacokinetic models were parameterised in terms of clearances and volumes, rather 
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than rate constants, in order to allow a meaningful implementation and interpretation of 
interindividual variability and potential covariate effects. The strategy of the development 
of the structural model is presented separately for the individual projects in section 2.5. 
2.3.3.2.2 Stochastic model 
The aim of the development of the stochastic model was to characterise the variability 
within the pharmacokinetics or pharmacodynamics of linagliptin. It was tested whether the 
residual variability was best described by either an additive, a proportional, or a combined 
(additive and proportional) model. Interindividual variability was tested sequentially in all 
model parameters and retained when it improved the data description. As described in 
section 2.3.1.2.1, interindividual variability was implemented using exponential random 
effect models. At first, no covariance between the different interindividual variabilities was 
estimated. If correlations between interindividual variabilities were found by graphical 
analysis, covariance was implemented and the correlation coefficient was estimated. 
Intraindividual variability was only explored on selected model parameters. 
2.3.3.3 Development of the covariate model  
The aim of the covariate analysis was to identify covariates affecting the pharmacokinetics 
or pharmacodynamics to an extent that their impact may be clinically relevant. The 
covariate analysis was performed in a stepwise manner: As a first step, a graphical 
exploratory analysis was performed, then a generalised additive modelling (GAM) analysis 
was conducted, and finally the covariates suggested by these procedures as well as some 
pre-selected covariates were tested in NONMEM using the forward inclusion backward 
elimination procedure. 
2.3.3.3.1 Explorative graphical investigation 
First, the correlation between the individual covariate values and individual parameter 
estimates were explored graphically. For continuous covariates, the medians of the 
individual values of the covariate of interest were plotted against the individual η values. 
The relationship between categorical covariates and individual η values were investigated 
using box-whisker plots.  
2.3.3.3.2 Generalised additive modelling 
In a next step, a GAM analysis was conducted within Splus to statistically investigate the 
correlation between the covariates and the individual parameter estimates. The GAM 
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analysis was introduced by Mandema et al. (143), to identify possible covariates before 
further testing in NONMEM. It is a multiple regression analysis in which the influence of 
different covariates is tested separately per model parameter. The GAM analysis follows a 
stepwise addition/deletion method. Addition of a covariate is possible through either a 
linear function or a spline function with one degree of freedom (df). At each step, the 
model is changed by addition or deletion of the single covariate term resulting in the 
greatest decrease in the Akaike information criterion (AIC) until a minimum AIC is 
reached. Equation 2-18 shows how the AIC was calculated. The AIC is dependent of the 
number of observations n, the number of parameters of the fitted model k, and the 
weighted least squares wss: 
2kln(wss)nAIC +⋅=            (Equation 2-18) 
The GAM analysis was performed using the difference between the median individual 
covariate value and the overall median covariate value for continuous covariates or the 
respective pre-defined categories for categorical covariates. 
2.3.3.3.3 Forward inclusion backward elimination in NONMEM 
As mentioned above, the covariates tested further within NONMEM were selected based 
on the correlation between covariates and individual parameter estimates (exploratory 
analysis) (144), as well as the results of the GAM analyses (143). Furthermore, the 
correlation between covariates was considered when selecting the covariates to be tested in 
NONMEM. Some covariates that were of special interest were pre-selected to be tested in 
NONMEM, independently of the results of the exploratory analysis or GAM analysis. 
These covariates are specified under the respective sections in the method part. 
The covariate analysis was performed using the forward inclusion and backward 
elimination procedure (145,146). In the first step of the forward inclusion, all covariates 
pre-selected as described previously were evaluated one by one in NONMEM with a 
function that seemed most appropriate from the plots of covariate values versus 
parameters. Then, the covariates showing a decrease of less than 3.84 in the objective 
function (OBJF) value (probability (p) ≤ 0.05, chi square distribution (χ2), 1 df) were 
removed. The remaining covariates were ranked, starting with the covariate that generated 
the largest drop in the OBJF value during forward inclusion. In the next step of the forward 
inclusion, the covariates were added to the base model sequentially in their ranking order. 
If the addition of a covariate resulted in a drop of the OBJF value of at least 3.84 (p ≤ 0.05, 
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χ2, 1 df), it was retained; otherwise it was removed. This was repeated until the full model 
was obtained. The forward inclusion of parameter-covariate relationships was followed by 
a backward elimination, which is essentially the reverse of the forward inclusion. The 
covariates were removed individually from the full covariate model. The covariates were 
again ranked according to the increase in the OBJF. If the increase in the OBJF was less 
than 10.8 points (p ≤ 0.001, χ2, 1 df) the corresponding covariate was removed and a new 
rank order was established based on removing the remaining covariates separately. This 
was continued until no more terms could be dropped. 
In addition to reducing the OBJF, a covariate that was to be retained should explain part of 
the variability in the model parameters, be physiologically plausible, and have a clinically 
relevant impact on the pharmacokinetics or pharmacodynamics. If this was not the case, a 
covariate might not be retained in the final model. 
2.3.4 Model evaluation 
Different techniques are available to test the performance of a model (115). In this thesis, 
the choice of evaluation methods was limited by processing power. Computer intensive 
approaches such as re-estimation of simulated or bootstrapped datasets were not consid-
ered. Instead, internal methods based on simulations were applied. The method which was 
chosen for a given project is outlined in the respective sections.  
2.3.4.1 Visual predictive check (VPC)  
When a visual predictive check (147) was performed, the response-time profiles of 1,000 
subjects were simulated per dose group based on the model to be investigated including 
interindividual, intraindividual and residual variability as well as the dosing and sampling 
scheme of the study. The simulations were conducted using the Trial Simulator software 
(Pharsight Corporation, Version 2.1.2, St. Louis, MO, USA). The median and the 5th and 
95th percentiles of the simulated concentrations at every time point were calculated per 
dose group and plotted against the observed concentration-time profile. The model was 
considered adequate in describing the observations if most of the data points were within 
the 5th to 95th percentile interval and were equally distributed around the median. 
2.3.4.2 Posterior predictive check 
For a posterior predictive check (140,148), one or more variables of interest were defined, 
which were of importance for the response and which could be directly obtained from the 
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original dataset, without the use of the model. One thousand new datasets with the same 
number of patients, the same covariates, and the same dosing history and sampling 
schedule as the original dataset were simulated in NONMEM, based on the final model. In 
the posterior predictive checks performed in this thesis the interindividual, intraindividual 
as well as the residual variability of the model were taken into account, but not the 
uncertainty in the parameter estimates. The median variable of interest was calculated for 
each simulated dose group. The distributions of the medians over the 1,000 simulations 
were presented as histograms and were compared to the observed median, per dose group. 
For the model to be accepted, the observed median of the variable of interest was to lie 
within the 90% confidence interval of the simulations. 
2.4 Statistical data analysis 
Descriptive statistics was applied to quantitatively summarise the contents of the NON-
MEM datasets as well as the results of the pharmacometric analyses. For categorical 
values, the mode (most frequently occurring number in a list) and frequency distributions 
were used. For continuous values, the following measures were used to describe the central 
tendency, or the average of a list of values. 
• Arithmetic mean: sum of all numbers of a list divided by the number of items in the list 
• Median: middle number of a group when the numbers were ranked in order 
• Geometric mean (gMean): exponential function of the arithmetic mean of the natural 
logarithms of all numbers of a list 
The statistical dispersion, or variability of a list of continuous values were illustrated by the 
following parameters. 
• Range: difference between the highest and lowest value 
• Variance: sum of squares of the deviations of the numbers of a list from their mean 
divided by the number of items minus 1 of the list  
• Standard deviation (SD): square root of the variance  
• Coefficient of variation (CV%): ratio of the standard deviation to the arithmetic mean 
• Geometric coefficient of variation (gCV): square root of the antilog of the variance of 
log-transformed data minus one times 100% 
• 5th, 95th percentile: values below which 5% or 95% of the observations fall, respec-
tively  
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2.5 Project characteristics 
2.5.1 Project 1: Population pharmacokinetic/pharmacodynamic 
analysis of  linagliptin in type 2 diabetic patients  
2.5.1.1 Objectives 
The pharmacokinetics of linagliptin is nonlinear in the therapeutic dose range (1–10 mg) 
with a less than dose-proportional increase in exposure. Nonlinear pharmacokinetics can be 
caused by several mechanisms as discussed in section 4.1.1. Linagliptin exhibited concen-
tration-dependent plasma protein binding in the low nanomolar range (<100 nM). Common 
plasma proteins like albumin or α-glycoprotein would not yet be saturated at these low 
concentrations (149). This led to the hypothesis that concentration-dependent binding of 
linagliptin to its target enzyme, DPP-4 might be responsible for the nonlinear pharmacoki-
netics of linagliptin. 
Thus, the objectives of Project 1 were (a) to characterise the nonlinear pharmacokinetics of 
linagliptin and the relationship between linagliptin plasma concentration and the DPP-4 
inhibition in type 2 diabetic patients and (b) to test the hypothesis that concentration-
dependent binding of linagliptin to its target, DPP-4 is responsible for its nonlinear 
pharmacokinetics in humans. A population pharmacokinetic/pharmacodynamic model 
incorporating concentration-dependent protein binding was to be developed, describing the 
nonlinear pharmacokinetics and the DPP-4 inhibition in a semi-mechanistic way. In 
addition, an initial covariate analysis was carried out to find patient characteristics 
explaining part of the individual variability in the model parameters. 
The final population pharmacokinetic/pharmacodynamic model formed the basis for 
several simulations contributing to a better understanding of the nonlinear pharmacokinet-
ics of linagliptin and its effects on DPP-4 activity in humans. 
2.5.1.2 Study design 
Two phase IIa studies with 47 and 77 type 2 diabetic patients (study I (104) and study II) 
were included in the analysis. Both trials were randomised, placebo-controlled, double-
blind multiple dose studies with a parallel group design. Subjects received either placebo, 
1, 2.5, 5, or 10 mg linagliptin as a powder in the bottle formulation once daily over twelve 
days of treatment (study I) or placebo, 2.5, 5, or 10 mg linagliptin as a tablet once daily 
over 28 days (study II). The studies were conducted at several centres throughout Europe. 
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Ethics committees reviewed and approved the study protocols and the study was conducted 
within the ethical standards established by the Declaration of Helsinki (150) and in 
accordance with applicable regulatory requirements. 
Plasma samples for full linagliptin plasma concentration-time and DPP-4 activity-time 
profiles were collected after the first and the last linagliptin administration in each study. 
Trough samples were taken at the schedule specified for each study. Due to the long 
terminal half-life of linagliptin, plasma concentration and DPP-4 activity were measured 
until 8 or 15 days after the last administration, respectively. The exact sampling schedules 
are given in the Appendix, Table 3. Linagliptin plasma concentrations and plasma DPP-4 
activity were determined as described in section 2.1.  
In study I, linagliptin was administered under supervision and date and time of each 
administration were recorded in the case report form (CRF) by clinic personnel. In study II, 
linagliptin was administered under supervision during the in-house stay (days 1–6 and 
days 26–28) and date and time of each administration were recorded in the CRF by clinic 
personnel. Date and time of tablet intake at home was entered by the patient in a patient’s 
diary and transferred into the CRF by the clinic personnel.  
The covariates listed in section 2.2.1.2 were investigated. In study I, demographic charac-
teristics were determined at screening. Laboratory values were measured at screening, 
optionally at a training visit if screening of safety measurements was done more than 14 
days ago and at the following days: −1, 1, 2, 3, 6, 10, 12, 13, 16 and during the end-of-
study evaluation (days 20–28). Fasting plasma glucose was determined daily on days −1–
13. Pre-dose DPP-4 activity was measured on day 1 before the first administration of 
linagliptin. In study II, demographic characteristics were determined at screening; weight 
was also measured on day 30. Laboratory values were measured at screening, at the 
training visit and at the following days: −1, 2, 6, 12, 19, 26, 28, 30, 36, as well as during 
the end-of-study evaluation (between days 43−50). Fasting plasma glucose was determined 
at days –1, 1, 2, 6, 12, 19, 26, 27, 28, 29, 30, 33, 36, 39, 41, and 43. Pre-dose DPP-4 
activity was measured at day 1 before the first administration of linagliptin. 
2.5.1.3 Modelling strategy  
The analysis was performed in a stepwise manner. First, the plasma concentration-time 
profiles were analysed. Due to the complexity of the structural model it was investigated 
whether the proposed pharmacokinetic model was identifiable. Finally, DPP-4 activity was 
   38 2 Methods and studies 
added to the dataset and plasma concentration- and DPP-4 activity-time profiles were 
analysed simultaneously. 
Pharmacokinetic base model. Initially, linear one-, two-, and three-compartment models 
were tested. To describe the less than dose-proportional increase in exposure, different 
models were investigated including saturable absorption, which may be caused by 
saturation of influx transporters, or saturable protein binding. For the protein binding 
model, the influence of concentration-dependent binding in the central compartment as 
well as a second binding partner located either in the central or in the peripheral compart-
ment were tested. The second binding partner may reflect tissue DPP-4 (either with or 
without a distribution process) in contrast to plasma DPP-4.  
The way the binding was implemented into the model was derived from literature (151-
155). All binding processes were considered to be reversible and competitive. When 
concentration-dependent binding was assumed at different sites, different amounts of 
binding partners were estimated but their binding affinities to linagliptin were assumed to 
be identical. Quasi-equilibrium conditions were assumed for the binding to simplify the 
estimation, i.e. the binding equilibrium was assumed to be reached faster than all other 
processes. 
Linagliptin was assumed to bind with a high affinity to a binding partner that is present in 
low amounts and thus has a low capacity for linagliptin. It was further assumed that only 
linagliptin that was not bound to the high affinity, low capacity binding partner could 
distribute between the compartments and be eliminated. The concentration of linagliptin 
bound to the high affinity, low capacity binding partner is referred to as ‘concentration 
bound’ throughout the thesis. The concentrations of unbound linagliptin and linagliptin 
linearly bound to other proteins were not distinguishable by the model and thus were 
regarded as a single concentration, referred to as ‘concentration unbound’. The observed 
total linagliptin plasma concentration was the sum of unbound linagliptin and linagliptin 
linearly bound to plasma proteins, as well as the concentration of linagliptin specifically 
bound to a soluble binding partner in the central compartment. 
As only linagliptin plasma concentration-time profiles after oral administration were 
available in the studies, only relative bioavailabilities could be estimated. Intraindividual 
variability was tested on all parameters with interindividual variability (bioavailability, rate 
of absorption, concentration of the binding partner in the central compartment) and on 
clearance. For intraindividual variability two occasions were defined. The first occasion 
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included the single-dose profile and the trough plasma concentrations (i.e. concentration at 
the end of the dosing interval, taken directly before the next administration Ctrough) until 
halfway through treatment, followed by the second occasion including the Ctrough levels of 
the second half of treatment and the steady-state profile for each study. 
Identifiability of the pharmacokinetic model. The pharmacokinetic base model devel-
opment revealed that a two-compartment model with concentration-dependent protein 
binding in the central and the peripheral compartment described the plasma concentration-
time profiles best. As only total linagliptin plasma concentrations were available, it was 
unclear whether the data contained sufficient information to identify all model parameters 
of the complex model structure. Thus, four different approaches were used to investigate 
whether the model structure with concentration-dependent binding in the central and the 
peripheral compartment, could be identified given the study designs of Project 1. These 
investigations were performed based on a preliminary pharmacokinetic model (Table 3-1).  
Initially, the influence of the amounts of both binding partners, possibly reflecting plasma 
and tissue DPP-4, on the plasma concentration-time profiles was evaluated by two 
approaches. In the first approach, the concentration-time profiles of multiple daily doses of 
1, 5, and 10 mg linagliptin were simulated assuming varying amounts of central or 
peripheral binding partners (originally estimated amount ±50%). In the second approach, 
log-likelihood profiling was performed for the parameters reflecting the amounts of central 
and peripheral binding partner.  
Similarly to the method used by Waterhouse et al. (156), it was explored in the third 
approach whether NONMEM correctly identified the presence or absence of the peripheral 
binding. For this method, concentrations were simulated based on the design of study I and 
two different scenarios. In scenario S1 it was assumed that concentration-dependent 
binding only occurred in the central compartment. In scenario S2 concentration-dependent 
binding was assumed in both compartments, central and peripheral. The underlying model 
parameters used for the simulations were obtained from initial estimations of a model with 
binding only in the central compartment (M1) and a model with binding in the central and 
the peripheral compartment (M2) using the original dataset. In the next step, each simu-
lated dataset was re-estimated assuming binding either only in the central compartment 
(M1) or in both compartments (M2). For each dataset, the performance of the two nested 
models was compared using the objective function value. Only NONMEM runs reported to 
have converged successfully were evaluated. 
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The last method investigated the identifiability of the model using the Fisher information 
matrix given the study designs of Project 1 as well as a study design where the treatment 
group with the lowest dose (1 mg linagliptin once daily) was missing. The Fisher informa-
tion matrix was determined with the WinPOPT software (Version 1.1 (beta), University of 
Otago, New Zealand) (157). The Fisher information matrix is a measure of the amount of 
information that is available in a certain model (structural, stochastic) and study design 
(number of patients, sampling time points, dose groups) (156) to estimate a model 
parameter. The relative standard errors of the model parameter estimates were determined 
as the square roots of the diagonal elements of the inverse of the Fisher information matrix 
(157). In addition, the determinant was investigated as the summary measure of the Fisher 
information matrix. 
Pharmacokinetic/pharmacodynamic base model. To describe DPP-4 activity, standard 
drug response models (Emax and sigmoid Emax model) relating the estimated total linagliptin 
plasma concentration (Ctot) to the DPP-4 activity were tested first. These models are 
described in equations 2-19 and 2-20. The maximum effect parameter Emax represents the 
maximum DPP-4 inhibition in percent. The EC50 value is the total linagliptin concentration 
that leads to half-maximum DPP-4 activity. In the sigmoid Emax model the sigmoid 
character of the curve is determined by the Hill coefficient n. 
 
50tot
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Additionally, more mechanistic models were investigated based on the assumption that 
DPP-4, the target of linagliptin, was its binding partner in the population pharmacokinetic 
model. These models, described in equations 2-21, 2-22 and 2-23, relate the plasma DPP-4 
activity to either the unbound plasma linagliptin concentration (CUplasma) or the plasma 
DPP-4 occupancy, i.e. the fraction of DPP-4 molecules bound to linagliptin, both estimated 
by the population pharmacokinetic model: 
1. Emax model using CUplasma. In this model, the parameter Emax specifies the maximum 
DPP-4 inhibition in percent. The EC50 value reflects the unbound linagliptin concentra-
tion that leads to half-maximum DPP-4 activity. 
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2. Occupancy model. This model assumes a proportional relationship between the plasma 
DPP-4 activity and the plasma DPP-4 occupancy with linagliptin as ligand. The plasma 
DPP-4 occupancy can be calculated from the parameters of the pharmacokinetic model 
in two ways: (a) by dividing the plasma concentration of linagliptin bound to DPP-4 
(CBplasma) by the concentration of binding partner in the central compartment (Bmax,C) 
(b) by dividing CUplasma by the sum of CUplasma and the dissociation constant Kd (see 
equation 2-22). The parameter Emax represents the maximum DPP-4 inhibition. The 
dissociation constant Kd is a measure of the affinity of the binding between DPP-4 and 
linagliptin and is derived from the population pharmacokinetic model. 
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   (Equation 2-22) 
The occupancy model is mathematically very similar to the Emax model using CUplasma (see 
equations 2-21 and 2-22). The only difference is that instead of estimating an EC50 value, 
the dissociation constant Kd of the population pharmacokinetic model is used. Pharma-
cokinetic and pharmacodynamic parameters were estimated simultaneously in all investi-
gated models. 
Covariate model. Based on the population pharmacokinetic/pharmacodynamic model, a 
covariate analysis was performed. All covariates listed in section 2.2.1.2, except metformin 
co-treatment, were investigated on all parameters that showed interindividual variability. 
Metformin co-treatment could not be tested as concomitant antidiabetic treatments were 
excluded by the designs of studies I and II. Although no inter-individual variability was 
introduced for clearance and the volumes of distribution, the following covariates were 
pre-defined to be tested in NONMEM: Creatinine clearance and the liver enzymes alanine 
transaminase and gamma-glutamyl transferase were investigated for their impact on 
clearance, as well as weight was pre-defined to be tested on the volumes of distribution. To 
avoid individual outliers in the covariates, the median covariate value per subject was used 
for covariates measured more than once. 
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2.5.1.4 Model evaluation 
For the evaluation of the final population pharmacokinetic/pharmacodynamic model, a 
visual predictive check was performed as described under section 2.3.4.1 for linagliptin 
plasma concentration and DPP-4 activity.  
2.5.1.5 Simulation strategy 
The final population pharmacokinetic/pharmacodynamic model of Project 1 was used to 
illustrate the impact of the target-mediated drug disposition on the pharmacokinetics of 
linagliptin. These simulations were performed using the Berkeley Madonna software 
(Version 8.0.4, University of California, Berkeley, CA, USA). First, the total linagliptin 
plasma concentration-time profile was to be compared to the fraction of linagliptin 
specifically bound to plasma DPP-4. This simulation was conducted for a once daily 
dosing scheme of 5 mg linagliptin. In a second simulation, the typical profile of plasma 
occupancy of DPP-4 with linagliptin versus time was investigated for different dose groups 
(1, 2.5, 5, and 10 mg) assuming once daily dosing.  
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2.5.2 Project 2: Clinical trial simulations to support the development of  
linagliptin 
The overall aim of the following four simulation projects was to apply the model built in 
Project 1 to support the clinical development of linagliptin. 
2.5.2.1 Project 2a: Simulation to evaluate an equivalent dose for a twice-daily 
administration 
2.5.2.1.1 Objectives 
A fixed dose combination was planned in which linagliptin was to be given together with 
the anti-diabetic drug metformin. As metformin is generally taken twice daily, the fixed 
dose combination should also adhere to this schedule. Thus, the question was which dose 
of linagliptin, when given twice daily, would result in a bioequivalent extent of steady-
state exposure and similar steady-state DPP-4 inhibition compared to a 5 mg once daily 
dosing scheme. Due to the nonlinearity, this could not easily be answered without resorting 
to model-based simulations. Thus, the objective for Project 2a was to evaluate by simula-
tions an equivalent dose for a twice-daily linagliptin administration to be tested in a 
relative bioequivalence study. 
2.5.2.1.2 Simulation strategy 
The base population pharmacokinetic/pharmacodynamic model of Project 1 was used for 
the simulation. This was done under the following assumptions: (a) The pharmacokinetics 
and the relationship between pharmacokinetics and pharmacodynamics are not different 
between healthy volunteers and type 2 diabetic patients. (b) The tablet formulation used in 
the relative bioequivalence study was not different with respect to exposure to the formula-
tions used in Project 1. 
Firstly, population mean profiles were simulated using the Berkeley Madonna software 
assuming that 1, 1.5, 2, and 2.5 mg linagliptin were given twice daily. The area under the 
plasma concentration-time curve of one day at steady-state (AUC24h,SS) was calculated by 
directly integrating the concentration-time curves over 24 h. These values were then 
compared to the area under the plasma concentration-time curve at steady-state of one 
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dosing interval (AUCτ,SS) simulated for 5 mg linagliptin given once daily. The respective 
DPP-4 activity-time profiles were investigated graphically. 
Secondly, a clinical trial simulation was performed based on the following study design. 
The study was assumed to have a randomised, two-way change-over design with 5 mg 
linagliptin once daily (treatment A) and the dose determined in simulation 1 twice daily 
(treatment B). Both treatments were to be administered over seven days until steady-state 
with no wash-out period in between them. Thus, subjects receiving sequence AB first get 
treatment A and then treatment B, and vice versa for sequence BA. The number of healthy 
volunteers included in the study was assumed to be 16. Blood sampling was to take place 
at the last day of each treatment period, i.e. days 7 and 14, respectively. On both days, the 
following sampling schedule for linagliptin plasma concentration and DPP-4 activity was 
used: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.25, 12.5, 12.75, 13, 13.5, 14, 15, 16, 18, 
20, and 24 h after the first administration of linagliptin at the respective day. This study 
design was simulated 1,000 times using the software Trial Simulator. 
For each simulated individual and treatment, the AUC24h,SS was calculated using the lin-log 
computation implemented in Trial Simulator. Then, the geometric means of AUC24h,SS and 
the gCV were calculated per sequence, and per treatment for each of the 1,000 simulated 
studies. In the next step, the mean of the gMean AUC24h,SS values and their gCVs of the 
1,000 simulated studies were calculated by sequence and treatment. Based on this, the 
distribution of the AUC24h,SS were compared per sequence, to evaluate whether the 
treatment period of seven days was long enough, and per treatment to investigate whether 
the treatments were equal. Finally, the gMean ratio between AUC24h,SS of treatment A and 
treatment B and its 90% confidence interval were determined for the 1,000 simulated trials 
and compared to the acceptance interval of 0.80–1.25. 
2.5.2.2 Project 2b: Simulation to evaluate the impact of impaired clearance  
2.5.2.2.1 Objectives 
During the clinical development of linagliptin the question appeared whether patients with 
renal impairment should be excluded in phase IIb studies. In order to support this decision, 
alongside other criteria, the impact of an impaired clearance on the exposure of linagliptin 
was to be investigated. Again, the nonlinear pharmacokinetics made predictions without a 
model difficult.  
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2.5.2.2.2 Simulation strategy 
The typical linagliptin plasma concentration-time profiles were simulated using the 
Berkeley Madonna software. The simulations were based on the pharmacoki-
netic/pharmacodynamic base model developed within Project 1.  
The fraction of linagliptin excreted in urine at steady-state was only 3–6% after oral 
administration of 1–10 mg linagliptin. With higher single oral doses, the fraction excreted 
increased up to 33% in the 600 mg dose group. In animals the fraction of linagliptin-related 
radioactivity excreted in urine, which consisted mainly of parent compound, was less than 
25% after intravenous administration (cf. section 1.3.2). Based on these results, it was 
assumed that in the therapeutic dose range renal clearance accounts for a maximum of 
~25% of the overall clearance. In addition, a 50% reduction of the overall clearance was 
simulated to cover a worst case scenario.  
For the simulation, it was assumed that 5 mg linagliptin were administered once daily to 
patients having either 100%, 75%, or 50% of the original clearance of unbound linagliptin 
estimated within Project 1. The AUCτ,SS values were calculated by directly integrating the 
simulated plasma concentration-time profiles using the Berkeley Madonna software. The 
simulated increase in steady-state exposure (AUCτ,SS) corresponding to a 50% and a 25% 
decrease in clearance was calculated. 
2.5.2.3 Project 2c: Simulation of a design for a dose-proportionality study 
2.5.2.3.1 Objectives 
A study was planned to assess the dose-proportionality of different dosage strengths of 
linagliptin tablets (1, 2.5, and 5 mg) at steady-state using the final formulation. Linagliptin 
was to be given once daily to healthy volunteers in a randomised, three-period cross-over 
study. Due to the long terminal half-life of linagliptin a change-over design, without any 
washout between the periods was preferred. The objective of Project 2c was to determine 
by simulation the optimal treatment duration until a steady-state profile could be obtained 
within such a change-over design. 
2.5.2.3.2 Simulation strategy 
The simulations were based on the final population pharmacokinetic/pharmacodynamic 
model developed in Project 1. In the planned dose-proportionality study the final tablet 
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formulation was to be used. It was assumed that the final formulation used in this study 
was not different with respect to exposure to the earlier tablet formulations used in study II. 
Furthermore, it was assumed that there is no difference in the pharmacokinetics between 
healthy volunteers and type 2 diabetic patients.  
Under these assumptions, a randomised three-way change-over design with treatment 
groups of 1, 2.5, and 5 mg linagliptin given once daily was simulated using the Berkeley 
Madonna software. Initially, a treatment period of seven days was tested. It was graphi-
cally investigated whether steady-state was achieved for all treatments in all scenarios. 
2.5.2.4 Project 2d: Description and steady-state simulation of the drug-drug 
interaction between linagliptin and ritonavir 
2.5.2.4.1 Objectives 
A phase I drug-drug interaction study was performed to investigate whether the treatment 
with the P-glycoprotein and CYP3A4 inhibitor ritonavir had an effect on the pharmacoki-
netics of linagliptin. In this drug-drug interaction study, linagliptin was administered as a 
single dose. The objective of Project 2d was to predict the steady-state profile of linagliptin 
with ritonavir comedication.  
2.5.2.4.2 Study design 
The study was performed as an open-label, randomised, two-way crossover trial. Two 
treatments (test and reference) were tested. During the test treatment, volunteers received 
200 mg ritonavir twice daily for three days, plus a single oral dose of 5 mg linagliptin on 
the second day of the ritonavir treatment. During the reference treatment, volunteers 
received 5 mg linagliptin only. The sequence of treatments was assigned in a random 
order. The two different treatments were separated by a washout period of at least 35 days. 
Twelve healthy volunteers were included in the study. The study was conducted at the 
Boehringer Ingelheim Human Pharmacology Centre in Biberach an der Riß, Germany. 
Ethics committee reviewed and approved the study protocols and the study was conducted 
within the ethical standards established by the Declaration of Helsinki (150) and in 
accordance with applicable regulatory requirements. 
Linagliptin plasma concentrations were determined as described in section 2.1.1 and 
collected at the following time points of each treatment arm: pre-dose, 15, 30, 45 min, and 
1.0, 1.5, 2.0, 3.0, 5.0, 7.0, 9.0, 10.5, 12.0, 24.0, 48.0, 72.0, and 96.0 h after the linagliptin 
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administration. Compliance was ensured by administration of all study medication under 
supervision of the investigating physician or a designee. The only covariate tested within 
Project 2d was comedication with ritonavir. 
2.5.2.4.3 Modelling strategy 
For a reliable prediction of the steady-state profile the semi-mechanistic model developed 
in Project 1 was to be used. In Project 2d, only plasma linagliptin concentrations after a 
single dose of 5 mg linagliptin were available. This was not sufficient to support the 
complex target-mediated drug disposition model. Therefore, the previously developed base 
model was used as a framework for the current analysis. The model of Project 1 was 
developed for type 2 diabetic patients, but so far no major differences in the pharmacoki-
netics of linagliptin between healthy volunteers and patients are known. 
The model development was performed in three steps. Firstly, it was investigated which 
typical model parameters of the Project 1 model (called M3 from here on) had to be 
adapted to describe the linagliptin concentrations of the reference treatment. In the second 
step, the impact of the ritonavir interaction on all typical model parameters of linagliptin 
was explored. Finally, the interindividual variability of the model parameters was investi-
gated. 
Firstly, all typical model parameters were fixed to M3 to investigate whether M3 can 
describe the reference treatment. Then, only one parameter at a time was estimated while 
all other parameters were fixed to M3. Based on the drop of the OBJF, it was decided 
which parameter adaptation resulted in the best description of the observations. This was 
repeated until no further estimated parameter led to a decrease in the OBJF of more than 
3.84 points. During the entire procedure the interindividual variability was fixed to 0. The 
adapted model is referred to as M4. 
The next step was to determine the parameter(s) that needed to be adapted to describe the 
linagliptin concentrations when linagliptin was coadministered with ritonavir. Test and 
reference treatment were analysed together. First, the typical model parameters were fixed 
to M4 to investigate whether the adapted model could describe the test treatment. Then, 
only one parameter was estimated separately for the test treatment, while all other parame-
ters were fixed to M4. Based on the drop of the OBJF it was decided which of the sepa-
rately estimated parameters resulted in the best description of the test treatment. This 
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procedure was again repeated until no additional estimated parameter led to a decrease in 
the OBJF of more than 3.84 points. This adapted model is called M5. 
Insufficient information was available to estimate all typical model parameters together. 
Thus, interindividual variability was estimated by fixing all typical model parameters to 
M5. Interindividual variability was tested sequentially on all model parameters keeping the 
variability resulting in the best description of the individual profiles. This procedure was 
repeated until no further improvement was achieved by adding interindividual variability.  
2.5.2.4.4 Model evaluation 
The model was evaluated using visual predictive checks and posterior predictive checks as 
described in section 2.3.4. For the posterior predictive checks Cmax and the area under the 
plasma concentration-time curve from time point 0 to infinity (AUC0-inf) were used as 
variables of interest. 
2.5.2.4.5 Simulation strategy 
The steady-state concentration-time profiles for both treatments, linagliptin alone and 
linagliptin in combination with ritonavir, were to be simulated based on the final popula-
tion pharmacokinetic model of Project 2d. Firstly, the typical model parameters were used 
to simulate the mean population profiles for a multiple dosing of linagliptin with and 
without ritonavir comedication. It was assumed that 5 mg of linagliptin was given once 
daily over seven days for both treatments. The simulations were performed with the Trial 
Simulator software. It was assumed that a full profile was taken at day 1 and day 7 with 
samples pre-dose, 15, 30, 45 min, and 1.0, 1.5, 2.0, 3.0, 5.0, 7.0, 9.0, 10.5, 12.0, and 24.0 h 
after linagliptin administration. In between, daily Ctrough levels were simulated. Secondly, 
1,000 profiles were simulated based on the specified study design and the population 
pharmacokinetic model including the interindividual and residual variability. These 
simulated 1,000 profiles were used to calculate the gMean of the area under the plasma 
concentration-time curve from time point 0 to 24 hours (AUC0-24h) and AUCτ,SS, and the 
gMean of Cmax,SD and Cmax,SS for a once daily treatment with 5 mg linagliptin, with and 
without ritonavir comedication. 
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2.5.3 Project 3: Covariate analysis 
2.5.3.1 Project 3a: Pharmacokinetic covariate analysis 
2.5.3.1.1 Objectives 
The objective of Project 3a, extending Project 1, was to characterise the nonlinear pharma-
cokinetics of linagliptin in a larger patient population with the main focus on investigating 
the impact of weight, sex and age on the pharmacokinetics of linagliptin. For these 
covariates, no dedicated phase I studies were planned. In addition, other covariates of 
clinical relevance for the pharmacokinetics of linagliptin were to be identified.  
2.5.3.1.2 Study design 
Project 3a was based on four clinical studies: two phase IIa studies with intensive pharma-
cokinetic sampling schemes and two phase IIb studies with sparse pharmacokinetic 
sampling. The phase IIa studies were also used in Project 1 and are described in section 
2.5.1.2 in detail. A description of the phase IIb studies is given in the following.  
The phase IIb studies (study III and study IV) were both randomised, double blind, 
placebo-controlled studies, each with four parallel treatment arms. In study III, 0.5, 2.5, or 
5 mg linagliptin or placebo were administered once daily over twelve weeks. In study IV, 
1, 5, or 10 mg linagliptin given once daily were tested versus placebo as add-on treatment 
to metformin. The treatment duration was again twelve weeks. The tablet formulation used 
in both studies was identical but differed from that investigated in study II. Table 2-2 
summarises the main characteristics of the four studies used within Project 3a. 
Table 2-2  Summary of studies used in Project 3 
Study Phase Formulations Doses [mg] Duration Number of patients 
treated with linagliptin 
(planned) 
Add-on to 
metformin 
I IIa Powder in Bottle 1, 2.5, 5, 10 12 days 36 No 
II IIa Tablet 1 2.5, 5, 10 4 weeks 60 No 
III IIb Tablet 2 0.5, 2.5, 5 12 weeks 225 No 
IV IIb Tablet 2 1, 5, 10 12 weeks 225 Yes 
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The studies were conducted at several centres throughout Europe, North America, and 
Australia. Ethics committees reviewed and approved the study protocols and the studies 
were conducted within the ethical standards established by the Declaration of Helsinki 
(150) and in accordance with applicable regulatory requirements. 
The sampling schemes of the phase IIa studies I and II are presented in section 2.5.1.2. In 
studies III and IV, the blood samples of linagliptin plasma concentration measurements 
were taken at four visits (definitions see below) – always before, 1 h (±0.5 h), and 2 h 
(±1 h) after the linagliptin administration. In addition, one sample was taken at a follow-up 
visit. In both phase IIb studies, some flexibility was allowed in scheduling the visits 
according to the following time windows. The time interval between the first (first 
linagliptin administration) and second visit was 28–35 days (i.e. 4–5 weeks), between the 
second and the third visit 28–35 days (i.e. 4–5 weeks), between the third and the fourth 
visit 28–35 days (i.e. 4–5 weeks), and between the fourth and the follow-up visit 14–21 
days (i.e. 2–3 weeks). The linagliptin plasma concentrations were determined as described 
in section 2.1.1. 
In both phase IIb studies, the patients had to record the actual administration date and time 
of the last three doses before a clinic visit on the patient visit card; this information was 
transferred to the CRF by clinic personnel. The actual date and time of administration at 
the clinic visit was recorded in the CRF by the clinic personnel. 
The demographic characteristics were determined at screening, and weight was also 
measured at visits 1 and 4. The laboratory values were measured at screening, at the 
beginning of the placebo run-in, and at the visits 1, 2, 4, and the follow-up visit. Fasting 
plasma glucose was determined at all clinic visits. Pre-dose DPP-4 activity was measured 
at visit 1 before the first administration of linagliptin. 
2.5.3.1.3 Modelling strategy 
The plasma concentrations of the phase IIb studies were to be analysed using the target-
mediated drug disposition model developed in Project 1 to allow a meaningful interpreta-
tion of the covariates. The sparse sampling scheme performed in phase IIb did not allow 
estimating all parameters of the model. Thus, the datasets from the phase IIa and IIb 
studies were combined to perform a well-founded covariate analysis based on a physio-
logically plausible model. The base population pharmacokinetic model previously 
developed in Project 1 served as a starting point for the modelling analysis. 
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Base model. At first, it was tested whether the population pharmacokinetic model of 
Project 1 could describe the plasma concentrations of studies III (phase IIb mono-therapy 
study) and IV (phase IIb add-on to metformin study). All model parameters were fixed to 
the population pharmacokinetic model of Project 1 and individual Bayesian estimates for 
both studies were obtained. The distribution of the Bayesian estimates around the typical 
parameters and the description of the concentration-time profiles were investigated 
separately per study.  
Then, the model parameters were estimated based on all four studies. A possible effect of 
metformin treatment on the linagliptin pharmacokinetics was investigated. Necessary 
adjustments were implemented into the model. In addition to the variability already 
implemented in the population pharmacokinetic model of Project 1 (i.e. interindividual 
variability on relative bioavailability, absorption rate constant, and concentration of 
binding partner in the central compartment, intraindividual variability on relative bioavail-
ability), interindividual variability on clearance, and the volumes of distribution were 
investigated. Because of the sparse data, no further intraindividual variability was tested. 
For the phase IIa studies, the occasions for intraindividual variability were defined in 
section 2.5.1.3. For the phase IIb studies, every visit in which linagliptin concentrations 
were measured was handled as a separate occasion, visit 4 and the follow-up visit were 
treated as one visit as both belonged to one administration. The residual variability was 
described by an additive residual variability model for log-transformed data corresponding 
approximately to a proportional residual variability model using untransformed data.  
Covariate model. Once the base model was established, the impact of the covariates was 
investigated. Which covariate was tested on which parameter is listed in Table 2-3. The 
covariate analysis was mainly performed as described in 2.3.1.3. Due to extensive run 
times and η-shrinkage (158), the standard approach was adapted as follows. To decrease 
the run time, the major part of the forward inclusion and backward elimination procedure 
was conducted separately per model parameter and all model parameters were fixed to the 
estimates of the base model except the investigated typical pharmacokinetic parameter, its 
variability and the typical parameter of the covariate effect. In addition, during the forward 
inclusion, the addition of a covariate was required to result in a drop of the OBJF value of 
at least 6.635 points (p≤0.01, χ2, 1 df) – instead of 3.84 (p≤0.05, χ2, 1 df) points in the 
standard approach – in order to be retained, otherwise the covariate was removed. A 
forward inclusion criterion closer to the backward elimination criterion was applied to 
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restrict the inclusion of covariates during the forward inclusion step to the more relevant 
ones. Due to the η shrinkage, the Bayesian estimates might be biased leading to misleading 
results of the explorative and GAM analysis. For this reason, the covariates age, sex, and 
weight, that were of special interest, as well as the covariates found in the initial covariate 
analysis of Project 1, were pre-defined to be tested in NONMEM. 
Table 2-3  Covariates investigated in Project 3a 
Model parameter Covariate 
All model parameters with 
interindividual variability 
Demographic information: age, weight, height, body mass index, body 
surface area, sex, ethnic origin, smoking and alcohol status 
study number, randomisation group 
Absorption parameters with 
interindividual variability 
Formulation 
Distribution and elimination 
parameters with interindividual 
variability (including binding 
parameters) 
Laboratory values: serum creatinine, creatinine clearance, urea, alanine 
transaminase, aspartate transaminase, alkaline phosphatase, gamma-
glutamyl transferase, total bilirubin, creatine kinase, cholesterol, C-
reactive protein, triglyceride, fasting plasma glucose 
metformin treatment, pre-dose DPP-4 activity in RFU 
 
Finally, the impact of the statistically significant covariates on the AUCτ,SS values was to 
be investigated to evaluate the clinical relevance of the covariates. These investigations 
were performed using the Berkeley Madonna software. For continuous covariates, the 
typical concentration-time profiles of a subject with the median or either of the extreme 
covariate values (5th and 95th percentiles of the covariate distribution) were simulated. For 
categorical covariates, these simulations were performed for each category. The AUCτ,SS 
values were calculated by integrating the typical concentration-time profiles directly using 
the Berkeley Madonna software. 
2.5.3.1.4 Model evaluation 
The description of the base model was investigated per study and dose group using a visual 
predictive check as described in 2.3.4.1. The final model was evaluated by a posterior 
predictive check performed per dose group as described in 2.3.4.2 using Cmax and Ctrough 
levels as variables of interest. 
2 Methods and studies   53 
 
 
2.5.3.2 Project 3b: Pharmacodynamic covariate analysis 
2.5.3.2.1 Objectives 
The objectives of this analysis were to characterise the relationship between linagliptin 
plasma concentration and plasma DPP-4 activity in type 2 diabetic patients and to identify 
clinically relevant covariates affecting this correlation.  
2.5.3.2.2 Study design 
Project 3b used the linagliptin plasma concentrations and DPP-4 activities of the same four 
clinical studies as Project 3a. The study designs are reported in sections 2.5.1.2 and 
2.5.3.1.2 in detail. DPP-4 activity was always measured at the same time points as the 
respective linagliptin plasma concentrations. Linagliptin plasma concentrations and plasma 
DPP-4 activity were measured as described in 2.1. 
2.5.3.2.3 Modelling strategy 
Initially, this analysis was planned to extend the population pharmacokinetic model 
developed in Project 3a. However, this was not possible due to the very long run time of 
more than five days of the population pharmacokinetic model. As the linagliptin plasma 
concentrations and the plasma DPP-4 activity were measured at the same time points and a 
direct relationship with no hysteresis observed graphically between both measurements, it 
was possible to correlate the linagliptin plasma concentrations directly to the DPP-4 
activity.  
For this covariate analysis, the dataset had to be changed as follows: The four single 
datasets were harmonised, merged, and re-organised to create a dataset containing plasma 
DPP-4 activity as dependent variable and the corresponding plasma linagliptin concentra-
tion measured at the same time points in a separate column. No dosing information was 
included into the dataset. For reasons unknown, linagliptin concentrations were measured 
for nine patients before any dose of linagliptin was administered. For these patients, all 
pre-dose information (linagliptin plasma concentration and plasma DPP-4 activity) was 
removed. For all other patients, a zero was implemented in the concentration column, when 
the dependent value column contained a pre-dose DPP-4 activity or when the patients were 
randomised to placebo. If the patients under linagliptin treatment contained either only a 
concentration measurement or only a DPP-4 activity at a certain time point the respective 
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data were not included in the dataset. All modifications were conducted with a user-written 
Splus script. 
Base model. A simple Emax model and a sigmoid Emax model were tested to describe the 
correlation between linagliptin plasma concentration and plasma DPP-4 activity. Interindi-
vidual variability in all the typical parameters was to be investigated. No intraindividual 
variability was investigated. 
Covariate model. Once the base model was established, the impact of the covariates was 
investigated. All covariates listed in 2.2.1.2, except formulation and pre-dose DPP-4 
activity were tested on all parameters exhibiting interindividual variability. The covariate 
analysis was performed as described in detail in section 2.3.3.3.  
Finally, the impact of the covariates on the model parameter EC50 as well as on the 
concentration leading to 80% inhibition of plasma DPP-4 was to be investigated in order to 
evaluate the clinical relevance of the covariate. These investigations were performed in 
Excel. For continuous covariates, the impact of the median and of the extreme covariate 
values (5th and 95th percentiles of the covariate distribution) on these parameters were 
determined. For categorical covariates, the impact of each category on the parameters was 
calculated. 
2.5.4 Project 4: Estimation of  the absolute bioavailability of  linagliptin 
2.5.4.1 Objectives 
The standard approach (159) to determine the absolute bioavailability is dividing the dose-
normalised AUCp.o. by the dose-normalised AUCi.v.. However, this standard approach is 
only valid if the clearance calculated by CL = F·D/AUC of a drug is constant. This is not 
the case for linagliptin. One possibility to determine the absolute bioavailability despite 
nonlinear pharmacokinetics is to develop a population pharmacokinetic model that 
accounts for the nonlinear process (160). This approach was used for linagliptin. 
2.5.4.2 Study design 
Project 4 analysed a single dose, randomised, placebo-controlled, parallel trial, conducted 
in healthy men. The study was single-blind in terms of treatment within dose groups. Three 
treatment groups (1, 2, and 4) received single intravenous doses of linagliptin at dose levels 
0.5, 2.5, and 10 mg. In treatment group 3, subjects underwent a two-way randomised cross-
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over design, separated by at least 25 days of wash-out, receiving 5 mg linagliptin intrave-
nously, and 10 mg linagliptin as a tablet. The study design is presented in Figure 2-1. 
 
Group 3: 5 mg linagliptin i.v.
Group 1: 0.5 mg linagliptin i.v.
Group 2: 2.5 mg linagliptin i.v.
Group 3: 5 mg linagliptin i.v.
Group 4: 10 mg linagliptin i.v.
Group 3: 10 mg linagliptin oral Group 3: 10 mg linagliptin oral
 
Figure 2-1  Study design of Project 4. 
Within groups 1, 2, and 4, six subjects received linagliptin and two subjects received 
placebo, respectively. In Group 3, ten subjects received linagliptin and two subjects 
received placebo. The intravenous solutions were administered as an infusion over a time 
period of 90 min. The study was conducted at PHAROS GmbH, Pharmaceutical Research 
Outsourcing, Ulm. Ethics committees reviewed and approved the study protocols and the 
study was conducted within the ethical standards established by the Declaration of Helsinki 
(150) and in accordance with applicable regulatory requirements. 
Plasma samples for pharmacokinetic assessments were taken pre-dose and at 30, 60, 90 
(end of infusion), 92, 95, 100, 105 min, 2.0, 2.25, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 12.0 and 
24.0 h after start of the infusion, as well as pre-dose and at 15, 30, 45 min, 1.0, 1.5, 2.0, 
3.0, 4.0, 6.0, 8.0, 12.0, and 24.0 h after oral administration. In addition, plasma samples 
were taken on days 3, 4, 5, 6, 8, and 9, when subjects attended the study unit for walk-in 
visits. Linagliptin plasma concentrations were determined as described in section 2.1.1. 
Compliance was guaranteed by administration of the study medication under the supervi-
sion of the investigating physician or a designee on all study days.  
2.5.4.3 Modelling strategy 
The model development was performed in a stepwise manner. Firstly, it was investigated 
whether the model structure of Project 1 was also adequate to describe the linagliptin 
plasma concentrations after intravenous administration or whether adaptations were 
necessary. Then, the plasma concentrations after oral administration were added and both 
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datasets were analysed simultaneously to estimate the absolute bioavailability of lina-
gliptin. 
In order to test whether the model structure of Project 1 was also valid to describe plasma 
concentrations after intravenous administration, a bottom-up approach was used. First, it 
was tested whether a one-, two-, or three-compartment model could describe the linagliptin 
plasma concentrations after intravenous administration and whether incorporating concen-
tration-dependent binding in the central or the central plus a peripheral compartment 
improved the description of the data. The way the binding was implemented in the model 
is described in detail for Project 1. When the plasma concentrations after oral administra-
tion were added, the disposition of linagliptin was assumed to be identical between 
intravenous and oral data. To model the absorption of linagliptin a first-order process with 
lag-time was used. The stochastic model was investigated as described in 2.3.3.2.2.  
2.5.4.4 Model evaluation 
The evaluation of the population pharmacokinetic model was performed using a visual 
predictive check as described in section 2.3.4.1.  
2.5.5 Project 5: Model-based pharmacokinetic analysis of  linagliptin in 
wildtype and DPP-4-deficient rats 
2.5.5.1 Objective 
The objective of Project 5 was to test the hypothesis that concentration-dependent binding 
of linagliptin to its target DPP-4 in plasma and tissue has a major impact on the pharma-
cokinetics of linagliptin. This was to be tested by comparing the pharmacokinetics of 
linagliptin in wildtype and DPP-4-deficient rats using a model-based analysis. The model 
was to describe the pharmacokinetics in both rat strains simultaneously by possibly 
accounting for concentration-dependent binding of linagliptin to DPP-4 only in wildtype 
rats. This pharmacokinetic model was used for further simulations illustrating the impact 
of target-mediated drug disposition on the pharmacokinetics of linagliptin.  
2.5.5.2 Study design 
Single intravenous doses of 0.01, 0.1, 0.3, 1, 3, 10, and 50 mg/kg of [14C]linagliptin were 
administered to male DPP-4-deficient or wild-type Fischer rats in a parallel group design. 
In each dose group, four DPP-4-deficient and four wildtype animals were included, except 
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for the 0.01 mg/kg dose level which was not investigated in DPP-4-deficient rats due to the 
limit of quantification of the linagliptin assay and the expected very low plasma levels. The 
study was conducted by the group Nonclinical Pharmacokinetics, Boehringer Ingelheim. 
Radiolabelled linagliptin was used because post mortem tissue radioactivity was measured 
to quantify tissue concentrations from the same animals (161). These concentrations were 
not used for the pharmacokinetic model. 
Male wildtype Fischer rats of the strain F344/DuCrl were supplied by Charles River, 
Germany and DPP-4-deficient male Fischer rats of the strain F344/DuCrlCrlJ were 
supplied by Charles River, Japan. In the latter, only a mutant and enzymatically inactive 
form of the DPP-4 protein is initially synthesised, that is not further processed to the 
mature DPP-4 and rapidly degraded (81,82). 
The compound was dissolved in a small volume of 0.1 M hydrochloric acid and further 
diluted with sterile 0.9% NaCl solution to the final concentration. The formulation was 
administered as a single bolus injection into a lateral tail vein.  
Blood samples were taken from the sublingual vein under isoflurane anaesthesia 2 and 
5 min, as well as 1, 4, 8, 24, 48, and 72 h after administration. Total linagliptin plasma 
concentrations (labelled and unlabelled compound) were determined as described in 
section 2.1.1.  
2.5.5.3 Modelling strategy 
Only the dose groups 0.01–1 mg/kg were included in the model-based analysis, as a 
DPP-4-related difference was mainly obvious for these doses. At higher dose groups a 
second nonlinearity with a more than dose-proportional increase in exposure was found in 
both rat strains. This second nonlinearity is most likely not relevant for the therapeutic 
concentration range and was therefore not further investigated. 
The analysis was carried out in a stepwise manner. Firstly, it was investigated which model 
adequately described the linagliptin plasma concentration in DPP-4-deficient rats. Due to 
the linear pharmacokinetics of linagliptin in DPP-4-deficient rats in the investigated dose 
range (0.1–1 mg/kg), only linear one-, two-, and three-compartment models were tested. In 
the second step, the plasma concentrations from DPP-4-deficient rats and wildtype rats 
were analysed together. This analysis was performed under the assumption that the 
distribution and elimination of linagliptin were identical in both rat strains, with the 
exception of concentration-dependent binding to DPP-4 which was only existent in wild-
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type rats. Thus, the pharmacokinetic model derived from DPP-4-deficient rat data was 
expanded to include saturable binding in either the central and/or the peripheral 
compartment(s) in order to test which model adequately described the plasma 
concentrations of wild-type animals. During model development, the DPP-4 independent 
parameters were fixed to those from the DPP-4-deficient rat model. In the final model, all 
parameters were estimated simultaneously.  
The concentration-dependent binding was implemented into the model as described in 
Project 1. For the final model structure, the assumption of quasi-equilibrium conditions for 
the binding of linagliptin to DPP-4 was tested. In the quasi-equilibrium model, it was 
assumed that the binding equilibrium was reached faster than all other processes, requiring 
only an estimation of the state of equilibrium by means of the dissociation constant (Kd). 
When the assumption of quasi-equilibrium conditions was abandoned, a description of the 
binding equilibrium by means of the association rate constant (KON) and the dissociation 
rate constant (KOFF) was required, with Kd = KOFF/KON. Because of the difficulty in 
precisely estimating KON and KOFF together (152), the KOFF value was fixed to the value of 
0.108 h−1 determined in vitro (101).  
2.5.5.4 Model evaluation 
The models were evaluated using goodness-of-fit plots. In addition, the model parameters 
for CL, central volume of distribution (VC), and VSS of unbound linagliptin were compared 
to those calculated by the noncompartmental analysis for DPP-4-deficient rats. The model-
estimated binding parameters were compared to those derived by an equilibrium plasma 
protein binding study (162). 
2.5.5.5 Simulation strategy 
The final pharmacokinetic model, which describes the pharmacokinetic profiles of DPP-4-
deficient rats and wildtype rats simultaneously, was used for simulations to further 
characterise the impact of the target-mediated drug disposition on the pharmacokinetics of 
linagliptin in wildtype rats. The simulations were performed using the Berkeley Madonna 
software. The time courses of total linagliptin concentration and the DPP-4 bound concen-
tration in the central compartment, as well as the time course of linagliptin in the peripheral 
compartment(s) in wildtype and DPP-4-deficient rats were simulated. In addition, the 
influence of altered amounts of binding partner in the central and peripheral compartments 
(±50% each) on the total linagliptin plasma concentration, the unbound plasma concentra-
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tion, and the fraction of DPP-4 bound to linagliptin (i.e. occupancy) were investigated for 
wildtype animals. 
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3 Results 
3.1 Project 1: Population pharmacokinetic/pharmaco-
dynamic analysis of  linagliptin in type 2 diabetic patients  
The objective of this project was to characterise the nonlinear pharmacokinetics of 
linagliptin and the relationship between its pharmacokinetics and the DPP-4 activity in 
type 2 diabetic patients.  
The analysis was based on studies I and II, two multiple dose phase IIa studies with 47 and 
77 type 2 diabetic patients, respectively. The vast majority of patients was male, only five 
female patients participated in study II. The mean ages of patients were 56.0 (range: 36–
65) and 60.1 (range: 40–69) years, and the mean body mass indices were 28.6 (range: 
22.4–34.6) and 28.8 (range: 20.4–34.9) kg/m2, respectively. Only Caucasian patients were 
included in the trials. The distribution of all covariates and the correlation between the 
covariates are summarised in the Appendix, Tables 4 and 5, as well as Figures 1 and 2, 
respectively. As the fraction of females included into the studies was less than 10%, sex 
was not tested as a covariate. No unexpected correlations between the covariates were 
observed (Appendix, Figures 1 and 2). 
The dataset comprised 3,210 pharmacokinetic observations, i.e. plasma samples with a 
valid measurement of linagliptin plasma concentrations above the limit of quantification, 
from 96 patients. One patient in study II, randomised to 5 mg linagliptin treatment, was 
withdrawn from the study for safety reasons (ventricular extra systoles) after the first 
linagliptin administration (163). The distribution of the numbers of patients and pharma-
cokinetic observations per dose group is presented in the Appendix, Table 6. As 1 mg 
linagliptin was tested only in study I, this dose group contained less patients and pharma-
cokinetic observations compared to the other dose groups. The individual linagliptin 
plasma concentration-time profiles per study and dose group are shown in the Appendix, 
Figure 3. Linagliptin exhibited nonlinear pharmacokinetics with a less than dose-
proportional increase in the linagliptin plasma concentration-time profiles (104). The 
pharmacokinetic profiles indicate the low and dose-dependent accumulation of linagliptin 
as described in section 1.3.2.2. Surprisingly, the profiles in study II were higher compared 
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to those of study I when the same doses were compared, especially in the higher dose 
levels, although the formulations had been tested to be bioequivalent in a separate study. 
A total of 4,350 plasma DPP-4 activities from 124 patients were included in the dataset. 
The distribution of DPP-4 activity per dose group is presented in Appendix, Table 6. Again 
the 1 mg dose group contained less observations compared to the other dose groups. No 
DPP-4 activity measurement was removed from the dataset. Linagliptin led to a dose-
dependent inhibition of DPP-4 with a more than 80% steady-state DPP-4 inhibition over 
24 h in the 5 and 10 mg dose groups (Appendix, Figure 4). The linagliptin plasma concen-
trations and the plasma DPP-4 activity were well correlated in a sigmoid manner with a 
steep concentration-effect relationship (Figure 3-1). 
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Figure 3-1  Correlation between linagliptin plasma concentration and plasma DPP-4 activity for 
studies I and II. Placebo and pre-dose observations not shown due to logarithmic scale. 
3.1.1 Model development 
3.1.1.1 Pharmacokinetic base model 
Linear one-, two-, and three-compartment models with first-order absorption and elimina-
tion failed to adequately describe the pharmacokinetics of linagliptin. A linear two-
compartment model was significantly better than a linear one-compartment model (∆OBJF 
−4,423.619) and not inferior compared to a linear three-compartment model (∆OBJF 0). 
Including one concentration-dependent binding process in the central compartment of a 
   62 3 Results 
two-compartment model improved the model fit significantly (∆OBJF −2,682.855) and 
was superior to the implementation of a saturable absorption into a two-compartment 
model (∆OBJF −112.003). Adding a second concentration-dependent binding process with 
equal binding affinity in the peripheral compartment resulted in a significantly better 
description of the plasma concentration-time profiles (∆OBJF −142.92), while adding a 
second peripheral compartment did not improve the model fit (∆OBJF 0). Adding the 
second peripheral binding partner to the central compartment, i.e. assuming that linagliptin 
binds without a distribution process to this second binding partner and linagliptin bound to 
this second binding partner is not longer measurable in plasma, did likewise not improve 
the model fit (∆OBJF 0). Thus, the nonlinear pharmacokinetics of linagliptin was best 
described by a two-compartment model with concentration-dependent protein binding in 
the central and the peripheral compartment (Figure 3-2).  
Interindividual variability was tested on all pharmacokinetic model parameters in a 
stepwise manner and implemented on the relative bioavailability, the absorption rate 
constant and the concentration of the central binding partner. Intraindividual variability 
was tested on these three parameters as well as on clearance, and was found necessary to 
be implemented on the relative bioavailability. Addition of further inter- or intraindividual 
variability on other parameters of the population pharmacokinetic model did either not 
result in a better description of the plasma concentrations or decreased the stability of the 
model. The residual variability was adequately described by an additive residual variability 
model for the log-transformed plasma concentrations (proportional residual variability 
model for untransformed data). The parameter estimates of the pharmacokinetic base 
model are presented in Table 3-4. 
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Figure 3-2  Structure of the final population pharmacokinetic model of Project 1. The pharmacoki-
netic model of linagliptin accounts for concentration-dependent and reversible binding of linagliptin 
to DPP-4 in plasma and in peripheral tissues. ´Linagliptin bound´ refers to linagliptin bound 
specifically and concentration-dependently to DPP-4. ´Linagliptin unbound´ refers to free linagliptin 
as well as to linagliptin bound non-specifically and non-saturably to proteins. The total linagliptin 
plasma concentration is the sum of unbound and bound linagliptin concentration in the central 
compartment. F, relative bioavailability; Ka, absorption rate constant; VC/F, apparent central volume 
of distribution; VP/F, apparent volume of distribution of the peripheral compartment; QP/F, apparent 
intercompartmental clearance between central and peripheral compartment; CL/F, apparent 
clearance; Bmax,C, concentration of binding partner in the central compartment; Amax,P/F, apparent 
amount of binding partner in the peripheral compartment; Kd, dissociation constant.  
3.1.1.2 Identifiability of the pharmacokinetic model 
Due to the complexity of the pharmacokinetic model, it was to be investigated whether the 
proposed model structure is identifiable given the available data. Structural identifiability 
is the ability of a model to uniquely estimate all parameters given ideal, error-free data. 
Deterministic or numeric identifiability is the ability of a model to uniquely estimate all 
parameters given actual, non-ideal data (140). Different methods were used in the follow-
ing to investigate whether the structure of a two-compartment model with two concentra-
tion-dependent bindings, one in the central and the other in the peripheral compartment, 
was structurally and numerically identifiable, paying particular attention to the identifiabil-
ity of the two binding partners. 
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3.1.1.2.1 Influence of binding on plasma pharmacokinetic profiles  
First, the influence of variations in the amount of the binding partner in the central and in 
the peripheral compartment on the plasma concentration-time profiles was investigated. 
This was done on the premise that perturbance in a model parameter must have an effect 
on the resulting plasma concentration-time profiles for the parameter to be estimated by the 
model. Changes in Bmax,C affected the concentration-time profiles of all dose groups 
(Figure 3-3, upper panels). 
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Figure 3-3  Predicted influence of altered (50%, solid line; 100% (original value), dotted line; 150%, 
dashed line) amounts of central (upper panels) and peripheral (lower panels) binding partner on the 
plasma concentration-time profiles for the treatment with 1 (left panels) and 10 mg (right panels) 
linagliptin once daily. Due to the small impact of altered amounts of peripheral binding partner on 
the plasma concentration-time profiles, the three profiles partly overlap (lower panels). 
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In contrast, changes in the amount of the binding partner in the peripheral compartment 
(Amax,P) affected the 1 mg dose group predominantly, but to a lesser extent (Figure 3-3, 
lower panels). The same trend was observed with regard to the log-likelihood profiles 
(Appendix, Figure 5): Bmax,C was estimated more precisely, with a relative standard error 
(RSE) of 3.3%, than Amax,P (RSE 10.0%). Taken together, both analyses suggest that the 
binding in both compartments is identifiable. 
3.1.1.2.2 Simulation and re-estimation 
Whether linagliptin actually binds to a peripheral binding partner has not been experimen-
tally proven thus far. With the following approach it was tested, whether in a simulated 
scenario for which the existence or non-existence of a peripheral binding is known, the 
model has the ability to identify the correct scenario. Thus, concentration-time profiles 
were simulated based on the given study design (study I) and two different simulation 
scenarios (S1, S2) with the binding partner being available only in the central (S1) or in 
both (S2) compartments (Figure 3-4). In the next step, each dataset was re-estimated 
assuming either binding only in the central compartment (M1) or in both compartments 
(M2). The re-estimations for S1 showed that in 69 out of 70 cases, M2 was not superior to 
M1 and thus the model was correctly identified (Figure 3-4, left flow chart). In contrast, 
the re-estimations for S2 showed that in 100% of the simulated datasets M2 was superior 
to M1 (Figure 3-4, right flow chart). Hence the correct model was chosen for both 
scenarios. 
PB
PB PB PB
PB PB
PB PB PB
98.6% 1.4% 0.0% 100%
S1
M2M1 M2M1
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Figure 3-4  Schematic representation of both simulation (S1, S2) and re-estimation (M1, M2) 
scenarios. PB, concentration-dependent protein binding. 
In Table 3-1 the inaccuracy and imprecision of the re-estimated parameters are presented 
when model M2 was used to re-estimate scenario S2. All population parameters were re-
estimated accurately and with an adequate precision, suggesting that the model in general, 
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and the peripheral binding in particular are identifiable. Again, the standard deviation of 
the typical population estimates indicated that Bmax,C was estimated more precisely than 
Amax,P (6.5% versus 22.9%). 
Table 3-1  Inaccuracy and imprecision of the re-estimated parameters using model M2 (estimated 
assuming binding in the central and the peripheral compartment) and simulation scenario S2 
(simulated assuming binding in the central and the peripheral compartment) 
  Ka VC QP VP CL Bmax,C Kd Amax,P ωF ωKa ωBmax,C σprop 
Parameters used 
in the simulation 
0.710 701 422 1,980 225 4.34 0.0706 1,630 0.183 0.348 0.0428 0.08 
Inaccuracy [%]1) -0.01 +4.4 +4.6 +0.8 +3.1 +0.4 +6.0 +2.5 -10.0 -11.5 +0.9 -0.4 
Imprecision [%]2) 11.8 9.0 13.3 16.9 17.7 6.5 9.6 22.9 37.5 26.1 26.2 4.7 
1)
 Inaccuracy was determined as the percent deviation of the re-estimated mean value from the parameter 
estimate used in the simulation. 
2)
 Imprecision was calculated as the coefficient of variation of the re-estimated parameters. 
 
3.1.1.2.3 Fisher-Information-Matrix 
In a third test, the identifiability of the model parameters was investigated using the Fisher-
Information-Matrix. The determinant of the Fisher-Information-Matrix was 1.52·1023 and 
thus far from zero, suggesting that the model is structurally identifiable (Prof. Stephen 
Duffull, personal communication). The relative standard errors calculated based on the 
Fisher-Information-Matrix are given in Table 3-2. The binding parameters Bmax,C and 
Amax,P were supposed to be determined precisely given the investigated study design, with 
relative standard errors of 4% and 26%, respectively. Interestingly, omitting the 1 mg dose 
group increased the relative standard errors for Amax,P from 26% to 56%. This shows that 
due to the nonlinear pharmacokinetics, a range of doses is required to reliably estimate all 
parameters, e.g. low doses were most informative for the estimation of the peripheral 
binding partner. 
Table 3-2  Relative standard errors determined by the Fisher-Information-Matrix 
  Ka VC QP VP CL Bmax,C Kd Amax,P ωF ωKa ωBmax,C σprop. 
RSE [%] 11.8 8.4 8.9 12.9 7.6 3.9 15.9 25.8 25.1 33.1 24.4 4.0 
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3.1.1.3 Pharmacokinetic/pharmacodynamic base model  
A descriptive sigmoid Emax model fitted the DPP-4 activities adequately and was superior 
to a simple Emax model (∆OBJF −3781.156, Emax estimate near the boundary (100%) in the 
simple Emax model). In addition, two semi-mechanistic models were tested, an Emax model 
using CUplasma and a model linking the occupancy, i.e. the fraction of DPP-4 molecules 
bound to linagliptin, proportionally to the DPP-4 activity. The CUplasma as well as the 
occupancy were both estimated in the pharmacokinetic part of the model. In the Emax 
model using CUplasma very similar values for Kd and EC50 were estimated (Kd: 0.0738 nM, 
EC50: 0.0723 nM). Both models described the DPP-4 activities equally well (∆OBJF 
−0.306). Thus, based on the principle of parsimony, the simpler occupancy model was 
selected for further development. The performance of the descriptive sigmoid Emax model 
was compared to the occupancy model. As both models were not nested, a comparison 
based on the OBJF was not possible. The occupancy model was chosen as final model for 
the following reasons: (a) standard goodness-of-fit plots were similar for both models, (b) 
the occupancy model required two parameters less, (c) the residual variability for pharma-
cokinetics and pharmacodynamics was higher in the descriptive sigmoid Emax model, (d) 
relating the DPP-4 activity to the DPP-4 occupancy is in line with the hypothesis that the 
saturable binding observed in plasma was due to the binding of linagliptin to DPP-4. 
The only pharmacodynamic parameter in the occupancy model was Emax. Interindividual 
variability on Emax was estimated to be very low (<2%) and was therefore not implemented 
into the model. The residual variability was adequately described by a proportional 
residual variability model; adding an additive variability model was not supported by the 
data. The parameter estimates of the base population pharmacokinetic/pharmacodynamic 
model are shown in Table 3-4. 
3.1.1.4 Covariate selection  
The covariate analysis was performed as described in section 2.3.3.3. The covariates pre-
selected by graphical exploration and by GAM analysis are listed in Table 3-3. The 
preselected covariates and the predefined covariates listed in section 2.5.1.3 were then 
tested in NONMEM using the forward inclusion backward elimination procedure. The 
statistically significant covariates depicted by this procedure are presented in Table 3-3.  
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Table 3-3  Covariates selected during the different phases of the covariate screening process 
 
Graphical exploration GAM analysis Forward inclusion and 
backward elimination 
procedure in NONMEM 
Bioavailability Study/formulation Study/formulation, age Study/formulation 
Rate of absorption Study/formulation, 
dose group 
Alanine transaminase, 
triglycerides, alcohol status, 
dose group 
Dose group 
Concentration of 
central binding partner 
Baseline DPP-4 
activity (raw data) 1) 
Aspartate transaminase, 
alkaline phosphatase, dose 
group, triglycerides, C-
reactive protein, baseline 
fasting plasma glucose 
Aspartate transaminase 
Apparent volumes of 
distribution 
NA NA None 
Apparent clearance NA NA Alanine transaminase 
1)
 Not tested in GAM and NONMEM to allow the detection of otherwise hidden correlations between the 
concentration of central binding partner and laboratory values, e.g. liver enzymes 
NA, not applicable 
 
The effects of the covariates on the linagliptin plasma concentration- and plasma DPP-4 
activity-time profile were small. The following covariates were statistically significant but 
not included into the final covariate model for the stated reasons: The absorption rate 
constant decreased with increasing dose. This effect was predominantly observed for the 
powder in the bottle formulation (study I) and not for the tablet (study II) which is the 
intended formulation for further development. The concentration of the central binding 
partner increased with increasing aspartate transaminase values. However, this relationship 
was driven by only four data points. The unbound clearance was slightly increased with 
increasing aspartate transaminase values. Physiologically, an increase of alanine transami-
nase, suggesting a deterioration of the hepatic function, is expected to correlate with a 
decrease of the clearance.  
Thus, the only covariate impact remaining in the final covariate model was a 30% decrease 
of bioavailability in study I compared to study II. Due to the different formulations in both 
studies, different inter- and intraindividual variabilities were implemented. As the interin-
dividual variability in bioavailability in study I could not be estimated precisely (RSE 
353%), it was fixed to zero and only intraindividual variability was implemented. All 
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covariates mentioned in the previous paragraph were predefined to be tested in NONMEM 
together with the phase IIb data (Project 3a). 
3.1.2 Final model 
Supporting the initial hypothesis, that concentration-dependent binding of linagliptin to 
DPP-4 is responsible for the nonlinear pharmacokinetics of linagliptin, the plasma 
concentration-time profiles were best described by a two-compartment model with 
concentration-dependent binding in the central and the peripheral compartments (Figure 
3-2). The compound reaches the central compartment by a first-order process. In the 
central compartment, the unbound compound either binds competitively and reversibly to a 
high affinity, low capacity binding partner, is eliminated via a first-order process, or is 
distributed to the peripheral compartment. In the peripheral compartment the compound 
can again bind competitively and reversibly to a high affinity, low capacity binding partner 
which has the same binding affinity for the compound as the one in the central compart-
ment. The population pharmacokinetic/pharmacodynamic model was based on the 
assumption that the high affinity, low capacity binding partner in the population pharma-
cokinetic model reflects DPP-4. In line with this assumption, the individual estimates for 
the concentration of binding partner in the central compartment correlated well with the 
pre-dose DPP-4 activity raw data (Figure 3-5). 
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Figure 3-5 Individually estimated concentrations of the central binding partner (most likely DPP-4) 
versus pre-dose DPP-4 activity in RFU 
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Plasma DPP-4 activity was incorporated into the model in a semi-mechanistic way using 
Clark's receptor occupancy theory, which states that drug effect is proportional to occu-
pancy. The more linagliptin is bound to DPP-4, the lower is the DPP-4 activity until all 
DPP-4 molecules are blocked by linagliptin and the maximal effect is reached.  
The parameter estimates of the final population pharmacokinetic/pharmacodynamic model 
are presented in Table 3-4. The apparent clearance estimated by the model refers to the 
CL/F of unbound linagliptin. This clearance is independent of dose within the investigated 
dose range. CL/F was estimated to be high (220 L/h) indicating that linagliptin not bound 
to DPP-4 is efficiently eliminated. Likewise, the apparent volumes of distribution 
calculated by the model refer to unbound linagliptin. These values were estimated to be 
570 L for the central volume of distribution and 2,090 L for the peripheral volume of 
distribution, showing that unbound linagliptin is still widely distributed. Bmax,C was 
estimated to be 4.62 nM which is within the range expected for the plasma DPP-4 
concentration (79,80). The model-estimated dissociation constant for the concentration-
dependent binding was 0.0738 nM and is thus in good agreement with the dissociation 
constant obtained in vitro from plasma samples employing equilibrium dialysis (Kd: 
0.05 nM, as calculated by Kd = 1/K1) (162). In line with the observed linagliptin 
concentration-time profiles (Appendix, Figure 3), a lower bioavailability was found for 
study I during the covariate analysis. This was accounted for by estimating a separate 
bioavailability in each study. 
Interindividual variability could be established for the parameters bioavailability (F), 
absorption rate constant (Ka), and Bmax,C, and intraindividual variability could be estimated 
for F. The inter- and intraindividual variability ranged between 18.9% and 60.8% 
(Table 3-4). The residual variability of the log-transformed linagliptin concentrations was 
modelled using an additive random effect model corresponding approximately to a 
proportional model for untransformed data. It was estimated to be low (16.0%, Table 3-4). 
The residual variability for the DPP-4 activity was adequately described by a proportional 
random effect model and was also estimated to be low (17.4%, Table 3-4).  
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Table 3-4  Parameter estimates of the base pharmacokinetic and pharmacoki-
netic/pharmacodynamic model and the final model 
  PK Base Model PK/PD Base Model PK/PD Final Model 
 Unit Estimate RSE [%] Estimate RSE [%] Estimate RSE [%] 
Typical Parameter     
F study I/II  % 100 fixed NA 100 fixed NA 69.8/100 fixed 7.28/NA 
Ka  h-1 0.845 13.0 0.631 8.59 0.633 8.29 
VC/F  L 776 12.2 648 7.48 570 10.4 
QP/F L/h 412 16.2 508 12.9 446 12.3 
VP/F L 1,650 10.6 2,390 8.33 2,090 8.09 
CL/F L/h 289 11.9 251 6.53 220 7.36 
Bmax,C nM 4.85 5.15 4.62 2.27 4.62 2.29 
Kd nM 0.0652 9.88 0.0738 7.06 0.0738 7.80 
Amax,P/F nmol 1,650 12.7 2,170 12.9 1,900 11.2 
Emax  % NA NA 93.5 0.24 93.5 0.24 
Inter- and intraindividual variability    
ωF study I/II CV% 32.7 22.1 37.3 21.2 NA/37.3 NA/23.1 
ωKa CV% 57.6 16.9 60.7 13.1 60.8 13.0 
ωBmax,C CV% 20.2 18.9 18.8 14.7 18.9 14.7 
piF study I/II CV% 34.6 26.5 30.2 19.0 34.1/33.0 16.1/23.7 
Residual variability      
σprop,PK
1)
 % 14.1 3.66 16.0 3.89 16.0 3.89 
σprop,PD % NA NA 17.3 7.91 17.4 7.88 
1)
 Estimated on log-transformed data 
NA, not applicable 
 
The parameters of the final model were estimated with good precision (relative standard 
errors ranging from 0.24–23.7% for the final model, cf. Table 3-4). The goodness-of-fit 
plots in Appendix, Figure 6 and Figure 7 indicate that the population pharmacoki-
netic/pharmacodynamic model described the linagliptin plasma concentrations and plasma 
DPP-4 activity adequately, except for an under-prediction of a few Cmax values. 
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3.1.3 Model evaluation 
For the evaluation of the final population pharmacokinetic/pharmacodynamic model, a 
visual predictive check was performed. Generally there was a good agreement between the 
simulated and the observed linagliptin plasma concentrations and DPP-4 activities 
(Appendix, Figures 8 and 9). The model slightly over-estimated the variability of DPP-4 
activity and the inhibitory effect in the 1 mg dose group.  
3.1.4 Simulation 
Typical concentration-time profiles for a daily administration of 5 mg linagliptin, which is 
the therapeutic dose tested in the clinical phase III programme, were simulated. According 
to these simulations the total AUCτ,SS is composed to the greater part (~70%) of linagliptin 
bound to DPP-4, while only the smaller fraction is not bound to DPP-4 (Figure 3-6, left 
panel). This results in a target-mediated drug disposition that has to be taken into account 
in the interpretation of the linagliptin pharmacokinetics. Simulations showed that the 
steady-state occupancy is >90% over 24 h for both the 5 mg and the 10 mg dose group 
(Figure 3-6, right panel). 
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Figure 3-6  Left panel: Predicted linagliptin plasma concentration-time profiles for bound (dotted 
line) and total (solid line) linagliptin following a once daily 5 mg linagliptin administration. Right 
panel: Predicted time profile of the occupancy of plasma DPP-4 with linagliptin for the four 
investigated dose groups, 1, 2.5, 5 and 10 mg linagliptin, following a once daily linagliptin admini-
stration. 
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3.2 Project 2: Clinical trial simulations to support the 
development of  linagliptin 
3.2.1 Project 2a: Simulation to evaluate an equivalent dose for a twice-
daily administration  
The objective of this project was to determine the optimal dose for a twice-daily admini-
stration of linagliptin that is bioequivalent with regard to steady-state exposure (AUC24h,SS) 
and shows similar steady-state DPP-4 inhibition as a 5 mg dose given once daily.  
The simulation using the base pharmacokinetic/pharmacodynamic model of Project 1 
indicated that despite the nonlinear pharmacokinetics, administering 2.5 mg linagliptin 
twice daily can be expected to result in a very similar exposure and DPP-4 inhibition 
compared to 5 mg linagliptin once daily (Figure 3-7). The corresponding AUC24h,SS values 
were 147.1 nM·h for the 5 mg linagliptin once daily (qd) regimen and 116.4, 128.2, 138.4, 
and 148.0 nM·h for 1, 1.5, 2, and 2.5 mg linagliptin twice daily (bid), respectively.  
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Figure 3-7  Predicted typical plasma concentration- (left panel) and plasma DPP-4 activity- (right 
panel) time profiles at steady-state of 1, 1.5, 2, and 2.5 mg linagliptin given twice daily (grey lines) 
in comparison to 5 mg linagliptin given once daily (black line). 
In addition, a clinical trial simulation was performed in order to predict the outcome of a 
relative bioavailability study testing 5 mg linagliptin once daily (treatment A) versus 
2.5 mg twice daily (treatment B). Table 3-5 lists the mean of 1,000 simulated geometric 
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mean (+ gCV) AUC24h,SS values per sequence and treatment. According to the results of 
the simulation, the exposures at steady-state for treatments A and B are expected to be 
independent of the tested treatments. In addition, no obvious sequence effect was visible, 
indicating that a seven day period in the change-over design would be sufficiently long.  
Table 3-5  Mean of the geometric mean (+gCV) AUC24h,SS values per sequence and treatment of 
1,000 simulated relative bioavailability studies testing 5 mg linagliptin once daily versus 2.5 mg 
twice daily. 
 Treatment A 
(5 mg linagliptin once daily) 
Treatment B 
(2.5 mg linagliptin twice daily) 
 Mean gMean [nM·h] Mean gCV [%] Mean gMean [nM·h] Mean gCV [%] 
Sequence AB 149.97 21.02 151.08 21.03 
Sequence BA 149.81 20.71 150.43 20.70 
 
The mean of the gMean ratios between the AUC24h,SS of treatment A and treatment B was 
100.90% (90% confidence interval 91.90%–110.80%) for the 1,000 simulated trials. Of the 
1,000 simulated trials only one confidence interval was outside the acceptance interval of 
0.80–1.25. These simulations clearly supported the use of 2.5 mg linagliptin as adequate 
dose of a twice-daily treatment. 
3.2.2 Project 2b: Simulation to evaluate the impact of  impaired 
clearance 
The objective of Project 2b was to investigate the impact of an impaired renal clearance on 
the nonlinear pharmacokinetics of linagliptin.  
The typical linagliptin plasma concentration- and plasma DPP-4 activity-time profiles 
following 5 mg linagliptin once daily were simulated under the assumption that the 
clearance of unbound linagliptin is as originally estimated in Project 1 or decreased by 
25% and 50% (Figure 3-8). The simulation revealed that for patients with only 75% or 
50% of the clearance of a typical patient, the exposure of linagliptin would in average 
increase by 11% or 31%, respectively. The increased linagliptin exposure is predicted to 
result in a slightly higher DPP-4 inhibition (Figure 3-8, right panel).  
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Figure 3-8 Prediction of the typical linagliptin plasma concentration- and plasma DPP-4 activity-
time profiles following 5 mg linagliptin once daily under the assumption that the clearance of 
unbound linagliptin is as originally estimated in Project 1 or decreased by 25 and 50%. 
3.2.3 Project 2c: Simulation of  a design for a dose-proportionality 
study 
The objective in Project 2c was to determine the treatment duration required for a change-
over study to assess dose-proportionality of different dose strengths of linagliptin tablets 
(1, 2.5, and 5 mg) at steady-state. 
The simulations based on the final model of Project 1 suggested that steady-state is 
achieved by day 5 in all investigated dose groups in every tested scenario (Figure 3-9). 
Steady-state was reached first in the highest dose group (5 mg) and the time to steady-state 
increased with decreasing doses. Within the simulated 1 mg dose group, steady-state was 
reached latest when linagliptin is administered in the first period. For this treatment group, 
the time to reach steady-state was predicted to be approximately five days. Thus, adminis-
tering linagliptin over seven days is predicted to assure steady-state in each sequence. In 
summary, the simulation suggested that the proposed randomised change-over design in 
which 1, 2.5, and 5 mg linagliptin are administered once daily over seven days is adequate 
to compare the steady-state profiles of the investigated dose groups. 
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Figure 3-9 Typical profiles of the six possible scenarios for a randomised change-over design 
where 1, 2.5, and 5 mg linagliptin are given once daily for seven days in each sequence. 
3.2.4 Project 2d: Description and steady-state simulation of  the drug-
drug interaction between linagliptin and ritonavir 
The objective of Project 2d was to predict the steady-state profile of linagliptin under 
ritonavir comedication. 
The dataset consisted of linagliptin plasma concentrations from twelve healthy volunteers 
with a mean age of 37.1 years (range: 25–50 years) and a mean body mass index of 
25.4 kg/m2 (range: 21.8–29.5 kg/m2). The volunteers received a single dose of 5 mg 
linagliptin alone and in combination with ritonavir in a cross-over design. Both treatment 
arms included 192 plasma concentration measurements, respectively. The plasma concen-
tration-time profiles of linagliptin were elevated when linagliptin was given in comedica-
tion with ritonavir (Figure 3-10).  
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Figure 3-10  Plasma concentration-time profiles of linagliptin after a single dose of 5 mg linagliptin 
alone (left panel) and in combination with ritonavir (right panel) 
3.2.4.1 Model development 
The model development was performed in a stepwise manner. Firstly, the model parame-
ters of the base model developed in Project 1 (called M3) were re-estimated to describe the 
plasma concentrations of linagliptin monotherapy (reference treatment). The thus adapted 
model (called M4) was then adjusted to describe the plasma concentrations when lina-
gliptin was given in combination with ritonavir (test treatment). 
Model adaptation for the linagliptin reference treatment. Based on the approach 
outlined in section 2.5.2.4.3, re-estimating the parameters dissociation constant (∆OBJF 
−18.844), lag time (∆OBJF −16.231), and apparent central volume of distribution (∆OBJF 
−21.785) significantly improved the description of the plasma concentrations following the 
administration of linagliptin reference treatment compared to model M3. The parameters of 
the thus adapted model M4 in comparison to M3 are presented in Table 3-6. Figure 3-11 
illustrates the influence of the parameter adaptation on the description of the linagliptin 
plasma concentration-time profiles. 
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Figure 3-11  Description of the reference treatment of Project 2b using model M3 (previously 
developed model in Project 1) and the adapted model M4. Straight and dashed lines are the typical 
profile for model M3 and M4, respectively. The observed plasma concentrations of the reference 
treatment are presented as open circles. 
Model adaptation for the linagliptin test treatment. Re-estimating the parameters 
relative bioavailability (∆OBJF −635.374) and lag time (∆OBJF −55.133) of model M4 
resulted in a significantly improved description of the plasma concentrations following the 
administration of the test treatment. A further decrease in the OBJF of more than 3.84 was 
estimated for Bmax,C (∆OBJF −9.027), Kd (∆OBJF −7.672), CL (∆OBJF −7.155) and Amax,P 
(∆OBJF −4.497). Based only on the OBJF the best model would have been the one with an 
elevated Bmax,C when linagliptin was coadministered with ritonavir. However, under 
ritonavir comedication nearly no metabolite formation was observed. Thus, a decrease in 
the linagliptin clearance was considered more likely than an increase in Bmax,C. No further 
decrease in the OBJF of more than 3.84 points was reached when either a separate Bmax,C, 
Kd, or Amax,P was estimated in addition to a separate lag time, bioavailability, and clear-
ance, when linagliptin was coadministered with ritonavir. The parameter estimates of the 
so adjusted pharmacokinetic model (called M5) are presented in Table 3-6. The influence 
of the parameter adaptation on the description of the linagliptin plasma concentrations of 
the test treatment is presented in Figure 3-12. 
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Figure 3-12  Description of the linagliptin plasma concentrations when linagliptin was given 
together with ritonavir using model M4 (adapted to describe the control group in Project 2b) and 
model M5 (adapted to describe the treatment group linagliptin plus ritonavir). Straight and dashed 
lines are the typical profiles for models M4 and M5, respectively. The observed plasma concentra-
tions of the test treatment are presented as open circles. 
Testing for interindividual variability in the model parameters. Interindividual 
variability in F, Ka, Bmax,C and intercompartmental clearance between central and periph-
eral compartment (QP) improved the description of the individual plasma concentrations of 
both treatment arms (Table 3-6). 
3.2.4.2 Final model 
The population pharmacokinetic model of linagliptin developed for Project 2d is based on 
the previous model M3 (Project 1). To describe the reference treatment adequately, a lag 
time (0.202 h), a lower apparent central volume of distribution (542 L) and a higher 
affinity constant (0.106 nM) were estimated. The resulting change in the typical plasma 
concentration-time profile between M3 and M4 was only small. The elevated plasma 
concentration-time profiles under ritonavir were best described by estimating a ~4-fold 
elevated bioavailability, a slightly shorter lag time (0.143 h) and a decrease in the clearance 
of ~16%. Interindividual variability, implemented on F, Ka, Bmax,C, and QP/F, was small to 
moderate (15.6–44.6%). The residual variability, described by a combined (additive and 
proportional) residual variability model, was moderate (additive residual variability 
0.330 nM, proportional residual variability 21.7%). The parameter estimates of the final 
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model are presented in Table 3-6. The goodness-of-fit plots in Appendix, Figure 10 
suggest an adequate description of the linagliptin plasma concentrations of both treatments. 
Table 3-6  Parameter estimates of the structural models M3, M4, and M5 as well as the interindi-
vidual variability of the population parameters of the structural model M5 
  Original Model M3 Adapted Model M4 Adapted Model M5 Interindividual 
variability of M5 
 Unit Estimate RSE [%] Estimate RSE [%] Estimate RSE [%] Estimate RSE [%] 
Typical Parameter 
F % 100 fix NA 100 fix NA 100 fix 
/3941) 
NA 
/11.81) 
100/3941) 
fix 
NA 
Ka h-1 0.845 fix NA 0.845 fix NA 0.845 fix NA 0.845 fix NA 
ALAG h NA NA 0.202 5.94 0.202 fix 
/0.1431) 
NA 
/24.31) 
0.202/ 
0.1431) 
fix 
NA 
VC/F L 776 fix NA 542 17.6 542 fix NA 542 fix NA 
QP/F L/h 412 fix NA 412 fix NA 412 fix NA 412 fix NA 
VP/F L 1650 fix NA 1650 fix NA 1650 fix NA 1650 fix NA 
CL/F L/h 289 fix NA 289 fix NA 289 fix 
/2431) 
NA 
/10.91) 
289/2431) 
fix 
NA 
Bmax,C nM 4.85 fix NA 4.85 fix NA 4.85 fix NA 4.85 fix NA 
Kd nM 0.0652 fix NA 0.106 23.3 0.106 fix NA 0.106 fix NA 
Amax,P/F nmol 1,650 fix NA 1,650 fix NA 1,650 fix NA 1,650 fix NA 
Interindividual Variability 
ωF CV% NA NA NA NA NA NA 43.2 39.7 
ωKa CV% NA NA NA NA NA NA 42.8 26.2 
ωQP CV% NA NA NA NA NA NA 44.6 47.6 
ωBmax,C CV% NA NA NA NA NA NA 15.6 47.3 
Residual Variability 
σprop
2)
 
% 39.5 50.3 36.6 32.7 37.1 22.8 21.7 17.9 
σadd
2)
 nM 0.590 151.7 0.466 28.7 0.428 44.2 0.330 30.5 
1)
 First value for linagliptin alone, second value for linagliptin in comedication with ritonavir 
2)
 Estimated on log-transformed data 
NA, not applicable 
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3.2.4.3 Model evaluation 
The model was evaluated using visual and posterior predictive checks. The visual predic-
tive check displayed an adequate description of the concentration-time profiles by the final 
model for both treatments (Appendix, Figure 11). The posterior predictive check displayed 
an adequate description of the AUC0-inf and Cmax values for both treatments by the final 
model with a tendency to slightly overestimate the Cmax values (Appendix, Figures 12 and 
13). 
3.2.4.4 Simulation 
Using the final population pharmacokinetic model of Project 2d, the impact of ritonavir 
comedication on the steady-state exposure of linagliptin was simulated. First, the typical 
concentration-time profiles for 5 mg linagliptin administered once daily either alone or in 
combination with ritonavir were simulated using M5. Based on the simulated Ctrough levels, 
steady-state was reached after ~2 days for both treatments (Figure 3-13). Ritonavir 
comedication increased the exposure of linagliptin but had no effect on the accumulation 
ratio of linagliptin. Irrespective of ritonavir comedication, a merely small increase in the 
predicted exposure for linagliptin treatment after single dose compared to steady-state was 
predicted (Figure 3-13). 
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Figure 3-13  Predicted linagliptin plasma concentration-time profiles using the final population 
pharmacokinetic model of Project 2d for treatment with 5 mg linagliptin administered once daily 
alone or in combination with ritonavir over seven days. A dense sampling scheme was assumed at 
day 1 and day 7; at days 2–6, only Ctrough levels were simulated. 
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Second, the final population pharmacokinetic model including variability was used to 
simulate 1,000 AUCτ,SS and Cmax values after single dose and at steady-state (day 7) for 
both treatments. The corresponding gMeans and gCVs are shown in Table 3-7. Based on 
the AUC, accumulation ratios of 1.20 and 1.13 were predicted by the model for linagliptin 
administered without and with ritonavir, respectively.  
Table 3-7  gMean and gCV of 1,000 predicted AUCτ and Cmax values for the treatment of linagliptin 
with and without ritonavir comedication after the first dose and at steady-state 
 Linagliptin without ritonavir Linagliptin with ritonavir 
 
First dose (gCV%) Steady-state 
(gCV%) 
First dose (gCV%) Steady-state 
(gCV%) 
gMean AUCτ [nM·h] 118 (25) 142 (21) 259 (29) 293 (29) 
gMean Cmax [nM] 10.3 (36) 12.7 (32) 31.7 (45) 35 (41) 
 
3.3 Project 3: Covariate analysis 
3.3.1 Project 3a: Pharmacokinetic covariate analysis 
The objective of this project was to characterise the nonlinear pharmacokinetics of 
linagliptin in a larger patient population. The main focus was to investigate the impact of 
weight, sex, and age on the pharmacokinetics of linagliptin. In addition, other covariates 
that are of clinical relevance for the pharmacokinetics of linagliptin were to be identified. 
The dataset of Project 3a consisted of single dose and steady-state concentration-time 
profiles of the two phase IIa studies used for Project 1 as well as of two additional phase 
IIb studies. 462 patients with type 2 diabetes were treated with linagliptin, 302 males and 
160 females. The mean age of the population was 59.1 years (56.1, 59.9, 58.1, and 60.2 
years per study), ranging from 30–78 years. The mean body mass index was 31.0 kg/m2 
(29.0, 28.8, 31.2, and 31.9 kg/m2 per study) ranging from 20.4–42.2 kg/m2. Descriptive 
statistics of baseline categorical and continuous covariates are shown in Appendix, 
Tables 7 and 8. Only 0.43% of patients consumed alcohol to an extent that it could 
interfere with the trial. Also, less than 10% of patients belonged to study I. More than 90% 
of the patients were Caucasians. Thus, ethnic origin and influence of alcohol consumption 
were only graphically explored. The ranges of all continuous covariates were relatively 
wide and thus a robust assessment of their influence was possible. Descriptive statistics of 
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time-dependent covariates were calculated at baseline and in case of the phase IIb studies 
also for each visit separately (data not shown). At baseline and at all visits under treatment 
the descriptive statistics were comparable, indicating that treatment with linagliptin did not 
significantly influence these covariates. Bivariate scatter plots were prepared to investigate 
correlations between covariates (Appendix, Figures 14 and 15). No unexpected correla-
tions between covariates were observed. 
In total, the dataset of Project 3a consisted of 6,907 linagliptin concentration 
measurements. For unknown reasons, the phase IIb studies included nine patients with pre-
dose linagliptin measurements. These measurements are not plausible and cannot be 
handled by NONMEM. Therefore, they were removed from this analysis. The distributions 
of the number of patients and of linaglitin plasma concentrations per dose group are shown 
in Appendix, Table 9. The distribution of observations and patients per dose group was 
unbalanced; ~30% of observations and subjects were in the 5 mg treatment group, whereas 
the 0.5 mg treatment group included merely ~10% of all subjects and observations. 
The distribution of linaglitptin plasma concentrations by time after dose per study is shown 
separately for each dose group in the Appendix, Figure 16. In general, the plasma concen-
tration-time profiles of the phase IIb studies showed higher variability compared to the 
phase IIa studies. In addition, the linagliptin plasma concentrations were apparently higher 
for study IV. 
3.3.1.1 Model development 
3.3.1.1.1 Base model 
First, it was tested whether the population pharmacokinetic base model previously 
developed in Project 1 (called M6 from here onward) could describe the linagliptin plasma 
concentrations collected during the phase IIb study where linagliptin was given as mono-
therapy (study III). All parameters were fixed to M6 and individual Bayesian estimates for 
study III were obtained. The standard goodness-of-fit plots (based on the Bayesian 
estimates) showed that the linagliptin concentrations of study III could be adequately 
described by M6 (Appendix, Figure 17). The Bayesian estimates were equally distributed 
around their typical parameters for F and Bmax,C, whereas the mean of the individual Ka 
values was lower compared to the previously determined typical parameter for Ka (Appen-
dix, Figure 19, upper panels). In a next step, the model parameters were estimated based on 
all three studies together. Due to the sparse data from phase IIb, not all model parameters 
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could be estimated. Therefore, only the typical parameters for which variability was found 
in M6 (except F which was already fixed to 1 in M6) were estimated. In addition, clearance 
was estimated as an interesting parameter for the covariate analysis. Hence, the typical 
parameters for Ka, Bmax,C, CL, and the inter- and intraindividual variabilities as imple-
mented in M6 (η in F, Ka, Bmax,C, and κ in F) were estimated. The parameter estimates for 
CL and Bmax,C were very similar to those in M6 (CL: 287 L/h vs. 289 L/h, Bmax,C: 4.77 nM 
vs. 4.85 nM), whereas Ka was estimated to be slightly lower (0.698 h-1 vs. 0.845 h-1). 
In a second step, it was tested whether M6 could also describe the linagliptin plasma 
concentrations of study IV in which linagliptin was given as add-on to metformin. In an 
exploratory comparison of the pharmacokinetic profiles, a higher exposure was observed 
for study IV (Appendix, Figure 16). This observation was confirmed when the Bayesian 
estimates of M6 were investigated for this study: The standard goodness-of-fit plots 
showed that the linagliptin concentrations were underestimated and could thus not be 
adequately described by M6 (Appendix, Figure 18). The underprediction by the model was 
also obvious when investigating the distribution of the Bayesian estimates of study IV 
around the previously estimated typical parameters. Besides a lower mean of Ka as already 
observed for study III, higher Bayesian estimates for F and Bmax,C were obtained compared 
to the typical parameters of the previous studies I and II (Appendix, Figure 19, lower 
panels). 
When permitting a separate clearance for study IV, this clearance was estimated to be 
lower than for the other three studies (210 L/h compared to 290 L/h). In addition there was 
a clear trend towards a higher individual relative bioavailability (high ETABAR-value, 
indicating that the arithmetic mean of η-estimates (i.e. ETABAR) is not zero). When 
estimating a separate F for study IV, the relative bioavailability was estimated to be 
increased by 51% in study IV. The η-distributions of all parameters as well as the good-
ness-of-fit plots were adequate. The model assuming a separate relative bioavailability for 
study IV decreased the OBJF by 32.546 points more than the model assuming a separate 
apparent clearance for study IV. Thus, the higher exposure in study IV was accounted for 
by estimating a separate bioavailability for this study. During the covariate analysis it was 
further investigated whether another parameter was needed to be adapted for study IV. 
When phase IIa and phase IIb studies were analysed together, higher interindividual (e.g. 
ωKa increased from 58% to 87%) and intraindividual variabilities (piF increased from 33% 
to 55%) as well as higher random residual variability (26.9% compared to 14.1% in M6) 
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were estimated compared to M6. As the plasma concentrations of the phase IIb studies 
suggested a higher residual variability than those of the phase IIa studies (Appendix, 
Figure 16), a separate residual variability dependent on the type of studies was estimated. 
A drop in the OBJF by 2256.997 points supported this decision. Interindividual variability 
in CL, VC, and volume of distribution of the peripheral compartment (VP) was investigated 
in addition to the variability already implemented in M6 (i.e. η in F, Ka, Bmax,C, and κ in F). 
Adding variability on CL and VC led to a significant decrease in the OBJF and was 
therefore kept in the model. Diagonal elements of the variance-covariance matrix of 
interindividual random effects (Ω-matrix) were estimated first. Based on graphical analysis 
a correlation between the individual F and CL was found. Thus covariance between both 
parameter was included in the model. The parameter estimates of the base model are 
presented in the Appendix, Table 10. 
3.3.1.1.2 Covariate selection 
In the next step a covariate analysis was conducted. Due to η-shrinkage (27% F, 35% CL, 
22% Ka, 24% Bmax,C, 58% VC) the results of the explorative and GAM analyses needed to 
be regarded with caution as both methods are based on the Bayesian η-estimates (158). 
Appendix, Table 11 presents the covariates pre-selected by exploratory analysis and GAM 
analysis, the covariates pre-defined to be tested in NONMEM as well as the covariates that 
remained in the model after the forward inclusion and backward elimination procedure 
performed separately per model parameter. The latter, i.e. the remaining covariates (weight 
on relative bioavailability, formulation and dose group on rate of absorption, gamma-
glutamyl transferase on unbound clearance, weight on central volume of distribution, as 
well as pre-dose DPP-4 activity, dose, age, and sex on the concentration of central binding 
partner) were tested together in one run. Again, a backward elimination was performed 
where the covariates were individually eliminated from the model. The OBJF increased 
less than 10.8 points for weight on volume (∆OBJF +0.135), gamma-glutamyl transferase 
on clearance (∆OBJF +2.284) and sex on Bmax,C (∆OBJF +8.695). In addition, for these 
three covariates the typical parameter describing the covariate-parameter relationship 
decreased. In the case of weight on volume, there was even a switch from a positive to a 
negative correlation, indicating that the effect of weight on volume was no longer mean-
ingful. For all other covariates, the typical parameters describing the covariate effect stayed 
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within the range of the previously estimated value when the covariates were tested 
individually per parameter. 
Based on these results, weight on the apparent central volume of distribution was not 
included in the final model, because weight was already implemented on the bioavailabil-
ity and was therefore not required on VC. During the backward elimination process, 
gamma-glutamyl transferase on clearance and sex on Bmax,C did not reach a statistically 
significant effect. Nevertheless, they were kept in the model as the corresponding runs did 
not converge properly and could therefore not be considered as final models. 
3.3.1.2 Final model 
The linagliptin plasma concentrations of both phase IIa and both phase IIb studies were 
adequately described by a model that takes the binding of linagliptin to its target DPP-4 
into account. To describe the pharmacokinetic profiles of study IV (add-on to metformin 
study) adequately, a separate, significantly elevated relative bioavailability was estimated 
for this study. During the covariate analysis the following covariates were also found to be 
statistically significant: F decreased with increasing weight; the formulation and the dose 
group showed a statistically significant influence on the rate of absorption; the unbound 
clearance was slightly decreased in case of increased gamma-glutamyl transferase; the 
model-calculated concentration of the central binding partner was influenced by the pre-
dose DPP-4 activity, dose, age, and sex. 
Compared to the base model, the variability in the η-parameters only decreased for Ka 
(76.4% compared to 87.6%) and Bmax,C (15.0% compared to 29.6%) and was in the same 
range for F, clearance and VC, showing that only a small part of the interindividual 
variability can be explained by these covariates. To finalise the model building process, the 
necessity to account for intraindividual variability and covariance was re-evaluated. Since 
the intraindividual variability did not decrease (base model 39.2%, final model 40.0%) and 
since the correlation between F and CL did not decrease (base model −0.704, final model 
−0.765) it was concluded that the necessity to account for the intraindividual variability 
and variance-covariance still existed. The parameter estimates of the final model are given 
in Table 3-8. The standard goodness-of-fit plots display an adequate description of the 
plasma concentrations (Appendix, Figure 20). 
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Table 3-8 Parameter estimates of the final population pharmacokinetic model of Project 3a 
 Unit Estimate Description 
Typical Parameter   
F % 100 fix Typical relative bioavailability 
Fstudy IV  % 169 Typical relative bioavailability in study IV (metformin comedica-
tion) relative to F 
weight_F1) % -0.00958 % change in F per kg change from the median weight of the 
population 
Ka,PIB  h-1 0.933 Typical absorption rate constant for the powder in bottle 
formulation 
Ka,T1 h-1 0.795 Typical absorption rate constant for the tablet 1 formulation 
Ka,T2 h-1 0.441 Typical absorption rate constant for the tablet 2 formulation 
Dose_Ka 2) % -0.0651 % change in Ka per dose unit change from the 5 mg dose group 
VC/F  L 715 Typical central volume of distribution 
QP/F  L/h 412 fix Typical inter-compartmental clearance between central 
compartment and peripheral compartment 
VP/F  L 1,650 fix Typical volume of distribution of the peripheral compartment 
CL/F [L/h] L/h 258 Typical clearance of the unbound concentration 
GGT_CL3) % -0.0339 % change in CL/F per U/L change from the median gamma-
glutamyl transferase of the population 
Bmax,C nM 4.97 Typical concentration of binding partner in the central compart-
ment (male) 
DPP_ Bmax,C 4) % 0.00332 % change in Bmax,C per RFU change from the median pre-dose 
DPP-4 activity of the population 
dose_ Bmax,C 4) % 3.41 % change in Bmax,C per dose unit change from the 5 mg dose 
group 
age_ Bmax,C 4) % 0.561 % change in Bmax,C per year change from the median age of the 
population 
sex_ Bmax,C 4) nM 0.457 Absolute change in Bmax,C between males and females 
Kd  nM 0.0652 fix Typical affinity constant of the saturable binding 
Amax,P/F  nmol 1,650 fix Typical amount of binding partner in the peripheral compartment 
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Table 3-8 Parameter estimates of the final population pharmacokinetic model of Project 3a (cont.) 
 Unit Estimate Description 
Inter-and intraindividual variability 
ωF  CV% 47.4 Interindividual variability in the relative bioavailability 
Corr F_CL  -0.765 Correlation between ωF and ωCL 
ωCL  CV% 27.5 Interindividual variability in the clearance of the unbound 
concentration 
ωKa CV% 76.4 Interindividual variability in the absorption rate constant 
ωVC CV% 24.4 Interindividual variability in the central volume of distribution 
ωBmax,C CV% 15.0 Interindividual variability in the concentration of central binding 
partner 
piF CV% 40.0 Intraindividual variability in the absolute bioavailability 
Residual variability 
σprop, phase IIa 
5)
 % 13.6 Residual variability phase IIa 
σprop, phase IIb
5)
 % 38.3 Residual variability phase IIb 
1)
 Fio = F·(1+weight_F·(weight-88))·exp(ηF+κF) 
2)
 Kai  = Ka·(1+dose_ Ka·(dose-5))·exp(ηKa) 
3)
 CLi = CL·(1+GGT_CL·(GGT-33))·exp(ηCL) 
4) Bmax,C,i  = (Bmax,C+sex_Bmax,C·sex)·(1+DPP_Bmax,C·(DPP-12497))·(1+dose_Bmax,C·(dose-5))· 
(1+age_ Bmax,C·(age-60))·exp(ηBmax,C) 
5) Estimated on log-transformed data 
 
3.3.1.3 Model evaluation 
The visual predictive check displayed an adequate description of the linagliptin concentra-
tions by the base model. In the Appendix, Figure 21, the description of the pharmacoki-
netic profiles at steady-state per dose group and study, respectively, are shown.  
The posterior predictive check showed an adequate description of the Ctrough and Cmax 
levels by the final model. In the Appendix, Figures 22 and 23, the simulated distributions 
of the median Ctrough and Cmax levels at steady-state per dose group are shown. The median 
Ctrough and Cmax levels per dose group are well described and lie within the 90% confidence 
interval. The only exceptions were the Cmax values of the lowest (0.5 mg) and highest 
(10 mg) dose groups, which were slightly out of the 90% confidence interval. 
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3.3.1.4 Simulation 
The statistically significant covariates were evaluated for their influence on the pharma-
cokinetics of linagliptin. The impact of the different covariates on the AUCτ,SS after a once 
daily administration of 5 mg linagliptin was <20% for each covariate individually 
(Table 3-9). In comparison to the overall variability in the plasma concentration-time 
profiles the impact of weight, age and sex was very small (Figure 3-14). In the two worst-
case scenarios, i.e. (a), an old (73 years), low-weight (67 kg), female patient on metformin 
medication with high gamma-glutamyl transferase (158 U/L) and high pre-dose DPP-4 
activity (18,623 RFU), or (b), a young (42 years), high-weight (117 kg), male patient with 
low gamma-glutamyl transferase (9.4 U/L) and low pre-dose DPP-4 activity (8,025 RFU), 
the exposure increased or decreased by only 63% or 26%, respectively. 
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Figure 3-14  Impact of the covariates weight, age and sex on the linagliptin plasma concentration-
time profiles after administration of 5 mg linagliptin once daily in comparison to the overall 
variability (grey shaded area). The overall variability was determined as the 90% confidence 
interval of 1,000 simulated concentration-time profiles based on the base population pharmacoki-
netic model of Project 3a.  
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Table 3-9  Predicted covariate influence on AUCτ,SS after administration of 5 mg linagliptin once 
daily 
Model 
Parameter 
Covariate Category AUCτ,SS [nM·h] % difference 
No 154.23 NA Study IV (metformin 
comedication) Yes 184.81 +19.8 
5th percentile (67 kg) 163.38 +5.9 
Mean (88 kg) 154.23 NA 
F 
Weight 
95th percentile (117 kg) 140.9 -8.7 
1 153.66 -0.4 
2 153.75 -0.3 
Formulation 
3 154.23 NA 
0.5 153.99 -0.2 
5 154.23 NA 
Ka 
Dose 
10 154.67 +0.4 
5th percentile (8025 RFU) 137.4 -10.9 
Mean (12497 RFU) 154.23 NA 
Pre-dose DPP-4 
activity 
95th percentile (18623 RFU) 177.3 +15.0 
0.5 136.8 -11.3 
5 154.23 NA 
Dose 
10 173.6 +12.5 
5th percentile (42 years) 142.8 -7.4 
Mean (60 years) 154.23 NA 
Age 
95th percentile (73 years) 162.5 +5.4 
Male 154.23 NA 
Bmax,C 
Sex 
Female 164.65 +6.8 
5th percentile (9.4 U/L) 153.84 -0.25 
Mean (33  U/L) 154.23 NA 
CL Gamma-glutamyl 
transferase 
95th percentile (158  U/L) 156.38 +1.4 
NA, not applicable 
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3.3.2 Project 3b: Pharmacodynamic covariate analysis 
The objectives of this analysis were to characterise the relationship between linagliptin 
plasma concentration and the plasma DPP-4 activity in type 2 diabetic patients and to 
identify clinically relevant covariates impacting this correlation.  
The database of Project 3b consisted of the four studies used in Project 3a. 607 patients 
with type 2 diabetes were included. The mean age of the population was 59.2 years, 
ranging from 30–78 years, and the mean body mass index was 31.0 kg/m2 ranging from 
20.4–42.2 kg/m2. Descriptive statistics of categorical and continuous covariates using 
baseline values are shown in the Appendix, Tables 12 and 13. For the reasons described in 
Project 3a, the influence of ethnic origin and alcohol consumption were only tested in an 
explorative manner. The ranges for all continuous covariates were relatively wide and thus 
a robust assessment of their influence was possible. Bivariate scatter plots were carried out 
to investigate correlations between covariates (Appendix, Figures 24 and 25). No unex-
pected correlations between the covariates were observed.  
The dataset included 9,674 plasma DPP-4 activities and linagliptin plasma concentrations, 
respectively, from 607 type 2 diabetic patients. The distribution of the number of patients 
and the number of observations is given in the Appendix, Table 14. The distribution was 
unbalanced, as most patients were randomised to either placebo or 5 mg linagliptin. The 
DPP-4 activity correlated well with the linagliptin plasma concentration (Figure 3-15).  
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Figure 3-15  Correlation of linagliptin plasma concentration and plasma DPP-4 activity in studies I, 
II, III, and IV. Placebo and pre-dose observations not shown due to logarithmic scale. 
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3.3.2.1 Model development 
3.3.2.1.1 Base model 
A simple Emax model and a sigmoid Emax model were tested. The sigmoid Emax model 
performed significantly better (∆OBJF −6,399.422). Interindividual variability was tested 
sequentially on all model parameters. It was found that interindividual variability in pre-
dose DPP-4 activity (BSL) and EC50 improved the model fit. Both parameters showed 
moderate interindividual variability with 21.6% in BSL and 18.4% in EC50. The individual 
BSL and EC50 values were correlated. It was assumed that this correlation is physiologi-
cally plausible. The more DPP-4 molecules are available the more linagliptin molecules 
are needed to reduce 50% of the DPP-4 activity. Previous analyses showed a good 
correlation between baseline plasma DPP-4 activity and plasma DPP-4 concentration (data 
not shown). Thus, pre-dose DPP-4 activity can be used as a correlate for DPP-4 concentra-
tion. The higher the pre-dose DPP-4 activity, the higher is the DPP-4 concentration which 
in consequence results in a higher EC50 value. Implementing this correlation like a 
covariate effect of BSL on EC50 in the model was significantly better than estimating a 
correlation between BSL and EC50 using the block option (∆OBJF −75.928). Furthermore, 
it is advantageous that the covariates that impact the EC50 value solely through their effect 
on pre-dose DPP-4 activity need only be accounted on the pre-dose DPP-4 activity and not 
on the EC50 value. For these reasons, the pre-dose DPP-4 activity was implemented on the 
EC50 value like a covariate effect: 
)exp(η))11600(BSLBSL_EC(1ECEC EC50i505050i ⋅−⋅+⋅=    (Equation 3-1) 
In this equation EC50i is the individual EC50 parameter which depends on the typical EC50 
parameter, the typical covariate effect parameter BSL_EC50, the difference between the 
individual predicted baseline estimate (BSLi) and the typical baseline value of 
11,600 RFU, as well as the interindividual variability of EC50 η(EC50). 
The residual variability was adequately described by a proportional residual variability 
model and was estimated to be 15.7%. The parameter estimates of the base model are 
presented in the Appendix, Table 15. 
3.3.2.1.2 Covariate selection 
The covariates selected in the different steps of the covariate analysis are depicted in the 
Appendix, Table 16. Even though some covariates were found to be significant by the 
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forward inclusion and backward elimination procedure they were not kept in the model for 
the following reasons:  
There was a study difference in baseline DPP-4 activity as well as in EC50. The baseline 
DPP-4 activity was 10.3% lower in study II. EC50 was estimated to be 2.68 nM in study II, 
2.85 nM in study I, and 3.12 nM in studies III and IV. These interstudy differences could 
not be explained by any of the tested covariates, and were not regarded to be relevant and 
thus were not included into the final model.  
Alanine transaminase and aspartate transaminase both significantly contributed to a better 
description of the linagliptin plasma concentrations when implemented on the baseline 
DPP-4 activity. However, as both liver enzymes were highly correlated (Appendix, Figure 
25), and the covariate effect of aspartate transaminase was estimated only imprecisely 
(RSE 69.1%), only alanine transaminase was included into the final model. 
Asian ethnicity was not kept in the final model as a covariate on baseline DPP-4 activity 
because of the small sample size (eleven patients, representing less than 2% of the 
population). However, for these few patients a significantly higher baseline DPP-4 activity 
of 13,200 RFU was estimated compared to 10,600 RFU of the residual population. It 
should be further evaluated whether Asian patients have higher baseline DPP-4 activities. 
3.3.2.2 Final model 
The correlation between linagliptin plasma concentrations and plasma DPP-4 activity was 
best described by a sigmoid Emax model. The correlation between the individual EC50 and 
BSL values was taken into account by assuming a covariate effect of the individual BSL 
values on EC50. The final model included a covariate effect of gamma-glutamyl trans-
ferase, alanine transaminase, fasting plasma glucose, triglycerides, cholesterol and sex on 
the baseline DPP-4 activity as well as an additional effect of triglycerides on the EC50 
parameter. The influence of gamma-glutamyl transferase on baseline was implemented as a 
hockey-stick function: baseline increased linearly with gamma-glutamyl transferase 
concentration until a breakpoint of 175 U/L gamma-glutamyl transferase was reached. 
Beyond the breakpoint, the baseline was constant and elevated by 21.3% compared to the 
typical baseline DPP-4 activity. The breakpoint was chosen by log-likelihood profiling. 
Interindividual variability was reduced compared to the base model (16.9% versus 21.6% 
for BSL and 15.4% versus 18.4% for EC50). In addition, a smaller residual variability was 
estimated compared to the base model (14.8% versus 15.7% in the base model). The 
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parameter estimates of the final model are given in Table 3-10. All parameters were 
estimated precisely. As demonstrated by the standard goodness-of-fit plots (Appendix, 
Figure 26), the model described the DPP-4 activities adequately, except for two extreme 
DPP-4 activity data points of one patient which could not be properly described. 
Table 3-10  Parameter estimates of the final population pharmacokinetic/pharmacodynamic model 
of Project 3b 
 Unit Estimate RSE [%] Description 
Typical Parameters    
BSL,male  RFU 10,700 1.08 Typical baseline DPP-4 activity for males 
BSL
 female
1
 RFU 11,565 20.5 Typical baseline DPP-4 activity for females 
Emax  % 92.4 0.12 Typical maximum decrease in DPP-4 activity 
EC50 nM 3.06 1.56 Typical linagliptin concentration that leads to 50% of 
maximum decrease in DPP-4 activity 
Hill  3.22 1.82 Typical hill coefficient 
BSL_EC503 % 0.00792 7.98 % change in EC50 per RFU change from the median 
baseline DPP-4 activity of the population 
GGT_BSL2 % 0.153 20.39 % change in pre-dose DPP-4 activity per U/L change 
from the median baseline gamma-glutamyl transferase 
of the population until 175 U/L 
GGT_BSL2 % 21.3 18.5 % change in pre-dose DPP-4 activity if gamma-
glutamyl transferase > 175 U/L 
ALT_BSL2 % 0.175 18.5 % change in pre-dose DPP-4 activity per U/L change 
from the median baseline alanine transaminase of the 
population 
FPG_BSL2 % 1.46 12.3 % change in pre-dose DPP-4 activity per mM change 
from the median baseline fasting plasma glucose of 
the population 
TRIG_BSL2 % 0.0294 13.9 % change in pre-dose DPP-4 activity per mg/dL 
change from the median baseline triglycerides of the 
population 
CHOL_BSL2 % 0.0261 43.7 % change in pre-dose DPP-4 activity per mg/dL 
change from the median baseline cholesterol of the 
population 
TRIG_EC503 % -0.0153 13.1 % change in EC50 per mg/dL change from the median 
baseline triglycerides of the population 
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Table 3-10  Parameter estimates of the final population pharmacokinetic/pharmacodynamic model 
of Project 3b (cont.) 
 Unit Estimate RSE [%] Description 
Interindividual variability   
ωBSL CV% 16.9 7.61 Interindividual variability in the baseline DPP-4 activity 
ωEC50 CV% 15.4 15.8 Interindividual variability in the EC50 
Residual variability   
σprop  % 14.8 6.64 Residual variability  
1) Estimated as BSLmale+865 RFU 
2)
 BSLi = BSL·(1+GGT_BSL·(GGT-32.3))·(1+ALT_BSL·(ALT-28.8))·(1+FPG_BSL·(FPG-8.90))· 
(1+TRIG_BSL·(TRIG-160))·(1+CHOL·(CHOL-183))·exp(ηBSL)  
if GGT>175: BSLi = BSL·(1+GGT_BSL2))·(1+ALT_BSL·(ALT-28.8))·(1+FPG_BSL·(FPG-8.90))· 
(1+TRIG_BSL·(TRIG-160))·(1+CHOL·(CHOL-183))·exp(ηBSL) 
3) EC50i = EC50·(1+BSL_ EC50·(BSLi-11600))·(1+TRIG_ EC50·(TRIG-160))·exp(ηEC50) 
 
3.3.2.3 Simulation 
The statistically significant covariates were evaluated for their influence on the EC50, as 
well as on the concentration leading to 80% DPP-4 inhibition (EC80%)2. The individual 
impact of the different continuous covariates on both parameters was <20% (Table 3-11). 
Regarding the categorical covariate sex, females had higher EC50 and EC80% values 
compared to males (3.05 nM versus 2.84 nM, and 5.44 nM versus 5.07 nM, respectively). 
Even the two worst-case scenarios, i.e. (a), high gamma-glutamyl transferase (139 U/L), 
high alanine transaminase (64.7 U/L), high fasting plasma glucose (13 mM), high 
triglycerides (439 mg/dL), high cholesterol (278 mg/dL), and female, or (b), low gamma-
glutamyl transferase (10.9 U/L), low alanine transaminase (9.6 U/L), low fasting plasma 
glucose (5.9 mM), low triglycerides (59.8 mg/dL), low cholesterol (100 mg/dL), and male, 
led to a minimum EC50 value of 2.49 nM and to a maximum EC50 value of 4.14 nM 
(EC80%: minimum 4.44 nM and maximum 7.38 nM), respectively.  
 
                                                 
2
  80% DPP-4 inhibition was shown to be maximally effective for glucose lowering. Therefore, the linagliptin 
concentration resulting in 80% DPP-4 inhibition is of interest. EC80% is not the same as EC80, the concen-
tration leading to 80% of the maximum effect, as the maximum effect is 92,4% and not 100%.  
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Table 3-11  Impact of the statistically significant covariates on the EC50 and the EC80% for continu-
ous covariates using the 5th and 95th percentiles of the covariate distribution 
 
 
Extreme 
covariate value 
Impact of extreme 
covariate value on 
EC50 (absolute) 
Differ-
ence 
[%] 
Impact of extreme 
covariate value on 
EC80% (absolute) 
Differ-
ence 
[%] 
Percentiles 5th 95th 5th 95th  5th 95th  
Gamma-glutamyl 
transferase [U/L] 
10.9 139 2.76 3.27 16.7 4.92 5.83 16.7 
Alanine transami-
nase [U/L] 
9.6 64.7 2.75 3.00 8.2 4.92 5.36 8.1 
Fasting plasma 
glucose [mM] 
5.9 13 2.73 3.00 8.8 4.87 5.35 9.0 
Triglycerides [mg/dL] 59.8 439 2.81 2.92 3.6 5.01 5.21 3.7 
Cholesterol [mg/dL] 100 278 2.79 2.91 3.9 4.97 5.19 4.0 
 
3.4 Project 4: Estimation of  the absolute bioavailability of  
linagliptin 
In Project 4, the mean age of the 28 healthy male volunteers was 39.4 years (range: 26–
50 years) and the mean body mass index was 25.0 kg/m2 (range: 18.9–29.4 kg/m2). One 
subject was Afro-American, the other 27 subjects were Caucasians. 
The dataset comprised 862 linagliptin plasma concentrations from healthy volunteers 
treated with a single dose of linagliptin administered either orally or intravenously. No 
subject or concentration was excluded from the analysis. Appendix, Table 17 shows that 
the distribution of healthy volunteers and concentrations per dose group correspond to the 
study design. The plasma concentration-time profiles of linagliptin after intravenous 
administration of 0.5, 2.5, 5, and 10 mg linagliptin increased less than dose-proportionally 
(Figure 3-16). The variability of linagliptin plasma concentrations after intravenous 
administration was very small in all dose groups (Figure 3-16), whereas linagliptin 
exhibited a moderate variability after oral administration (Figure 3-17).  
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Figure 3-16  Arithmetic mean (±SD) (left panel) and dose-normalised arithmetic mean (right panel) 
plasma concentration-time profiles of linagliptin after intravenous administration of 0.5, 2.5, 5, and 
10 mg linagliptin. 
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Figure 3-17  Arithmetic mean (±SD) of plasma concentration-time profiles of linagliptin after the 
administration of 5 mg linagliptin intravenously and 10 mg linagliptin orally. 
Due to the nonlinear pharmacokinetics of linagliptin, the standard approach to determine 
the absolute bioavailability led to dose-dependent estimates. Dividing the dose-normalised 
AUCp.o. of 10 mg linagliptin by the dose-normalised AUCi.v. of the four different doses 
resulted in mean values of 12.0% for 0.5 mg, 30.7% for 2.5 mg, 40.3% for 5 mg, and 
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68.3% for the 10 mg dose. The dose-dependent estimates of the bioavailability illustrate 
the inappropriateness of this approach for the given data. 
3.4.1 Model development 
The model development was performed in a stepwise manner. Initially, the plasma 
concentrations after intravenous administration were analysed separately, then the plasma 
concentrations after oral administration were included and both datasets were evaluated 
simultaneously to estimate the absolute bioavailability.  
Linear one-, two-, and three-compartment models did not allow a description of the 
linagliptin plasma concentration-time profiles after intravenous administration of 0.5, 2.5, 
5, and 10 mg linagliptin. The fits of all three compartment models were significantly 
improved by implementing concentration-dependent binding in the central compartment 
(∆OBJF −981.577, −802.743, and −795.454 for a one-, two-, and three-compartment 
model, respectively). Of the models including concentration-dependent binding in the 
central compartment, a three compartment model performed best (∆OBJF −249.835 
compared to a two compartment model with concentration-dependent binding). Incorporat-
ing concentration-dependent binding also in one of the peripheral compartments further led 
to a significantly better description of the plasma concentrations (∆OBJF −73.820). This 
three-compartment model with binding in the central and one peripheral compartment 
performed significantly better than a two-compartment model with binding in the central 
and one peripheral compartment (∆OBJF −216.477). Interindividual variability after 
intravenous administration was low (Figure 3-16). Addition of interindividual variability 
on the pharmacokinetic parameters, e.g. CL resulted in a skewed distribution of the 
individual parameters in the 0.5 mg treatment group and was therefore not implemented. 
Inclusion of additional nonlinear processes which might be the reason for this observation, 
e.g. saturable elimination, did not improve the model significantly (∆OBJF −1.683; 
parameters for the saturable elimination could only be estimated imprecisely 
(RSE >145%)). Thus, no interindividual variability was implemented on the disposition 
parameters.  
In the next step, the plasma concentrations after oral administration were included in the 
analysis. When the disposition parameter were fixed to the typical values of the intrave-
nous model and the absorption was modelled as a first-order process with lag time, the 
linagliptin plasma concentrations could be described adequately. In addition, when 
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estimating the model parameters simultaneously using linagliptin plasma concentrations 
after intravenous and oral administration, the disposition parameter estimates remained 
nearly identical (Table 3-12). Including interindividual variability for all absorption 
parameters sequentially was possible and improved the description of the plasma concen-
trations after oral administration. Therefore, interindividual variability was included for the 
absorption parameters. 
3.4.2 Final model 
The plasma concentrations after intravenous and oral administration were best described 
by a three-compartment model accounting for concentration-dependent binding of 
linagliptin in the central and one peripheral compartment. The structure of the final model 
is depicted in Figure 3-18. The model parameters are given in Table 3-12.  
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Figure 3-18  Structure of the final pharmacokinetic model of Project 4. F, absolute bioavailability; 
Ka, absorption rate constant; ALAG, lag time; VC, central volume of distribution; VP1, volume of 
distribution of the peripheral compartment 1; QP1, intercompartmental clearance between central 
and peripheral compartment 1; VP2, volume of distribution of the peripheral compartment 2; QP2, 
intercompartmental clearance between central and peripheral compartment 2; CL, clearance; 
Bmax,C, concentration of binding partner in the central compartment; Amax,P, amount of binding 
partner in the peripheral compartment 1; Kd, dissociation constant. See Figure 3-2 for details. 
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Table 3-12  Parameter estimates of the population pharmacokinetic models of Project 4 
  Population pharmacokinetic 
model (i.v.) 
Population pharmacokinetic 
model (i.v. and p.o.) 
 Unit Estimate RSE [%] Estimate RSE [%] 
Typical parameter      
F  % NA NA 29.5 14.7 
ALAG  h NA NA 0.234 8.50 
Ka  h-1 NA NA 0.187 27.2 
VC L 15.0 7.13 15.8 7.66 
QP1  L/h 23.5 9.91 24.3 10.0 
VP1  L 291 14.7 293 14.0 
QP2 L/h 70.7 5.46 69.9 5.42 
VP2 L 93.8 10.6 93.4 10.2 
CL L/h 26.6 7.86 26.9 7.96 
Bmax,C nM 3.26 11.2 3.44 9.74 
Kd  nM 0.0763 10.5 0.0835 11.8 
Amax,P nmol 437 27.5 548 20.8 
Interindividual variability     
ωF CV% NA NA 46.7 34.0 
ωALAG CV% NA NA 82.0 29.1 
ωKa CV% NA NA 27.6 66.9 
Residual variability     
σprop
1)
  % 16.6 5.28 17.6 5.14 
σadd
1)
 nM 0.277 21.3 0.255 27.3 
1)
 Estimated on log-transformed data  
NA, not applicable 
 
All typical parameters could be estimated precisely (RSE ranging from 5.42–20.8%). The 
concentration of binding partners in the central compartment was 3.44 nM, the dissociation 
constant for the concentration-dependent binding was 0.0835 nM. The unbound apparent 
volume of distribution at steady-state was 402.2 L, indicating an extensive DPP-4 inde-
pendent distribution of linagliptin. The clearance of unbound linagliptin was high 
(26.9 L/h). Interindividual variability, estimated on the absorption parameters bioavailabil-
ity, rate constant of absorption, and lag time, was moderate to high (28–82%). The 
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standard goodness-of-fit plots showed that the model performed adequately (Appendix, 
Figure 27). For the 10 mg linagliptin dose group the absolute bioavailability estimated by 
the model was 29.5%, with a high inter-individual variability of 46.7% (range: 12.9–
60.8%). 
3.4.3 Model evaluation 
The visual predictive check presented in the Appendix, Figure 28 demonstrated that the 
model adequately described the plasma concentrations after oral and intravenous admini-
stration of all dose groups. 
3.5 Project 5: Model-based pharmacokinetic analysis of  
linagliptin in wildtype and DPP-4-deficient rats 
The objective of Project 5 was to test the impact of concentration-dependent binding of 
linagliptin to its target DPP-4 on the pharmacokinetics of linagliptin using plasma concen-
trations from wildtype and DPP-4-deficient rats.  
The mean animal weights per dose group and rat strain were comparable (Appendix, 
Table 18). The dataset included 182 linagliptin plasma concentrations of 28 animals 
determined after single intravenous administration of 0.01, 0.1, 0.3, or 1.0 mg/kg lina-
gliptin. Each of the four dose groups contained four wildtype and four DPP-4-deficient 
rats, except for the lowest dose group (0.01 mg/kg) in which only wildtype rats were 
included. The distribution of observations per dose group and rat strain is summarised in 
Appendix, Table 19. The number of observations is equally distributed between the dose 
groups, but it tends to be lower in DPP-4-deficient rats, as for most of these rats linagliptin 
concentrations after 24 h were below the limit of quantification. No observation was 
excluded from the analysis. The linagliptin plasma concentration-time profiles of both rat 
strains are depicted in Figure 3-19.  
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Figure 3-19  Mean (±SD) of dose-normalised linagliptin plasma concentration-time profiles after 
single intravenous (bolus) administration of linagliptin to DPP-4-deficient (left panel) and wildtype 
(right panel) rats. 
In the dose range up to 1 mg/kg, pronounced differences in the plasma concentration-time 
profiles of linagliptin were observed between DPP-4-deficient and wildtype rats (Figure 
3-19). DPP-4-deficient rats showed a markedly faster decrease in dose-normalised 
linagliptin plasma concentrations over time, leading to a notably lower exposure in this 
dose range. The pharmacokinetics was dose-proportional in DPP-4-deficient rats (Figure 
3-19, left panel), whereas the pharmacokinetics in wildtype Fischer rats was dose-
dependent. This nonlinearity is evident in the dose-normalised pharmacokinetic profiles of 
wildtype rats not being superimposable due to a less than dose-proportional increase in 
exposure (Figure 3-19, right panel). 
3.5.1 Model development 
Linear one-, two-, and three-compartment models were tested to describe the plasma 
concentration-time profiles of DPP-4-deficient rats. The three-compartment model 
performed best. It was superior to a one-compartment model (∆OBJF −223.022) and a 
two-compartment model (∆OBJF −133.458). Estimating interindividual variability on the 
typical population parameters did not improve the description of the plasma concentrations 
and was thus not implemented. The parameter estimates are listed in Table 3-13. 
In the next step, this three-compartment model was extended to describe the pharmacoki-
netics of DPP-4-deficient and wildtype rats simultaneously by assuming saturable binding 
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of linagliptin to DPP-4 for wildtype rats. First, concentration-dependent binding to a single 
binding partner in the central compartment was tested which resulted in a good description 
of the plasma concentrations. Adding saturable binding also to one peripheral compartment 
further improved the fit (∆OBJF −80.085); no further improvement could be reached by 
additionally implementing saturable binding in the second peripheral compartment 
(∆OBJF 0). In addition, implementing the ‘tissue’ binding partner in the peripheral 
compartment was superior to incorporating two binding partners in the central compart-
ment, one which is soluble in plasma (i.e. soluble plasma DPP-4) and one which is easily 
accessible via plasma but not part of the plasma (e.g. membrane bound DPP-4 on lympho-
cytes or on the endothelium) (∆OBJF −80.085). In the latter case, the amount of ‘tissue’ 
binding partner was estimated to be zero. Accounting for interindividual variability on the 
binding parameters was not required. During the model development the distribution 
parameters of unbound linagliptin were fixed to those of the DPP-4-deficient rats’ model. 
When estimating all model parameters simultaneously, the parameter estimates were 
nearly identical (Table 3-13).  
In the last step of model development, the model assumptions were tested if possible (cf. 
section 2.5.5.3). One model assumption was that the binding affinity of linagliptin to 
central and peripheral DPP-4 is identical. This assumption was maintained for the model, 
as the data did not allow to independently estimate two dissociation constants. Another 
assumption was that the binding equilibrium was reached faster than other pharmacoki-
netic processes. This assumption of quasi-equilibrium binding had only negligible effects 
on the model results (e.g. parameter estimates, goodness-of-fit plots), and was therefore 
abandoned for the final model.  
3.5.2 Final model 
Confirming the hypothesis, that the nonlinear pharmacokinetics is caused by concentra-
tion-dependent binding of linagliptin to DPP-4, the plasma concentrations of both wildtype 
and DPP-4-deficient rats were best described by a three-compartment model accounting 
for concentration-dependent binding of linagliptin to plasma and tissue DPP-4 in wildtype 
rats. The structural model is depicted in Figure 3-20.  
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Figure 3-20  Schematic representation of the pharmacokinetic model for linagliptin accounting for 
concentration-dependent and reversible binding of linagliptin to DPP-4 in wildtype rats. In DPP-4-
deficient rats, no binding to DPP-4 is existent simplifying the model to a linear three-compartment 
model. VC, central volume of distribution; VP1, volume of distribution of first peripheral compartment; 
VP2, volume of distribution of second peripheral compartment; QP1, intercompartmental clearance 
between central and first peripheral compartment; QP2, intercompartmental clearance between 
central and second peripheral compartment; CL, clearance; Bmax,C, concentration of binding partner 
in the central compartment; Amax,P, amount of binding partner in the second peripheral compart-
ment; KON, second-order rate constant of the association of the linagliptin/DPP-4 complex; KOFF, 
first-order rate constant of the dissociation of the linagliptin/DPP-4 complex. 
No interindividual variability was required. The residual variability was 19.9% and was 
coded as an additive residual variability model for log-transformed data, approximately 
corresponding to a proportional residual variability model for untransformed data. The 
parameter estimates are shown in Table 3-13. The standard goodness-of-fit plots (Appen-
dix, Figure 29) highlight that the model performs adequately for DPP-4-deficient and 
wildtype rats. A slight misspecification can be observed for the linagliptin concentrations 
at the early time points which may be caused by variations in the actual sampling time of 
the 2 min values. 
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Table 3-13  Parameter estimates of the final pharmacokinetic model for DPP-4-deficient and 
wildtype rats 
  DPP-4-deficient model Combined model 
 Unit Estimate RSE [%] Estimate RSE [%] 
Typical Parameter     
VC  L 0.487 7.72 0.569 5.18 
QP1 L/h 0.192 8.75 0.173 8.32 
VP1 L 1.48 6.30 1.73 12.5 
QP2  L/h 3.31 3.05 4.16 4.62 
VP2 L 1.48 2.60 1.81 5.40 
CL L/h 1.44 2.87 1.51 2.56 
Bmax,C nM NA NA 2.70 3.68 
KON L/(h·nmol) NA NA 2.50 12.8 
KOFF h-1 NA NA 0.108 fix NA 
Kd1)  nM NA NA 0.0432 NA 
Amax,P nmol NA NA 9.86 8.68 
Residual variability     
σprop
2)
  % 14.2 11.6 19.9 8.24 
1)
 Dissociation constant derived from Kd = KOFF/KON 
2)
 Estimated on log-transformed data 
NA, not applicable 
 
3.5.3 Model evaluation 
The disposition model parameter estimates (VC, VSS, CL) of unbound linagliptin were 
comparable to the disposition parameters of DPP-4-deficient rats determined by noncom-
partmental analysis (Table 3-14). The mean VSS was lower in the noncompartmental 
analysis, possibly due to the high number of values below the limit of quantification in 
DPP-4-deficient rats resulting in an underestimation of VSS values. 
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Table 3-14  Comparison of the parameters for volumes of distribution and clearance between the 
noncompartmental and the model-based analysis 
 VC (L/kg) VSS (L/kg) CL (mL/min/kg) 
Model-based 2.28 16.4 100.7 
Noncompartmental 2.51 9.2 94.6 
 
The dissociation constant of the saturable binding in wildtype rats was 0.0432 nM, or, 
reciprocally the association constant was 2.31⋅1010 M-1. In line with this estimate, the in 
vitro plasma protein binding study determined an association constant of 2.34⋅1010 M-1 for 
the binding of linagliptin to plasma DPP-4 in rats (162). The concentration of the binding 
partner in the central compartment was estimated by the model to be 2.70 nM. This 
parameter essentially reflects the plasma DPP-4 monomer concentration in rat, which was 
estimated in a previous study to be 3.84 nM (162).  
3.5.4 Simulation 
Based on the final model, the plasma concentration-time profiles of total linagliptin and 
linagliptin specifically bound to plasma DPP-4 were simulated for different doses (Figure 
3-21). These simulations indicated that in wildtype animals unbound linagliptin was 
eliminated efficiently and that the long terminal half-life was related to the fraction of 
linagliptin specifically bound to DPP-4. 
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Figure 3-21  Prediction of the plasma concentration-time profiles of total (solid line) and specifically 
bound (dashed line) linagliptin for the doses 0.01, 0.1, and 1.0 mg/kg. The curves showing the total 
and the specifically bound plasma concentration-time profiles completely overlap in the left panel, 
and partly overlap in the middle and right panels. 
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Furthermore, the time course of linagliptin in both peripheral compartments was simulated 
and compared between DPP-4-deficient and wildtype rats (Figure 3-22). In DPP-4-
deficient rats, the amount of linagliptin in tissue increased linearly with dose and was 
eliminated rapidly, whereas in wildtype rats the increase of linagliptin in tissue was less 
than dose-proportional in the dose range from 0.01−1.0 mg/kg. The decline of peripheral 
linagliptin was predicted to be much slower compared to DPP-4-deficient rats. At the end 
of the observation period (72 h), the amount of linagliptin in the peripheral compartments 
was predicted to be much higher in wildtype rats compared to DPP-4-deficient rats 
(Appendix, Figure 30). In addition, the less than dose-proportional increase of linagliptin 
in the peripheral compartments of wildtype rats was also evident 72 h after the intravenous 
bolus administration. 
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Figure 3-22  Prediction of the amount of linagliptin in both peripheral compartments over time for 
wildtype (left panel) and DPP-4-deficient rats (right panel) after an intravenous bolus administration 
of 0.01, 0.1, 0.3, and 1.0 mg/kg linagliptin. 
The impact of altered DPP-4 levels on the total linagliptin plasma concentration-time 
profiles, the plasma concentration-time profiles of unbound linagliptin, and the linagliptin 
occupancy-time profile of DPP-4 in plasma were to be investigated. Thus, simulations 
were performed assuming varying amounts of central and peripheral binding partners 
(original value ±50%). The impact at two dose levels (0.01 and 1 mg/kg) was investigated. 
Regardless of dose, varying amounts of plasma DPP-4 had an impact on the total lina-
gliptin plasma concentration if linagliptin plasma concentration levels were below the 
plasma DPP-4 concentration. Interestingly, varying concentrations of plasma DPP-4 only 
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had a minor effect on the predicted unbound linagliptin concentration and the predicted 
occupancy (Figure 3-23). In contrast, the impact of varying amounts of peripheral DPP-4 
was dose-dependent. In case of the 0.01 mg/kg dose group, a lower amount of peripheral 
DPP-4 initially led to a higher fraction of unbound linagliptin, as well as higher total 
plasma concentrations and higher plasma DPP-4 occupancy (Figure 3-24, upper panels). 
An opposite effect was observed at later time points. At time points >40 h in the 1 mg/kg 
dose group, a lower amount of peripheral DPP-4 resulted in slightly lower total plasma 
concentrations, a slightly lower fraction of linagliptin not specifically bound, and a slightly 
lower occupancy (Figure 3-24, lower panels). 
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Figure 3-23  Prediction of total plasma linagliptin concentration (left panels), unbound plasma 
linagliptin concentration (middle panels) and plasma DPP-4 occupancy with linagliptin (right panels) 
0-72 h after an intravenous bolus administration of 0.01 mg/kg (upper panels) and 1 mg/kg (lower 
panels) assuming different concentrations of central binding partner (original value ± 50%). 
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Figure 3-24  Prediction of total plasma linagliptin concentration (left panels), unbound plasma 
linagliptin concentration (middle panels) and plasma DPP-4 occupancy with linagliptin (right panels) 
0-72 h after an intravenous bolus administration of 0.01 mg/kg (upper panels) and 1 mg/kg (lower 
panels) assuming different amounts of peripheral binding partner (original value ±50%). 
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4 Discussion 
4.1 Nonlinear pharmacokinetics of  linagliptin 
One major challenge of linagliptin on the way through drug development was its nonlinear 
pharmacokinetics. For drugs with nonlinear pharmacokinetics it is of great importance to 
understand the reasons for the nonlinearity to allow a safe and efficacious therapy. 
4.1.1 Mechanisms of  nonlinear pharmacokinetics 
The term ‘linear pharmacokinetics’ implies that concentration-time profiles for a given 
drug and individual are superimposable when they are normalised for time and dose. In 
contrast, if these profiles are not superimposable, the pharmacokinetics is termed 
‘nonlinear’ (149,164). Nonlinear pharmacokinetics can be caused by nonlinear 
mechanisms in all kinetic processes, i.e. liberation, absorption, distribution, and 
elimination. The sources of nonlinearity can be divided into factors dependent on dose or 
concentration, and factors dependent on time. Table 4-1 summarises possible causes of 
concentration-dependent and time-dependent pharmacokinetics. 
Linagliptin exhibits nonlinear pharmacokinetics already after a single dose (103). This 
argues for a concentration-dependent effect rather than a time-dependent process. The 
AUC of linagliptin increases less than dose-proportionally with increasing dose. In 
consequence, saturation of first-pass metabolism, metabolizing enzymes, and active 
secretion in liver or kidneys, cannot be responsible for this kind of nonlinearity, as these 
processes lead to a more than dose-proportional increase in AUC. In addition, saturable 
liberation was regarded as unlikely because of the high solubility of linagliptin (100) and 
concentration-dependent renal elimination was considered unlikely due to the small 
fraction that was renally eliminated (104). Thus, the best explanation for the nonlinearity 
was either saturable active transport mechanisms in the absorption or saturable protein 
binding. The latter possibility was supported by human in vitro plasma protein-binding 
data showing concentration-dependent binding for linagliptin in the low nanomolar range 
(162).  
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Table 4-1  Common causes of nonlinear pharmacokinetics (adapted from (149)) 
 Process involved Parameter primarily 
affected 
Effect on AUC 
Dose-dependent processes 
Liberation Poor solubility, dissolution Bioavailability ↓ AUC ↓ 
Saturable active transport Bioavailability ↓ AUC ↓ Absorption 
Saturable first-pass metabolism Bioavailability ↑ AUC ↑ 
Saturation of plasma proteins Volume of distribution ↑, 
fuplasma ↑  Clearance ↑ 
AUC ↓ Distribution 
Saturation of tissue binding Volume of distribution ↓, 
futissue↑ 
AUC ↔ 
Metabolism Saturation of metabolizing enzymes Hepatic clearance ↓ AUC ↑ 
Saturable renal excretion due to active 
secretion 
Renal clearance
 
↓ AUC ↑ 
Concentration-dependent renal 
excretion due to active reabsorption 
Renal clearance
 
↑ AUC ↓ 
Elimination 
Saturable active biliary excretion Hepatic clearance ↓ AUC ↑ 
Time- (and dose-) dependent processes 
Metabolism Autoinduction Hepatic clearance ↑ with 
time 
AUC ↓ with time 
Elimination Toxic effects of a drug on its own renal 
or hepatic elimination 
Renal/hepatic clearance
 
↓ 
with time 
AUC ↑ with time 
Others Diurnal variations in renal function, 
urine pH, alpha-glycoprotein 
concentrations, gastrointestinal 
physiology (food, drink), cardiac output 
varies varies 
 
Concentration-dependent plasma protein binding not only influences the volume of 
distribution. As the free fraction is increasing with increasing drug concentrations, the 
clearance is also affected. In literature, there are various examples for drugs exhibiting 
concentration-dependent plasma binding (149,164). Naproxen, e.g., is a weak acid that 
binds concentration-dependently to albumin. Nonlinearity is only observed when su-
pratherapeutic doses are administered (165). Likewise, valproic acid, a drug with nonlinear 
pharmacokinetics and a small therapeutic window, exhibits concentration-dependent 
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binding to albumin, making interpretation of total valproic acid concentrations difficult 
(166). The basic drug disopyramide binds to α1-acid glycoprotein. Interestingly, its 
stereoisomers have different binding affinities (167). The class of angiotensin-converting 
enzyme (ACE) inhibitors, e.g. trandolaprilat, exhibits nonlinear pharmacokinetics due to 
concentration-dependent binding to their target enzyme ACE (149). In addition, the 
distribution and elimination of many therapeutic proteins, peptides, and monoclonal 
antibodies are likewise determined by target-mediated disposition due to specific high-
affinity binding to biological targets (168). 
The concentration-dependent plasma protein binding of linagliptin occurred in the low 
nanomolar range (<100 nM) where common plasma proteins like albumin or 
α-glycoprotein would not yet be saturated (149). This led to the hypothesis that lina-
gliptin’s target enzyme, DPP-4 might be the responsible binding partner. 
4.1.2 Nonlinear pharmacokinetics of  linagliptin is caused by target-
mediated drug disposition 
The results of Projects 1 and 5 confirmed the hypothesis that concentration-dependent 
binding of linagliptin to its target DPP-4 in plasma and tissues is the reason for the 
nonlinear pharmacokinetics in humans as well as in wildtype rats. 
4.1.2.1 Clinical findings in Project 1 
The linagliptin plasma concentration-time profiles of type 2 diabetic patients receiving oral 
doses of 1–10 mg linagliptin once daily over 12 or 28 days were successfully described by 
a model accounting for concentration-dependent protein binding of linagliptin in the 
central and the peripheral compartment. This model described the plasma concentrations 
significantly better than a model assuming saturable absorption, another possible cause for 
a less than dose-proportional increase in the exposure. Several lines of evidence argue that 
DPP-4 is the binding partner of linagliptin relevant for its concentration-dependent 
behaviour. In clinical studies, the concentration of binding partner in the central compart-
ment was estimated to be 4.62 nM, which is in the physiological range expected for the 
DPP-4 concentration in plasma (79,80). In addition, the individual estimates for the 
concentration of the binding partner in the central compartment correlated well with the 
observed pre-dose plasma DPP-4 activity (cf. Figure 3-5). Finally, the observed plasma 
DPP-4 activity under treatment was linearly related to the estimated plasma occupancy of 
the binding partner with linagliptin. DPP-4 is available in its soluble form in plasma and to 
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a great extent in its membrane-bound form in the endothelium and epithelium of various 
tissues. Thus, concentration-dependent binding of linagliptin in both the central and the 
peripheral compartment would be in accordance with physiology. 
4.1.2.2 Nonclinical findings in Project 5 
The findings from the clinical investigations were subsequently confirmed by a 
comparison of the linagliptin pharmacokinetics between wildtype rats and rats with a 
DPP-4-deficiency (Project 5). There was a striking difference between the plasma 
concentration-time profiles of both rat strains after single intravenous administration of up 
to 1 mg/kg linagliptin. The difference was most pronounced in the lowest dose group 
(0.1 mg/kg), and decreased with increasing doses. Wildtype rats exhibited a higher 
exposure and a markedly slower elimination compared to DPP-4-deficient rats. 
Furthermore, the pharmacokinetics in this dose range was nonlinear in wildtype rats, but 
linear in DPP-4-deficient rats. The linagliptin plasma concentrations in both rat strains 
were successfully described by one pharmacokinetic model accounting for concentration-
dependent binding of linagliptin in wildtype rats. Like in the model for patients, the 
binding was implemented in the central and one peripheral compartment, suggesting that 
concentration-dependent binding of linagliptin to both plasma and peripheral DPP-4 has an 
impact on the nonlinear pharmacokinetics of linagliptin. 
4.1.2.3 Further findings 
Beyond the analysis presented here, other nonclinical and in vitro experiments also found 
the concentration-dependent plasma and tissue binding of linagliptin to be caused by 
DPP-4. Plasma protein binding studies revealed a pronounced concentration-dependent 
binding of linagliptin in the plasma of wildtype rats and mice, as well as in human plasma 
(162). This concentration-dependency was characterised by a plasma protein binding of 
linagliptin >99% for linagliptin concentrations <1 nM, decreasing to 70–80% for lina-
gliptin concentrations >100 nM. In contrast, the plasma protein binding was constant in the 
concentration range of 0.1–10,000 nM in DPP-4-deficient rats and DPP-4 knockout mice. 
Similar findings for the tissue binding of linagliptin were obtained by whole body autora-
diography and tissue dissection (161). Tissue levels of drug-related radioactivity increased 
markedly less than dose-proportional in wildtype rats in all investigated tissues, whereas a 
nearly dose-proportional increase was observed in DPP-4-deficient rats. In line with the 
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idea of target-mediated drug disposition, higher levels of linagliptin were observed in the 
tissues of wildtype rats compared to DPP-4-deficient rats. 
4.1.3 Model assumptions 
4.1.3.1 Pharmacokinetic models 
The pharmacokinetic models developed in this work accounted for the saturable binding of 
linagliptin to DPP-4 in plasma and peripheral tissues. This is in line with the DPP-4 
distribution as well as the current knowledge about linagliptin as presented in section 4.1.2. 
The tissue binding was implemented in the peripheral compartment as this was superior to 
implementing a second binding partner in the central compartment which is easily 
accessible via plasma but not part of the plasma (e.g. membrane bound DPP-4 on lympho-
cytes or on endothelium). The latter approach has successfully been used previously to 
describe the target-mediated drug disposition of the angiotensin-converting enzyme 
inhibitor benazepril (153). A possible explanation for the difference between both models 
might be that membrane bound angiotensin-converting enzyme is predominantly located in 
the endothelium of blood vessels (169), whereas DPP-4 is to a high extent also expressed 
on the epithelia of various tissues (57,72-75). The investigations on the identifiability of 
the model structure also demonstrated that the proposed model structure not only reflects 
physiology best, but was also identifiable using the clinical data of Project 1. These 
investigations further suggested that an analysis of a wide range of doses (1–10 mg) is 
important to determine all model parameters adequately. 
Identical binding affinities of linagliptin for soluble plasma DPP-4 and membrane-bound 
tissue DPP-4 were assumed in the model. This was necessary as it was not possible to 
independently estimate two different binding affinities. Assuming identical binding 
affinities is justified as soluble DPP-4 is most likely a cleavage product of the membrane-
bound DPP-4 (57). 
The binding of linagliptin to DPP-4 was assumed to be reversible. This is in line with 
previous in vitro experiments (101). However, precisely estimating binding association and 
dissociation rate constants using a target-mediated drug disposition model is difficult 
(152). Thus, to simplify the estimation, quasi-equilibrium conditions were assumed for the 
high-affinity binding of linagliptin to DPP-4, i.e. it was assumed that the binding equilib-
rium is reached faster than all other processes. This assumption has previously been 
successfully applied by several authors (151-153,155). In Project 5, the assumption of 
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quasi-equilibrium conditions for the binding of linagliptin to DPP-4 was tested for the final 
model structure. Assuming that the binding equilibrium was reached instantly had only 
negligible effects on the description of the linagliptin plasma concentration-time profiles 
and the parameter estimates.  
4.1.3.2 Pharmacodynamic model 
In Project 1 it was assumed that plasma DPP-4 occupancy with linagliptin is directly 
proportional to the decrease of plasma DPP-4 activity. This implies that the interaction is 
readily reversible, independent of time, and not cooperative (170). The binding of lina-
gliptin to DPP-4 was found to be reversible in in vitro dissociation assays (101). No 
hysteresis was obvious in the relationship between linagliptin plasma concentration and 
plasma DPP-4 inhibition (103), suggesting that the interaction is time-independent. DPP-4 
monomers have only one active site, i.e. one linagliptin binding site (100). However, as 
DPP-4 molecules are often associated as dimers (57), cooperativity might be possible 
(100). Such a cooperative effect would not be covered by the current model.  
The basic concept of ‘receptor occupancy’ was introduced in the 1930s by Alfred J. Clark 
and has meanwhile been extended to allow the description of more complex scenarios, in 
which not only receptor occupancy, but also subsequent processes contribute to the 
response (170). As no processes subsequent to binding are involved in the DPP-4 inhibi-
tion by linagliptin, however, the basic model can be applied here.  
The pharmacokinetic/pharmacodynamic model of Project 1 assumed the in vivo (i.e. in 
plasma) and in vitro (i.e. in the assay) DPP-4 occupancies with linagliptin to be identical. 
The presumed DPP-4 occupancy with linagliptin in vitro may be lower than in vivo, 
however, as the in vitro assay requires the plasma samples to be diluted and substrate to be 
added in excess, affecting the binding equilibrium. Assuming different in vivo and in vitro 
DPP-4 occupancies would significantly improve the model fit (∆OBJF −28.092), but this 
would also increase the complexity of the model. In addition, visual predictive checks 
indicated only minor differences between the fits. Therefore, no difference in the in vitro 
and the in vivo occupancy was accounted for in the final model.  
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4.1.4 Implications of  the target-mediated drug disposition of  
linagliptin 
Simulations using the pharmacokinetic model of wildtype rats revealed that the binding of 
linagliptin to DPP-4 in plasma as well as in peripheral tissues has a major impact on the 
disposition of linagliptin (Project 5). In plasma and tissue, the fraction of linagliptin bound 
to DPP-4 was not directly available for elimination or re-distribution and acted as a 
‘reservoir’. In contrast, unbound linagliptin was cleared or re-distributed efficiently. Thus, 
the high affinity binding in wildtype rats led to a prolonged terminal half-life and a higher 
exposure of linagliptin in both plasma and tissue compared to DPP-4-deficient rats. With 
increasing doses, the percentage of linagliptin bound to DPP-4 decreased as DPP-4 became 
saturated, mitigating the impact of the binding on the pharmacokinetic profiles in both 
compartments. These simulations are in accordance with the differences observed in the 
plasma concentration-time profiles between DPP-4-deficient and wildtype rats. In addition, 
the predicted behaviour of linagliptin in the peripheral tissues very well matched the tissue 
distribution of [14C]linagliptin-related radioactivity in wildtype and DPP-4-deficient rats 
(161). Both, the simulated as well as the observed tissue distribution, suggested that 
saturation of ‘tissue’ DPP-4 with linagliptin was achieved with single intravenous bolus 
doses of less than 1 mg/kg linagliptin (0.04 mg/kg based on the model). 
Like in the animal model, the target binding of linagliptin plays a considerable role in 
humans when the compound is administered in the therapeutic dose range. Simulations of 
the steady-state profiles for the 5 mg linagliptin dose, which is the therapeutic dose tested 
in the clinical phase III programme, were performed. These simulations predicted that the 
total AUCτ,SS is actually composed to the greater part (~70%) of linagliptin bound to 
DPP-4, while only the smaller fraction is not bound to DPP-4. Thus, the target-mediated 
drug disposition of linagliptin must be taken into account in the interpretation of the 
pharmacokinetics of linagliptin. 
4.1.4.1 Impact on the pharmacokinetic parameters of linagliptin 
In clinical studies I and II, the AUC0-24h and AUCτ,SS of linagliptin increased less than 
dose-proportionally with increasing dose. Both clearance and VSS of linagliptin determined 
by noncompartmental analysis increased with increasing dose (cf. Table 1-1). Furthermore, 
despite a long terminal half-life of more than 100 h, the accumulation ratio based on AUC 
(RA,AUC) was small, ranging from 1.2–2.0, and steady-state was reached fast (2–6 days) 
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(104). Both the accumulation and the time to reach steady-state were dose-dependent for 
linagliptin. 
These particularities of linagliptin pharmacokinetics can be explained by the model 
accounting for target-mediated drug disposition. The elimination of linagliptin is governed 
by the high-affinity binding of linagliptin to its target DPP-4, leading to a long terminal 
half-life. Thus, the clearance of total linagliptin calculated by noncompartmental analysis 
is not only dependent on the linear clearance of unbound linagliptin but also on the affinity 
to and the concentration of DPP-4 in plasma and tissue. With increasing doses, the fraction 
of unbound linagliptin increases as the binding partner becomes saturated. This leads to an 
increase in the volume of distribution and the clearance of total linagliptin as determined 
by noncompartmental analysis and thus to a less than dose-proportional increase in the 
exposure of linagliptin.  
The accumulation of unbound linagliptin is low as the fraction of unbound linagliptin is 
eliminated efficiently (CL/F 220 L/h, in Project 1). The accumulation of linagliptin is dose-
dependent as well due to the concentration-dependent binding. When high doses (e.g. 
10 mg) are administered, saturation of DPP-4 and thus steady-state is effectively achieved 
after the first dose already (cf. Figure 3-6, right panel), resulting in a low accumulation 
ratio of 1.2. Conversely, when low linagliptin doses (e.g. 1 mg) were administered, 
saturation of DPP-4, and thus steady-state, was not achieved until 4–6 administrations. 
Accordingly, accumulation is higher (accumulation ratio 2.0) for low doses. 
4.1.4.2 Impact on linagliptin DPP-4 inhibition 
Due to the direct relationship between pharmacokinetics and pharmacodynamics via the 
occupancy of DPP-4 with linagliptin, the pharmacokinetic characteristics are also apparent 
in the DPP-4 inhibition. The plasma DPP-4 inhibition is long-lasting as it is likewise 
dependent on the slow dissociation of linagliptin from its target. Accordingly, the time 
until steady-state inhibition is reached is dose-dependent. While low doses of linagliptin 
are sufficient to elicit a marked DPP-4 plasma inhibition under steady-state conditions, 
DPP-4 occupancy keeps increasing after the first dose, and thus steady-state DPP-4 
inhibition is only reached after several administrations. In contrast, single high doses of 
linagliptin lead to an instant near-maximum saturation of DPP-4 and thus steady-state 
DPP-4 inhibition is reached already after the first dose.  
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4.1.4.3 Comparison to other DPP-4 inhibitors 
Interestingly, the impact of target-mediated drug disposition on the pharmacokinetics is 
higher for linagliptin compared to other DPP-4 inhibitors exhibiting approximately linear 
pharmacokinetics (108-111). This may be explained by a higher affinity of linagliptin to 
DPP-4 compared to other DPP-4 inhibitors. A recent study compared the in vitro IC50 
values of several DPP-4 inhibitors (101). Indeed, linagliptin inhibited DPP-4 most 
effectively with an in vitro IC50 of ~1 nM, compared to sitagliptin (19 nM), alogliptin 
(24 nM), saxagliptin (50 nM) and vildagliptin (63 nM). In line with their lower binding 
affinities, higher therapeutic doses for sitagliptin (100 mg qd), vildagliptin (50 mg qd or 
bid) and alogliptin (25 mg qd) were required. Also, the AUC values of these compounds 
are higher compared to linagliptin (Table 4-2).  
Table 4-2  Comparison of the therapeutic dose, AUC, fraction unbound, and IC50 of saxagliptin, 
alogliptin, vildagliptin, sitagliptin and linagliptin 
 Saxagliptin Aloglitpin2) Vildagliptin Sitagliptin Linagliptin 
 Parent Active 
Metabolite 
BMS-510849 
    
Dose [mg] 5 (qd) NA 25 (qd) 50 (qd) 100 (qd) 5 (qd) 
AUC [nM·h] 180 (111)3) 1,355 (111)4) 3,194 (110)5) 3,395 (173)6) 8,500 (108) 158 (104) 
fu 1.0 (111) 1.0 (111) Not specified 0.91 (171) 0.54-0.66 
(172) 
0.005-
22.7(162) 
IC50 [nM] (101) 50 ND1) 24 63 19 1 
1)
 Twofold less potent (111) 
2)
 Active metabolite with similar potency than parent in vitro, but only ~1% of AUC parent (110) 
3)
 AUC0-inf is reported to be 0.06 µg·h/mL and molecular weight of saxagliptin is 333.4 g/mol 
4)
 AUC0-inf is reported to be 0.43 µg·h/mL and molecular weight of saxagliptin metabolite is  
333.4 −16 = 317.4 g/mol 
5)
 AUCτ,SS is reported to be 1.474 µg·h/mL and molecular weight of alogliptin is 461.5 g/mol 
6)
 AUC0-inf is reported to be 1.030 µg·h/mL for 50 mg qd and molecular weight of vildagliptin is  
303.4 g/mol 
NA, not applicable 
 
In contrast, the doses as well as the exposures of saxagliptin and linagliptin are similar. 
Interestingly, saxagliptin has a pharmacologically active metabolite with a ~7-fold higher 
exposure than the parent compound which may possibly explain the similar dose and 
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exposure of linagliptin and saxagliptin despite the 50-fold lower affinity of saxagliptin for 
DPP-4. 
4.1.4.4 Clinical implications 
Due to its target-mediated drug disposition, the terminal half-life of linagliptin is not 
predictive with regard to accumulation. The accumulation for the low dose groups (e.g. 
1 mg, 2.5 mg) is dependent on the saturation of DPP-4 as well as the accumulation of 
unbound linagliptin. For higher doses (e.g. 5 mg, 10 mg), DPP-4 is saturated already after 
the first dose and thus, the accumulation is predominately dependent on unbound lina-
gliptin. The pharmacokinetics of unbound linagliptin is linear and thus the effective half-
life of unbound linagliptin is predictive with regard to the accumulation for higher dose 
groups. The model-derived effective half-life of unbound linagliptin is 7.7 h. This is in line 
with the accumulation half-lives of 11.4 h and 8.59 h determined by noncompartmental 
analysis for the 5 mg and 10 mg dose respectively (104).  
One consequence of the short terminal half-life of unbound linagliptin, in conjunction with 
the nonlinearity in the pharmacokinetics, is a less pronounced increase in the exposure for 
patients with a reduced CL/F of unbound linagliptin compared to compounds with linear 
pharmacokinetics (cf. section 4.3.2). The same holds true for increases in the 
bioavailability or overdosing. If e.g. 10 mg linagliptin was taken instead of 5 mg, the 
AUCτ,SS is predicted to increase only by 33% rather than to double.  
Conversely, due to the high-affinity binding of linagliptin to its target DPP-4 leading to a 
long terminal half-life and the long-term effect of linagliptin on the DPP-4 activity, a 
single missed 5 mg dose would in average still result in a DPP-4 inhibition after 48 h of 
71.4%. The long terminal half-life of linagliptin might also be problematic. In case of 
intolerance for example, linagliptin cannot be eliminated rapidly. This is a theoretical 
scenario, however, as linagliptin was very well tolerated in all studies performed so far 
(103,174). Furthermore, only the fraction bound to DPP-4 remains in the body longer, 
while the major fraction of linagliptin, which is not bound to DPP-4, is eliminated fast.  
The fraction of drug which is not bound by DPP-4 will not affect the DPP-4 activity, and 
will not contribute to the efficacy. Accordingly, and in line with the observed plasma 
DPP-4 activity, simulations showed that the occupancy for the 5 mg and the 10 mg dose 
groups is similar and >90% (cf. Figure 3-6, right panel). This favours 5 mg as the therapeu-
tic dose. 
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4.2 Characterisation of  the pharmacokinetics and the 
pharmacokinetic/pharmacodynamic relationship of  
linagliptin 
4.2.1 Structural model comparison 
The structures of the pharmacokinetic models of linagliptin were similar in rats, healthy 
volunteers, and type 2 diabetic patients. All three models included concentration-dependent 
protein binding in the central and one peripheral compartment. In Projects 4 and 5, a three-
compartment model was required to describe the plasma concentrations adequately, 
whereas in Project 1 a second peripheral compartment was not supported by the data. This 
difference between the structural models might be explained by the fact that plasma 
concentrations after intravenous administration were included in Projects 4 and 5, but not 
in Project 1. Possibly, the very fast initial distribution phase with α-phase half-lives of 
linagliptin of 0.085 h in Project 4 and 0.058 h in Project 5 is masked by the relatively slow 
absorption of linagliptin. 
4.2.2 Population parameters 
4.2.2.1 Volume of distribution and clearance of unbound linagliptin 
The volumes of distribution at steady-state of unbound linagliptin were found to be high in 
rats (Project 5), healthy volunteers (Project 4) and type 2 diabetic patients (Project 3a) 
(VSS: 16.6 L/kg, 5.1 L/kg, and VSS/F: 26.2 L/kg, respectively). All estimates by far 
exceeded the total volume of body water, indicating an extensive tissue distribution of 
unbound linagliptin. These findings are consistent with the extensive tissue distribution 
observed for unbound linagliptin in DPP-4-deficient rats as determined by autoradiography 
(161). 
The clearances of unbound linagliptin were estimated to be moderate to high in rats 
(Project 5), healthy volunteers (Project 4) and type 2 diabetic patients (Project 3a) 
(CL: 6.09 L/h/kg, 0.34 L/h/kg, and CL/F: 2.86 L/h/kg, respectively). The clearance 
normalised to body weight was considerably higher in rats compared to humans. This 
might possibly be caused by differences in the biliary excretion of linagliptin of rats and 
humans as biliary excretion is generally difficult to predict between different species 
(175,176). Assuming an absolute bioavailability of 29.5%, a ~2-fold higher clearance was 
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estimated in diabetic patients compared to the healthy volunteers of Project 4. In line with 
the lower clearance in Project 4, the linagliptin exposure was 21–41% higher in Project 4 
(AUC0-24h: 227 nM·h in Project 4) compared to Project 1 (AUC0-24h: 161 nM·h in study I, 
188 nM·h in study II) after oral administration of 10 mg linagliptin. Due to the 
nonlinearity, the effect of an enhanced clearance on the linagliptin plasma concentration-
time profile is lower than would be the case for linear pharmacokinetics. Accordingly, the 
predicted typical concentration-time profile of Project 4 was only slightly increased 
compared to those of the other projects (Figure 4-1). The reason for the different exposures 
in both projects is unknown. A difference between healthy volunteers and patients is 
unlikely, as similar exposures for healthy volunteers and type 2 diabetic patients were 
observed in other studies. For example, comparable AUC0-24h values were found for the 
healthy volunteers in the control group of Project 2d and the patients of Project 1 (122 
nM·h compared to 119 nM·h (study I) and 124 nM·h (study II) after oral administration of 
5 mg linagliptin). Also, the plasma concentration-time profiles of the healthy volunteers in 
Project 4 could be adequately described by the model developed for diabetic patients in 
Project 1 with only minor model adaptations (cf. section 3.2.4), suggesting that the 
differences in exposures between Project 4 and Project 3a are random inter-study effects. 
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Figure 4-1  Comparison of simulated typical linagliptin concentration-time profiles based on the 
pharmacokinetic models developed in Projects 1, 2d, 3a, and 4 assuming that a single oral dose of 
5 mg linagliptin was administered. The grey shaded area represents the overall variability 
determined as the 90% confidence interval of 1,000 simulated concentration-time profiles based on 
the base population pharmacokinetic model of Project 3a. 
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4.2.2.2 Binding parameters 
The concentrations of binding partner in the central compartment were estimated to be 
2.70 nM, 3.44 nM, and 4.97 nM for rats, healthy volunteers, and type 2 diabetic patients, 
respectively, and thus lie within the range expected for the plasma DPP-4 concentration 
(79,80). Based on the plasma protein binding assay, a similar concentration of plasma 
DPP-4 monomers of 3.84 nM for rats and 6.36 nM for humans was estimated (162). An 
elevated plasma DPP-4 concentration for type 2 diabetic patients would be in line with the 
finding of a higher DPP-4 activity in type 2 diabetic patients compared to healthy volun-
teers (177,178). 
The dissociation constants for the binding of linagliptin to DPP-4 were estimated to be 
0.043 nM, 0.0835 nM, and 0.0652 nM for rats, healthy volunteers and type 2 diabetic 
patients, respectively. Again these estimates are in good agreement with the dissociation 
constant obtained in vitro from plasma samples employing equilibrium dialysis 
(Kd: 0.043 nM for rats and 0.051 nM for humans, as calculated by Kd = 1/K1) (162). 
The total amount of the binding partner (DPP-4) normalised to body weight was estimated 
to be higher in rats compared to humans (46.0 nmol/kg in rats compared to 7.55 nmol/kg in 
healthy volunteers and 17.0 nmol/kg in patients, considering a bioavailability of 29.5%). 
So far no data for comparison have been published. A recent estimate based on differences 
in the linagliptin distribution of wildtype and DPP-4-deficient rats indicated a total DPP-4 
amount of 22 nmol in a 250 g rat corresponding to 88 nmol/kg (personal communication, 
H. Fuchs). 
4.2.2.3 Correlation between pharmacokinetics of linagliptin and DPP-4 activity 
The maximum decrease in DPP-4 activity in type 2 diabetic patients was estimated to be 
93.5% and 92.4% in Projects 1 and 3b, respectively. This may be an underestimation of the 
‘true’ maximum DPP-4 inhibition in vivo due to sample dilution and addition of the 
competitive substrate alanine-proline-7-amido-4-trifluoro-methylcoumarine during the 
DPP-4 activity assay (cf. section 2.1.2). 
The linagliptin concentration leading to half-maximum DPP-4 inhibition was determined 
by a sigmoid Emax model to be 3.06 nM (Project 3b). This concentration is in line with 
previous data from healthy volunteers in which a concentration of ~2–4 nM were estimated 
to lead to 50% inhibition of the DPP-4 enzyme (103). 
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4.2.2.4 Variability in the pharmacokinetic parameters of linagliptin 
Absorption is apparently the major source of variability in the pharmacokinetics of 
linagliptin. After intravenous administration of linagliptin to rats (Project 5) and healthy 
volunteers (Project 4) a very low variability in the disposition of linagliptin was observed 
(cf. Figure 3-16, Figure 3-19), whereas a moderate variability was apparent after oral 
administration of linagliptin to healthy volunteers and type 2 diabetic patients (cf. Figure 
3-17 and Appendix, Figure 16). 
A moderate to high variability in the absorption phase was also found during the investiga-
tion of inter- and intraindividual variability (Project 3a). This was accounted for by an 
inter-individual variability on the absorption parameters (ωF: 44.2%; ωKa: 87.6%) and an 
intraindividual variability on F (piF: 39.2%). A smaller variability was observed in the 
distribution and elimination parameters (ωBmax,C: 29.6%; ωVC: 22.6%; ωCL: 23.9%). 
4.2.3 Covariate selection 
An initial covariate analysis performed in Project 1 using data from two phase IIa studies 
revealed no major impact of any tested covariate on the pharmacokinetics and the plasma 
DPP-4 inhibition of linagliptin except an unexplained study difference in the relative 
bioavailability between studies I and II. 
The initial covariate analysis was extended by analyzing the two phase IIa studies and, in 
addition, two phase IIb studies together. The complexity of the pharmacokinetic model and 
the amount of analysed data led to extensively long run times. Therefore, two separate 
analyses, one for the pharmacokinetics and one for the pharmacokinetic/pharmacodynamic 
relationship, were performed. 
Of special interest were the effects of weight, age and sex on the pharmacokinetics and 
DPP-4 inhibition of linagliptin, because no dedicated studies are planned to investigate 
these effects. 
4.2.3.1 Covariates affecting the pharmacokinetics of linagliptin 
The structure of the target-mediated drug disposition model developed in Project 1 was 
used as the starting point for this analysis. Some model parameters could not be estimated 
and therefore had to be fixed according to the estimates obtained in Project 1. Neverthe-
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less, this model was preferred to a simpler model, as it allowed a physiologic interpretation 
of the relevant covariates. 
A significantly elevated relative bioavailability was estimated for study IV, the add-on to 
metformin study. In addition, the relative bioavailability decreased significantly with 
increasing weight. The formulation and the dose group showed a statistically significant 
influence on the rate of absorption. The unbound clearance tended to be decreased in case 
of increased gamma-glutamyl transferase but this effect was no longer significant when all 
parameters were estimated together. The model-calculated concentration of central binding 
partner was influenced by pre-dose DPP-4 activity, dose, age, and sex. In the following, 
the effects of the statistically significant covariates on the pharmacokinetics of linagliptin 
are discussed in detail. 
4.2.3.1.1 Age 
For linagliptin, the covariate analysis revealed only a minor effect of age on its pharma-
cokinetics. An average increase of 13.8% in the AUCτ,SS of a 73-year-old patient compared 
to a 42-year-old patient (representing the 95th and 5th percentiles of the age distribution, 
respectively) was found when 5 mg linagliptin were taken once daily. A significant effect 
of age was only found on the concentration of central binding partner. The older the 
patients, the higher were their Bmax,C values. In contrast, in a multiple regression analysis 
using measured plasma DPP-4 concentrations of phase IIb, no correlation between age and 
DPP-4 plasma concentration was observed (data not shown). Thus, it cannot be excluded 
that the underlying physiological reason of the age-dependent AUCτ,SS is not an increase of 
plasma DPP-4 levels, but related to a change in another pharmacokinetic parameter of 
linagliptin. Age-dependent changes in the distribution, metabolism and excretion are 
reported for many drugs (179). These changes often result in a reduced rate of elimination 
in elderly patients and in an increased exposure. The volume of distribution of hydrophilic 
drugs is often reduced in older patients due to reduced total body water, whereas the 
volume of distribution of lipophilic drugs is often elevated, due to an elevated fat mass 
(180). With a positive log D value of 0.4, linagliptin can be considered a slightly lipophilic 
drug and thus no major change in the volume of distribution is expected for linagliptin. In 
addition, elderly patients often exhibit a lower plasma protein binding due to ~10% lower 
serum albumin levels (181). The metabolic clearance can be reduced in elderly patients due 
to a lower phase I metabolism, as well as a reduction in blood flow or liver mass (182). In 
addition, renal clearance is often reduced in older patients. For linagliptin however, both 
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metabolism as well as renal elimination are minor pathways as it is mainly excreted 
unchanged via the faeces. 
4.2.3.1.2 Weight 
For linagliptin, only a small impact of weight was found on the exposure (5.9% and −8.7% 
on the AUCτ,SS after administration of 5 mg once daily for the 5th and 95th percentile of the 
weight distribution). Weight was found as a covariate for the relative bioavailability; 
however, since only linagliptin concentrations after oral administration were included in 
the combined analysis, it could not be differentiated whether weight indeed affected the 
bioavailability or rather accounted for the variability in the apparent clearance and/or in the 
apparent volumes of distribution. The second possibility would be physiologically more 
reasonable considering the typical pharmacokinetic peculiarities in obese subjects 
(183,184). Overweight subjects have a different tissue composition compared to normal 
subjects, characterised by a higher proportion of adipose tissue and lower proportions of 
muscles and body water. Lipophilic drugs typically have a larger volume of distribution in 
adipose patients, thus these patients often require higher loading doses of lipophilic drugs. 
In contrast, the pharmacokinetics of hydrophilic drugs is often not or only slightly changed 
for these subjects. In addition, for obese subjects, plasma protein binding (e.g. due to 
hyperlipidemia), metabolism (e.g. due to a fatty liver) as well as renal (e.g. due to changes 
in the glomerular filtration rate) and biliary elimination (e.g. due to gall stones) may also 
be changed.  
4.2.3.1.3 Sex 
For linagliptin, a small sex-related difference in the pharmacokinetics was found, leading 
to a 7% higher AUCτ,SS in females when 5 mg linagliptin was given once daily. The higher 
exposure was found to be due to a higher concentration of the binding partner in the central 
compartment for females. When co-estimating all covariate effects and then performing the 
backward elimination, the effect of gender on Bmax,C did no longer reach the required 
statistical level, but was still kept in the model for reasons of model stability. In accordance 
with the marginally higher estimated levels of the central binding partner in females, 
slightly but significantly higher plasma DPP-4 levels were found for females in a multiple 
regression analysis using observed DPP-4 concentrations from the phase IIb studies (data 
not shown). In general, pharmacokinetic differences due to sex are rare and if present they 
are small (185,186). Sex-related differences in the activity of some transporters and 
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metabolizing enzymes were reported (186). Of these, linagliptin pharmacokinetics might 
be affected by P-glycoprotein, which shows a higher expression in males. The major 
linagliptin metabolite CD1790 is produced by CYP3A4, for which no sex-related differ-
ences have been reported. In addition, females have a lower body weight and a lower 
glomerular filtration rate which might possibly also influence linagliptin pharmacokinetics.  
4.2.3.1.4 Other covariates 
In study IV when linagliptin was given as add-on to metformin, a ~20% higher exposure 
was observed compared to the mono-therapy linagliptin studies. The effect was best 
described by an increased bioavailability for this study. A decreased clearance of lina-
gliptin, however, cannot be ruled out. An interaction between metformin and linagliptin 
affecting the linagliptin clearance might be possible. In a drug-drug interaction study, a 
~20% higher linagliptin exposure was observed in combination with metformin whereas 
the Cmax concentrations and the terminal half-lives were comparable (187). However, the 
mechanism of a potential interaction between the two compounds remains unclear. 
Metformin is not metabolised and mainly excreted renally via the organic cation trans-
porter 2 (OCT2), which is predominately expressed in the distal renal tubules (188). 
Although linagliptin has been found to be a substrate for OCT2 in vitro (personal commu-
nication, W. Kishimoto), renal excretion plays a negligible role in the elimination of 
linagliptin (104). On the other hand, little information is available on the interaction of 
metformin with other transporters such as P-glycoprotein, which might influence the 
absorption of linagliptin. Although the higher exposure of linagliptin on metformin 
background treatment in study IV was in the range observed in the drug-drug interaction 
study with metformin, a pure study effect cannot be ruled out.  
Formulation and dose affected the rate of linagliptin absorption. The powder in bottle 
solution (study I) showed the fastest absorption (Ka: 0.933 h−1), followed by the tablet 
given in study II (Ka: 0.795 h−1), while the tablet of the formulation given in the studies III 
and IV showed the slowest absorption (Ka: 0.441 h−1). Differences due to the formulations 
are unlikely as their bioequivalence was shown in dedicated bioequivalence studies. The 
difference between studies I/II and studies III/IV might be due to the different sampling 
schemes or the fact that in the phase IIb studies, linagliptin was to be taken with a meal 
whereas it was to be taken fasted in the phase IIa studies. In favour of the latter possibility, 
a food effect study demonstrated that a high-fat meal reduced the rate of absorption, with 
the Cmax values being lowered by 15%. In the same study, no influence of food on the 
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extent of linagliptin exposure was found (personal communication, U. Graefe-Mody). The 
reason why dose affected the rate of absorption is unknown. It might be speculated that 
saturable processes in the absorption are involved. 
The model estimated the concentration of central binding partner to be correlated with the 
pre-dose DPP-4 activities. This physiologically plausible correlation is in line with the 
assumption that the concentration of central binding partner estimated by the model 
actually reflected the monomer concentration of plasma DPP-4 (cf. section 4.1.2). The 
dose correlated slightly with Bmax,C which might represent a minor model misspecification. 
When the impact of the covariates was tested separately per model parameter, the only 
statistically significant covariate found on the clearance of unbound linagliptin was a minor 
effect of the liver enzyme gamma-glutamyl transferase. The 95th percentile of the gamma-
glutamyl transferase distribution resulted in a clinically not relevant increase in the AUC of 
1.4%. When all covariates were tested together, the covariate effect of gamma-glutamyl 
transferase on clearance was no longer statistically significant, also pointing out the minor 
importance of this covariate effect. Thus, no major impact on the linagliptin pharmacoki-
netics resulted from the investigated liver enzymes, suggesting that liver impairment does 
not alter the pharmacokinetics of linagliptin. However, these results need to be confirmed 
in a dedicated study including patients with diverse symptoms of liver disease as assessed 
by the Child-Pugh score. 
Creatinine clearance was not found to impact the linagliptin clearance. This is in line with 
the finding that the renal elimination of linagliptin represents only a minor elimination 
pathway (in the therapeutic dose range ~4% of the linagliptin dose is eliminated via the 
kidneys). In addition, in the investigated studies, only patients with no or mild renal 
impairment were included (90% confidence interval of creatinine clearance: 65–
189 mL/min). The impact of moderately and severely impaired renal elimination on the 
pharmacokinetics of linagliptin needs to be further investigated. This is especially impor-
tant since renal impairment is common among type 2 diabetics. Furthermore, it was 
recently shown that renal impairment can also affect the pharmacokinetics of drugs that, 
like linagliptin, are predominantly eliminated by nonrenal processes (189). 
4.2.3.1.5 Clinical relevance 
Overall, the individual impact of the statistically significant covariates, including weight, 
age and sex on the AUCτ,SS of patients receiving 5 mg linagliptin once daily was less than 
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±20%. Also the exploratively investigated covariates like creatinine clearance and liver 
enzymes only showed a minor impact on the linagliptin pharmacokinetics, suggesting that 
an impairment of renal or hepatic clearance is unlikely to have a substantial impact on 
linagliptin exposure. However, this needs to be confirmed in dedicated studies including 
also patients with severely impaired renal and hepatic clearances. The low impact of the 
individual covariates of less than ±20% on the AUCτ,SS was regarded to be not clinically 
relevant, making a dose adjustment based on these covariates unnecessary. Even the 
combination of all covariates in a worst case scenario is with regard to the largest decrease, 
−26% for the 5 mg dose, still regarded as effective as the linagliptin exposure is in the 
range of the 2.5 mg dose group (study I: gMean AUCτ,SS 2.5 mg: 117 nM·h, 5 mg: 
158 nM·h; study II: gMean AUCτ,SS 2.5 mg: 116 nM·h, 5 mg: 148 nM·h). The worst case 
with regard to the largest increase (+63%) for the 5 mg dose can still be regarded as safe 
based on the safety data collected in the phase IIb and in the first-in-man study where a 
single dose of linagliptin up to 600 mg was administered and well tolerated (103).  
One reason for the lack of clinically relevant covariates is the nonlinear pharmacokinetics 
of linagliptin. The change in the relative bioavailability or clearance must be much more 
pronounced in case of linagliptin compared to a compound with a linear pharmacokinetics 
to result in the same decrease or increase in the exposure (Table 4-3, cf. section 4.1.4.4). 
Thus, even if a covariate affects the bioavailability or the clearance of unbound linagliptin, 
the clinically relevant influence on the exposure of linagliptin is much smaller. 
Table 4-3  Change in bioavailability and clearance required to achieve an increase or decrease of 
the steady-state exposure in terms of AUCτ,SS. For the pharmacokinetics of linagliptin a once daily 
administration of 5 mg linagliptin was assumed. 
 Linear pharmacokinetics Pharmacokinetics of linagliptin 
 Change in 
bioavailability 
Change in 
clearance 
Change in 
bioavailability 
Change in 
clearance 
Increase in the exposure (AUCτ,SS) of 25% +25% -20 % +82% -42 % 
Decrease in the exposure (AUCτ,SS) of 25% -25% +33% -68% +152% 
 
4.2.3.2 Covariates affecting the pharmacodynamics of linagliptin 
The correlation between linagliptin plasma concentration and plasma DPP-4 activity was 
best described by a sigmoid Emax model. The correlation between the individual EC50 
values and the pre-dose DPP-4 activities was taken into account by assuming a covariate 
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effect of the predicted individual pre-dose DPP-4 activities on EC50. The idea behind this 
was that a higher pre-dose DPP-4 activity corresponds to a higher DPP-4 plasma concen-
tration. A higher DPP-4 plasma concentration in turn necessitates more linagliptin for half-
maximum DPP-4 inhibition to be reached, corresponding to a higher EC50. By this coding 
the covariates affecting the pre-dose DPP-4 activity also have an indirect impact on EC50 
and EC80%. 
4.2.3.2.1 Age 
In the covariate analysis age had no impact on plasma DPP-4 activity. This is in line with 
the observation by Cordero et al. that the DPP-4 levels are not correlated to age. In 
contrast, different groups reported a significant inverse correlation between age and DPP-4 
activity in healthy subjects (190) and type 2 diabetic patients (178). Mannucci et al. found 
an inverse correlation in one group of type 2 diabetic patients and no correlation in another 
group (177). Thus, the impact of age on DPP-4 activity is only minor, if at all existent. 
4.2.3.2.2 Weight 
In accordance with published data from healthy volunteers (190) as well as from type 2 
diabetic patients (177), neither weight nor body mass index were found to influence the 
DPP-4 activity. 
4.2.3.2.3 Sex 
Females had a higher pre-dose DPP-4 activity (11,565 versus 10,700 RFU), and thus 
higher EC50 and EC80% values compared to males. In contrast to our findings, Durinx et al. 
reported slightly lower DPP-4 activity in females than in males (plasma 23.2 U/L vs. 
25.9 U/L), but these differences were no longer significant in their multiple regression 
analysis (190). No correlation between the DPP-4 levels and sex was reported by Cordero 
et al. (79). Thus, a sex-related difference in the DPP-4 activity is only minor, if at all 
existent. 
4.2.3.2.4 Other covariates 
In line with other studies (190-192), pre-dose DPP-4 activity was found to be correlated 
with the liver enzymes gamma-glutamyl transferase, alanine transaminase, and aspartate 
transaminase. However, due to the high correlation between alanine transaminase and 
   130 4 Discussion 
aspartate transaminase (cf. Appendix, Figure 25), only alanine transaminase and not 
aspartate transaminase was implemented in the final model. 
The covariate analysis of Project 3b revealed a correlation between fasting plasma glucose 
and pre-dose DPP-4 activity. This finding was in line with the correlation reported between 
HbA1c and fasting plasma glucose versus plasma DPP-4 activity in type 2 diabetic patients 
(177,178). In these reports, also higher DPP-4 activities in type 2 diabetic patients com-
pared to healthy volunteers were found, contradicting the results of Meneilly et al. (193). 
Durinx et al. found only a small effect of glucose on the DPP-4 activity in healthy 
volunteers in a multiple regression analysis (190). This might be explained by the lower 
plasma glucose concentration in healthy volunteers. Thus, in type 2 diabetic patients the 
plasma DPP-4 activity is apparently increased with increased plasma glucose levels. 
The lipid parameters triglycerides and cholesterol were both correlated to pre-dose DPP-4 
activity. When additionally accounting for an effect of triglyceride concentrations on the 
EC50 this covariate effect was negative, counteracting the influence of pre-dose DPP-4 
activity. The correlation between cholesterol and pre-dose DPP-4 activity was in line with 
the findings of Durinx et al., whereas an inverse correlation with triglycerides was reported 
in the same article (190).  
4.2.3.2.5 Clinical relevance 
The statistically significant covariates were evaluated for their influence on the EC50, as 
well as on the concentration leading to 80% DPP-4 inhibition. The individual impact of the 
different covariates on both parameters was <20%. Even the combined influence of all 
significant covariates only changed the EC50 value from a minimum of 2.49 nM to a 
maximum EC50 value of 4.14 nM (EC80%: minimum 4.44 nM and maximum 7.38 nM), 
respectively. This may be compared to a median plasma concentration at steady-state for 
5 mg linagliptin once daily of 12.5 nM at Cmax and 5.60 nM at Ctrough (cf. Appendix, 
Figures 22, 23). Thus, based on this analysis a dose adjustment does not seem to be 
justified for the tested covariates. 
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4.3 Clinical trial simulations to support the development of  
linagliptin 
The nonlinear pharmacokinetics of linagliptin made predictions solely based on noncom-
partmental parameters difficult. Thus, the target-mediated drug disposition model of 
Project 1 was not only used to investigate the impact of DPP-4 binding on the pharmacoki-
netics of linagliptin, but also to support the clinical development of linagliptin. 
4.3.1 Simulation to evaluate an equivalent dose for a twice-daily 
administration 
During development of the fixed dose combination of linagliptin with metformin the 
question for the adequate dose for a twice-daily treatment of linagliptin was addressed by 
simulations. It was predicted that despite the nonlinear pharmacokinetics, 2.5 mg lina-
gliptin twice daily would result in bioequivalent AUC24h,SS values as well as a similar DPP-
4 inhibition compared to 5 mg linagliptin once daily. The likely reason for this is that 
under steady-state conditions DPP-4 is nearly saturated over 24 h (cf. Figure 3-6, right 
panel). Thus, linagliptin that is not bound to DPP-4 behaves nearly linearly.  
Based on this simulation, a cross-over study was conducted in which 2.5 mg linagliptin 
administered twice daily (test treatment T) was tested versus 5 mg linagliptin administered 
once daily (reference treatment R) in 16 healthy volunteers. The 90% confidence interval 
of the adjusted gMean T/R ratio of the AUC24h,SS was 89.49–98.51% and thus within the 
acceptance interval of 0.80–1.25 (159,194). Therefore both dosage regimens were consid-
ered bioequivalent with regard to the extent of exposure at steady-state. In addition, both 
regimens resulted in a similar average trough DPP-4 inhibition of 85.3% for the 5 mg once 
daily regimen and 85.8% for the 2.5 mg twice-daily regimen. This bioequivalence study 
confirmed the previous simulation and demonstrated that the 2.5 mg linagliptin dose is the 
adequate dose for a twice-daily regimen. Thus, 2.5 mg linagliptin given twice daily is 
tested in combination with metformin in the phase III programme. 
4.3.2 Simulation to evaluate the impact of  impaired clearance 
In order to support the decision whether patients with a moderate renal impairment were to 
be included or excluded in phase IIb, the impact of an impaired clearance on the nonlinear 
pharmacokinetics of linagliptin was investigated. A 25% and a 50% reduction of the 
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overall clearance was simulated. The fraction excreted in urine after intravenous admini-
stration of linagliptin increased with dose with a maximum of 23% in the 10 mg dose 
group. Thus, a 25% reduction of the overall clearance would correspond to a complete loss 
of renal elimination. As renal impairment can also affect other elimination pathways (189), 
a 50% reduction of the overall clearance can be considered as a worst case scenario. 
The simulations revealed that for patients with only 75% or 50% of the clearance of a 
typical patient, the exposures of linagliptin would in average increase by 11% or 31%, 
respectively. In contrast, when assuming linear pharmacokinetics the impact of an 
impaired clearance on the exposure would be higher. Based on the equation 
CL = F·D/AUC the exposure is expected to increase by a third or to double if the clearance 
is reduced by 25% or by 50%, respectively (cf. section 4.1.4.4). 
4.3.3 Simulation of  a design for a dose-proportionality study 
Simulations suggested that a change-over study design without any washout between the 
periods is adequate to assess dose-proportionality of different dose strengths of linagliptin 
tablets (1, 2.5, and 5 mg) at steady-state when the treatment periods are at least seven days 
long. Steady-state was predicted to be reached first in the highest dose group (5 mg), and 
the time to steady-state was predicted to increase with decreasing doses. These predictions 
are in line with the observed steady-state characteristics reported in study I (104). Within 
the simulated 1 mg dose group, steady-state was reached latest when linagliptin is adminis-
tered in the first period. This indicates that the 1 mg dose administered without any 
previous linagliptin treatment is the treatment determining the duration of the periods. For 
this treatment group the time to reach steady-state is ~5 days as predicted by this simula-
tion and observed in study I (104). In conclusion, administering linagliptin over seven days 
is adequate to reach steady-state in each sequence. 
4.3.4 Description and steady-state simulation of  the drug-drug 
interaction between linagliptin and ritonavir 
Ritonavir is a potent inhibitor of CYP3A4 and P-glycoprotein. In a drug-drug interaction 
study the AUC0-inf of linagliptin increased 2-fold under comedication with ritonavir. The 
model-based analysis of Project 2d revealed a slightly reduced lag time, a 4-fold increase 
in the bioavailability of linagliptin, and a 16% decrease in the clearance of unbound 
linagliptin under ritonavir comedication. The high increase in bioavailability is plausible, 
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considering that the absolute bioavailability was estimated to be ~30% with a high inter-
individual variability (values ranged from 12.9–60.8%) (cf. section 4.4). Due to the 
nonlinear pharmacokinetics, a 4-fold increase in bioavailability does only result in a 2-fold 
increase in AUC0-inf. Compared to the bioavailability, the clearance of unbound linagliptin 
is predicted to be less affected by ritonavir. The low impact predicted on the clearance of 
linagliptin by ritonavir is in line with graphical investigations suggesting that the shapes of 
the linagliptin plasma concentration-time profiles were only slightly affected by ritonavir. 
Also the half-lives were comparable between linagliptin alone or in combination with 
ritonavir. In light of the absence of its major metabolite CD1790, normally representing 
17% of all drug-related species in plasma, a decrease in the metabolic clearance of 
unbound linagliptin under comedication of ritonavir is likely. As the metabolic clearance is 
only a minor elimination pathway of linagliptin, a low impact on the overall clearance does 
not contradict the current knowledge about linagliptin (cf. section 1.3.2).  
Differentiating between the impact of CYP3A4 or P-glycoprotein inhibition is difficult. 
However, considering the minor extent of metabolism of linagliptin and the major impact 
of ritonavir on the bioavailability of linagliptin, it seems likely that the effect of ritonavir is 
predominately driven by inhibition of P-glycoprotein during the absorption of linagliptin. 
Simulations predicted that under ritonavir comedication the increase in linagliptin exposure 
from the first dose to steady-state was small and comparable to linagliptin treatment alone. 
The accumulation ratio of the AUC of linagliptin was 1.13 when linagliptin was coadmin-
istered with ritonavir compared to 1.20 when linagliptin was given alone. Due to the near-
saturation of DPP-4 after the first 5 mg dose, the accumulation of linagliptin is predomi-
nantly dependent on the unbound fraction (cf. section 4.1.4.4). Due to the low impact of 
ritonavir on the clearance of unbound linagliptin, the effective half-life and thus the 
accumulation of unbound linagliptin were likewise only slightly affected. Thus, as 
observed after single dose, a ~2-fold increase in AUCτ,SS was predicted for steady-state.  
The predicted typical AUCτ,SS of 5 mg linagliptin once daily in comedication with ritonavir 
(293 nM·h) was far smaller than the AUC0-24h of the single dose administration of 600 mg 
linagliptin (33,010 nM·h) which was well-tolerated. In addition, 10 mg linagliptin once 
daily was shown to be well-tolerated over three months (174). Both study results suggest 
that a ~2-fold increase in the steady-state exposure of 5 mg linagliptin can be expected to 
be safe. However, this needs to be confirmed by further studies. 
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4.4 Absolute bioavailability of  linagliptin 
4.4.1 Estimation of  the absolute bioavailability of  linagliptin despite 
its nonlinear pharmacokinetics 
The absolute bioavailability is the percentage of the administered dose that reaches the 
general circulation (160). The standard approach to determine the absolute bioavailability 
of a compound is to divide the dose-adjusted AUCp.o. by AUCi.v. (159,194). However, this 
standard approach is only valid if the clearance calculated by CL = F·D/AUC of a drug is 
linear (160). This is not the case for linagliptin. 
One possibility to keep the clearance comparable between the oral and the intravenous 
treatment despite non-linear pharmacokinetics is to mimic the profile after oral administra-
tion by the intravenous administration. Congruent plasma concentration-time profiles after 
intravenous and oral administration would then allow a noncompartmental assessment of 
the absolute bioavailability (195). This approach was attempted within this study. Based on 
preclinical data, the absolute bioavailability was estimated to be ~50% (100). Therefore, a 
5 mg intravenous dose was compared to a 10 mg tablet in a cross-over design. As the 
maximum concentrations after oral administration were generally reached at a median tmax 
of 90 min in humans (104), the 5 mg intravenous dose was infused over 90 min. However, 
the profiles after intravenous and oral administration differed substantially (cf. 
Figure 3-17), making a meaningful noncompartmental assessment of the absolute bioavail-
ability impossible. Applying the standard approach of comparing AUCp.o. to AUCi.v. led to 
dose-dependent estimates of the absolute bioavailability ranging from 12% (10 mg oral 
compared to 0.5 mg intravenous) to 68% (10 mg oral compared to 10 mg intravenous).  
Another possibility to estimate the absolute bioavailability in case of a nonlinear 
pharmacokinetics is to divide the fraction excreted renally after oral administration by the 
fraction excreted renally after intravenous administration (160). The prerequisites for this 
approach are: (a) urine needs to be collected until almost all the drug has been excreted, (b) 
the ratio of renal clearance and total clearance must not change after intravenous and oral 
administration, and (c) renal elimination should represent a major elimination pathway. As 
the renal elimination is only a minor route of elimination for linagliptin and the ratio of 
renal clearance and total clearance increased with increasing intravenous doses, this 
approach was considered inadequate to estimate the absolute bioavailability of linagliptin. 
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An alternative approach to determine the absolute bioavailability despite nonlinear 
pharmacokinetics is to use a population pharmacokinetic model that accounts for the 
nonlinear process. Estimating the absolute bioavailability by a population pharmacokinetic 
model was successfully performed previously (196,197). Thus, the plasma concentrations 
after oral administration were analysed together with those after intravenous administration 
using the target-mediated drug disposition model (Project 4). The absorption of linagliptin 
was described by a first-order process with lag time. The disposition of unbound linagliptin 
and the binding of linagliptin to DPP-4 were assumed to be identical within a subject after 
intravenous and oral administration. In this way it was possible to estimate the absolute 
bioavailability. After accounting for the saturable binding, the absolute bioavailability was 
estimated to be 29.5% (range of individual values: 12.9–60.8%). 
4.4.2 Possible reasons for and consequences of  the moderate 
bioavailability of  linagliptin 
Linagliptin may be classified within the biopharmaceutics classification system (BCS) 
(198,199) as a class 3 drug: Linagliptin exhibits a high aqueous solubility in the pH range 
of 1–7.5 and a low gastrointestinal permeability, based on the extent of absorption (parent 
plus metabolite) as determined by a mass balance determination in humans (personal 
communication, U. Graefe-Mody). Wu and Benet postulated that drugs classified in the 
BCS class 3 are poorly metabolised, but highly dependent on transporters (200). This is in 
line with the low metabolism observed for linagliptin and the elimination of primarily 
unchanged linagliptin in the urine and faeces. Thus, according to this theory, the moderate 
absolute bioavailability of linagliptin may be explained by transporters that prevent the 
complete absorption of the drug. This explanation is in line with the increase in the 
exposure of linagliptin in the drug-drug interaction study with P-glycoprotein and CYP3A4 
inhibitor ritonavir (cf. section 4.3.4). 
Low to moderate bioavailability is often a major source of variability in the pharmacoki-
netics of a compound (160,201). For example, given an absolute bioavailability of 5%, a 
subject with a numerically small increase in the absolute bioavailability of another 5% 
(10% in total) would have a 2-fold higher bioavailability and thus a 2-fold higher exposure 
assuming linear pharmacokinetics. For linagliptin, the major source of variability is indeed 
the absorption (cf. section 4.2.2.4).  
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In addition, compounds with a low to moderate bioavailability exhibit a higher risk for 
drug-drug interactions as the bioavailability allows room for an increased exposure (160). 
Due to the absolute bioavailability of linagliptin of ~30%, the absolute bioavailability can 
rise ~3.4-fold. Indeed, a ~4 fold increase was observed in the bioavailability of linagliptin 
under comedication with ritonavir (cf. Project 2d) corresponding to the worst case of a 
drug-drug interaction on the bioavailability of linagliptin, as the bioavailability under 
ritonavir comedication is most likely in average ~100%. Due to the nonlinear pharmacoki-
netics of linagliptin, the maximum 4-fold increase in the absolute bioavailability was only 
related to a 2-fold maximum increase in the AUC. 
4.5 Impact of  pharmacometrics on the drug development of  
linagliptin 
Different publications describe the potential impact of pharmacometrics on the develop-
ment of a drug (115,117,131,132). In this section, the impact of the results of this thesis on 
the clinical development of linagliptin is outlined. 
4.5.1 Understanding and characterizing the nonlinear pharmaco-
kinetics of  linagliptin in the therapeutic concentration range 
One major objective of this work was to contribute to a better understanding and charac-
terisation of the nonlinear pharmacokinetics of linagliptin in the therapeutic dose range. 
For compounds with nonlinear pharmacokinetics, an in-depth understanding of the reasons 
for their nonlinearity is important to allow a safe and efficacious therapy. 
A population analysis was used to test different hypotheses for mechanisms resulting in 
nonlinear pharmacokinetics in a clinical setting. A model assuming concentration-
dependent protein binding of linagliptin to DPP-4 in plasma and tissues resulted in the best 
description of the plasma concentrations. This assumption was confirmed by a subsequent 
nonclinical study comparing the pharmacokinetics of wildtype and DPP-4-deficient rats. 
Both analyses corroborated the hypothesis that concentration-dependent binding of 
linagliptin to plasma and tissue DPP-4 is responsible for the nonlinear pharmacokinetics of 
linagliptin.  
The target-mediated drug disposition of linagliptin has several clinically relevant implica-
tions (cf. section 4.1.4.4). Alterations of the bioavailability or the clearance of unbound 
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linagliptin, e.g., only translate to relatively small changes in its AUCτ,SS, a parameter often 
considered as a correlate for safety and efficacy. 
By analytical methods it would not have been possible to determine the fraction of free 
linagliptin or linagliptin specifically bound to DPP-4, especially in peripheral tissues and 
for low plasma concentrations where nearly all available linagliptin is bound to DPP-4. 
The target-mediated drug disposition models developed within Projects 1 and 5 allowed to 
differentiate between bound and unbound linagliptin in plasma and peripheral tissues and 
thus allowed further insights into the nonlinear pharmacokinetics of linagliptin. 
4.5.2 Covariate analysis 
In a written response to a briefing package, the FDA agreed that no further studies were 
necessary to investigate the impact of age, sex, and weight on the pharmacokinetics of 
linagliptin. Thus, the population pharmacokinetic analysis presented in Project 3a saved 
three dedicated phase I studies to investigate these factors. The population analysis, in 
contrast to phase I studies, also allowed to investigate the impact of covariate combinations 
on the pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of 
linagliptin. None of the investigated covariates warrants a dose adjustment of linagliptin 
due to their clinically irrelevant impact on the pharmacokinetics or the plasma concentra-
tion/plasma DPP-4 activity relationship. Thus, no adjustment of the linagliptin dose is 
required for e.g. elderly or overweight patients, simplifying the therapy and thereby 
making it safer. 
4.5.3 Clinical trial simulations 
In case of the nonlinear pharmacokinetics of linagliptin the availability of a semi-
mechanistic model greatly helped to design future studies. The simulation of an adequate 
linagliptin dose for a twice-daily treatment required for the fixed dose combination with 
metformin (Project 2a) saved one exploratory dose finding study. Furthermore, it allowed 
the development of the fixed dose formulation to start earlier, accelerating the fixed dose 
combination programme by about one year. 
The simulation of the impact of impaired linagliptin clearance on the linagliptin exposure 
(Project 2b), alongside other considerations (e.g. high safety margin, predominantly 
eliminated by nonrenal processes), allowed including patients with a moderate renal 
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impairment in the phase IIb programme. Including these patients represented the type 2 
diabetic population better, as they often suffer from renal impairment, and thus allowed to 
investigate the impact of moderate renal impairment on the pharmacokinetics of linagliptin 
in phase IIb. 
The change-over design simulated for the dose-proportionally study in Project 2c helped to 
reduce the study duration by the length of two wash-out periods of ≥35 days each.  
Furthermore, the model-based analysis of the pharmacokinetics of linagliptin under 
comedication with ritonavir suggested that coadministration with ritonavir resulted in a 
4-fold increase in bioavailability and a 16% decrease in the clearance of linagliptin 
(Project 2d). Based on these assumptions, a simulation of the steady-state exposure of 
linagliptin was conducted. As observed after single dose, the simulation predicted a 2-fold 
increase in the AUC at steady-state for linagliptin under comedication with ritonavir. No 
major accumulation for linagliptin was predicted. These results, alongside other criteria, 
led to the evaluation that no dose adaptation is required for patients receiving 
P-glycoprotein or CYP3A4 inhibitors in comedication. However, this needs to be con-
firmed by future studies. 
4.5.4 Further applications of  the model 
Without a population model that accounted for the nonlinear pharmacokinetics of lina-
gliptin it would have been difficult to determine the absolute bioavailability of linagliptin. 
With the developed model the absolute bioavailability was estimated to be ~30% (Pro-
ject 4). Knowledge of the absolute bioavailability is important to identify possible sources 
of variability and to anticipate possible under- or overexposures of a compound. 
4.5.5 Outlook 
Plasma DPP-4 inhibition is a valid proof-of-mechanism biomarker. It provides evidence of 
target engagement and is correlated to glucose lowering as shown for various DPP-4 
inhibitors (105,106). In a future model development step, disease-related biomarkers which 
are more intimately linked to clinical outcome such as glucose or HbA1c may be included 
into the model. Using such an extended model, the relationship between linagliptin 
exposure and/or DPP-4 activity and disease-related biomarkers could be characterised, and 
factors impacting the biomarker response could be identified. Thus, one might differentiate 
subgroups of patients highly benefiting from linagliptin treatment and potential non-
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responders. A disease model quantifying the relationship between glucose and HbA1c, the 
natural disease progression, and a placebo effect would to a high degree be compound-
independent. Such a glucose/HbA1c model would allow long-term predictions based on 
short-term data, and would thus be of great help in designing phase IIb and phase III trials 
for the development of subsequent antidiabetic compounds. An example for a disease 
model applicable for different compounds is the tumour-size survival model for non-small 
cell lung cancer (202). Also in the field of diabetes, different compound-independent 
approaches exist, e.g. a glucose-insulin model describing glucose tolerance test data 
(203,204). Such models, quantitatively summarizing prior knowledge of the compound and 
the disease, will guide and thereby improve future clinical drug development (202). 
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Summary  
Linaglipin is a novel dipeptidyl-peptidase 4 (DPP-4) inhibitor in clinical development for 
the treatment of type 2 diabetes. This thesis investigated the nonlinear pharmacokinetics of 
linagliptin as well as the relationship between linagliptin pharmacokinetics and plasma 
DPP-4 activity using nonlinear mixed-effect modelling. The developed models supported 
the clinical drug development of linagliptin by clinical trial simulations.  
Based on previous in vitro plasma protein binding studies, concentration-dependent protein 
binding was considered to be the most likely cause of the nonlinear pharmacokinetics of 
linagliptin. This hypothesis was tested by analysing linagliptin plasma concentrations and 
plasma DPP-4 activities from two phase IIa studies in type 2 diabetic patients. A model 
assuming concentration-dependent protein binding of linagliptin in plasma and tissues 
resulted in the best description of the linagliptin plasma concentrations, supporting the 
initial hypothesis. Several lines of evidence suggested that the binding partner of lina-
gliptin responsible for the nonlinear pharmacokinetics is its target, DPP-4. Accordingly, 
plasma DPP-4 activity was included in the model in a semi-mechanistic way by relating it 
to the model-calculated plasma DPP-4 occupancy with linagliptin. The assumption of 
target-mediated drug disposition was confirmed in a subsequent nonclinical study. In this 
nonclinical study, wildtype rats exhibited a higher systemic exposure and a longer terminal 
half-life of linagliptin compared to DPP-4 deficient rats. These differences could be 
described by a single pharmacokinetic model assuming concentration-dependent protein 
binding in the plasma and tissue of wildtype rats and no binding for DPP-4 deficient rats. 
Taken together, both analyses suggest that concentration-dependent binding of linagliptin 
to plasma and tissue DPP-4 is responsible for the nonlinear pharmacokinetics of lina-
gliptin. 
The nonlinear pharmacokinetics of linagliptin complicate predictions that are based solely 
on noncompartmental parameters. The availability of the target-mediated drug disposition 
model allowed simulations that greatly supported the design of future clinical studies. A 
twice-daily dosing strategy for a fixed dose combination of linagliptin with metformin was 
simulated. The simulations predicted that despite the nonlinear pharmacokinetics, 2.5 mg 
linagliptin twice daily would result in a bioequivalent extent of exposure (AUC24h,SS) as 
well as a similar DPP-4 inhibition compared to 5 mg linagliptin once daily. Other simula-
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tions demonstrated that due to its nonlinear pharmacokinetics, the impact of impaired 
linagliptin clearance on the systemic exposure was sufficiently small to allow patients with 
a moderate renal impairment to participate in the phase IIb programme. Further simula-
tions were performed to investigate the optimal duration of a treatment period in a change-
over design to adequately test the dose-proportionality of linagliptin at steady-state. It was 
shown that a treatment period of seven days was sufficient to attain steady-state for 1, 2.5, 
and 5 mg linagliptin once daily in each sequence. In addition, steady-state exposure of 
linagliptin under ritonavir comedication was simulated based on a pharmacokinetic model 
describing the single dose plasma concentration-time profiles from a drug-drug interaction 
trial. The simulation predicted a 2-fold increase in the AUCτ,SS with no major accumulation 
of linagliptin under ritonavir comedication. 
Covariate analyses were performed to identify clinically relevant covariates for the 
pharmacokinetics and the pharmacodynamics of linagliptin. The analyses were based on 
linagliptin plasma concentrations and DPP-4 activities of type 2 diabetic patients from two 
phase IIa and two phase IIb studies. Demographic information, laboratory values including 
liver enzymes and creatinine clearance, as well as study related factors like metformin co-
treatment were investigated. None of the covariates individually affected the AUCτ,SS of 
patients receiving 5 mg linagliptin once daily by more than ±20% and thus no covariate 
was considered to be clinically relevant. Likewise, the impact of the covariates on the EC50 
or the concentration leading to 80% DPP-4 inhibition was less than ±20%. Based on these 
analyses, no dose adjustment is expected to be necessary for the tested covariates. 
For compounds with nonlinear pharmacokinetics, the standard approach to determine the 
absolute bioavailability is not valid. Thus, linagliptin plasma concentrations after single 
oral administration of 10 mg linagliptin and single intravenous administrations of 0.5, 2.5, 
5, or 10 mg linagliptin were analysed by the target-mediated drug disposition model. Using 
this approach, the absolute bioavailability could be estimated despite the nonlinear 
pharmacokinetics. The absolute bioavailability was estimated to be 29.5%. 
In conclusion, the work presented in this thesis contributes to a comprehensive understand-
ing and characterisation of the nonlinear pharmacokinetics of the novel DPP-4 inhibitor 
linagliptin and significantly supports the clinical development of this promising compound 
to be used for the treatment of type 2 diabetes. 
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Appendix 
A-1 Tables 
Table 1  Validated linagliptin concentration ranges and measurement sites of the studies investi-
gated 
Study Validated range [nM] Measurement site 
I 0.106 - 106 Boehringer Ingelheim 
II 0.106 - 106 Boehringer Ingelheim 
III 0.100 - 100 Covance Laboratories 
IV 0.100 - 100 Covance Laboratories 
V 0.100 - 20 Covance Laboratories 
VI 0.100 - 100 Boehringer Ingelheim 
VII 0.100 - 100 Boehringer Ingelheim 
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Table 2  Inaccuracy and imprecision of plasma quality control samples of the studies investigated 
Study Nominal 
concentration of 
quality control 
sample [nM] 
Number of 
replicates 
Inaccuracy1) [%] Imprecision2) [%] 
0.265 34 1.0 3.9 
5.29 34 3.1 2.6 
I 
84.6 33 -6.2 2.9 
0.265 74 1.4 3.6 
5.29 74 4.2 3.5 
II 
84.6 74 -7.3 3.6 
0.250 62 1.2 11.4 
5.00 64 1.8 4.9 
III 
80.0 64 -4.6 3.9 
0.250 84 1.6 7.3 
5.00 84 2.0 5.6 
IV 
80.0 84 -3.4 5.5 
0.250 16 -14.0 7.1 
1.00 16 -0.9 5.2 
V 
15.0 16 -6.0 3.9 
0.250 24 4.5 6.1 
5.00 24 5.2 4.2 
VI 
80.0 24 -1.1 3.5 
0.250 23 -3.4 12.4 
5.00 23 -0.7 6.4 
VII 
80.0 24 -5.8 6.8 
1)
 Assay inaccuracy was determined as the percent deviation of replicate analyses from the nominal value 
in quality control samples. 
2)
 Imprecision was calculated as the coefficient of variation of the quality control samples. 
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Table 3  Sampling scheme for linagliptin plasma concentration and plasma DPP-4 activity in 
studies I and II 
Sample type Study Day Time 
I 1 Single-dose 
profile 
II 1 
Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 h 
after first administration 
I 2-11 Ctrough levels 
during treatment 
II 2, 6, 12, 19, 26, 27 
Before linagliptin administration 
I 11 Overnight sample 
II 28 
18 h after drug administration of day 10 or 27, 
respectively 
I 12 Steady-state 
profile 
II 28 
Before, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 h after 
last administration 
I 13, 14, 16, 18, 20 Samples after last 
dose 
II 29, 30, 33, 36, 39, 41, 43 
In the morning 
 
Table 4  Distribution of categorical covariates in Project 1 
Covariate Categories Number of patients 
(percentage) 
No alcohol 39 (31.5%) Alcohol status 
Average alcohol consumption, during 
studies alcohol was not allowed 
85 (68.5%) 
I 47 (37.9%) Study 
II 77 (62.1%) 
Male 119 (96.0%) Sex 
Female 5 (4.0%) 
Never smoker 56 (45.2%) 
Ex-smoker 50 (40.3%) 
Smoking status 
Current smoker, during studies 
smoking was not allowed 
18 (14.5%) 
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Table 5  Distribution of continuous covariates in Project 1 
Covariate Unit N Mean Median Range 5th Percentile 95th Percentile 
Age years 124 58.6 61 36-69 44 68 
Weight  kg 124 89.4 89 64-121 71.2 111.9 
Height  cm 124 176.7 177 159-198 166 186.9 
Body mass 
index 
kg/m2 124 28.8 28.7 20.4 -34.9 23.3 33.9 
Body surface 
area 
m2 124 2.07 2.07 1.71-2.55 1.81 2.36 
Serum 
creatinine 
mg/dL 124 0.98 1.01 0.6-1.15 0.71 1.11 
Creatinine 
clearance 
mL/min 124 105.2 101.2 61.4-208.9 67.4 145.6 
Urea mM 124 2.91 2.93 1.42-4.25 2.19 3.51 
Alanine 
transaminase 
U/L 124 38.3 33.6 8.71-115.7 17.9 69.5 
Aspartate 
transaminase  
U/L 124 32.3 30.0 11.0-93.9 16.0 59.5 
Alkaline 
phosphatase  
U/L 124 117.6 106.6 14.6-288.3 52.7 191.2 
Gamma-
glutamyl 
transferase  
U/L 124 39.1 30.7 9.3-276.6 14.9 91.2 
Bilirubin  mg/dL 124 0.61 0.55 0.26-2.15 0.28 1.15 
Creatine 
kinase 
U/L 124 209.6 188.4 76.8-492.4 99.3 405.2 
Cholesterol  mg/dL 124 187.9 188.5 142.6-237.0 153.5 220.5 
C-reactive 
protein 
mg/dL 124 0.21 0.17 0-1.15 0.05 0.46 
Triglycerides mg/dL 124 176.1 164.1 71.7-445.7 89.9 324.9 
Fasting plasma 
glucose 
mM 124 8.55 8.35 5.11-13.99 5.80 12.0 
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Table 6  Distribution of the number of subjects and pharmacokinetic and pharmacodynamic 
observations per dose group in Project 1 
Linagliptin 
dose group 
[mg] 
Number of 
subjects 
Percentage 
of total 
subjects [%] 
Number of 
PK 
observations 
Percentage 
of total PK 
observations 
[%] 
Number of 
PD 
observations 
Percentage 
of total PD 
observations 
[%] 
Before 
treatment 
0 0 0 0 201 4.6 
Placebo 28 22.6 0 0 937 21.5 
1 9 7.3 313 9.8 315 7.2 
2.5 35 28.2 1,169 36.4 1,169 26.9 
5 24 19.4 786 24.5 786 18.1 
10 28 22.6 942 29.3 942 21.7 
Total 124 100 3,210 100 4,350 100 
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Table 7  Distribution of categorical covariates in Project 3a 
Covariate Categories Number of patients 
(percentage) 
No alcohol 199 (43.07%) 
Average consumption 261 (56.49%) 
Alcohol status 
Above-average consumption 2 (0.43%) 
I 35 (7.58%) 
II 61 (13.20%) 
III 170 (36.80%) 
Study 
IV 196 (42.42%) 
Caucasian 429 (92.86%) 
Black 8 (1.73%) 
Asian 7 (1.52%) 
Ethnic origin 
Hispanic 18 (3.90%) 
Male 302 (65.37%) Sex 
Female 160 (34.63%) 
Never smoker 254 (54.98%) 
Ex-smoker 150 (32.47%) 
Smoking status 
Current smoker 58 (12.55%) 
0.5 mg linagliptin 58 (12.55%) 
1 mg linagliptin 74 (16.02%) 
2.5 mg linagliptin 92 (19.91%) 
5 mg linagliptin 145 (31.39%) 
Treatment group 
10 mg linagliptin 93 (20.13%) 
Powder in bottle 35 (7.58%) 
Tablet of study II 61 (13.20%) 
Formulation 
Tablet of studies III + IV 366 (79.22%) 
No 266 (57.58%) Add-on to metformin 
Yes 196 (42.42%) 
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Table 8  Distribution of continuous covariates using the baseline values in Project 3a 
Covariate Unit Number Mean Median Range 5th 
Percentile 
95th 
Percentile 
Age years 462 59.1 60 30-78 42.0 73.0 
Weight  kg 462 90.3 88.6 57-132 67.1 117.0 
Height  cm 462 170.5 171 146-198 155 185 
Body mass index kg/m2 462 31.0 30.6 20.4-42.2 25.1 38.9 
Body surface area m2 462 2.02 2.02 1.56-2.56 1.70 2.37 
Serum creatinine mg/dL 462 0.86 0.85 0.45-1.69 0.59 1.12 
Creatinine clearance mL/min 462 177.9 112.2 47.9-318.1 65.0 188.9 
Urea mM 462 3.11 3.04 1.42-5.74 2.30 4.18 
Alanine transaminase U/L 462 35.2 28.8 0-232 9.6 81.7 
Aspartate transaminase  U/L 462 26.8 20.8 0-236.5 5.7 65.2 
Alkaline phosphatase  U/L 462 154.2 147.3 14.6-513.5 69.2 255.2 
Gamma-glutamyl 
transferase  
U/L 462 56.8 34.3 -1.9-1,048.2 9.4 157.4 
Bilirubin  mg/dL 462 0.42 0.36 0.02-2.15 0.13 0.93 
Creatine kinase U/L 462 207.1 183.0 51.3-924.7 89.4 425.5 
Cholesterol  mg/dL 462 181.5 179.9 14.5-507.2 94.3 279.6 
C-reactive protein mg/dL 462 0.32 0.17 0-3.94 0.06 1.03 
Triglycerides mg/dL 462 208.7 163.7 8.9-4,363.1 56.1 482.5 
Fasting plasma glucose mM 462 10.0 9.9 5.1-20 6.5 13.7 
Pre-dose DPP-4 activity RFU 462 12,809 12,497 1,075-
47,519 
8,033 18,618 
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Table 9  Distribution of the number of subjects and pharmacokinetic observations per dose group in 
Project 3a 
Linagliptin dose 
group [mg] 
Number of  
subjects 
Percentage of total 
subjects [%] 
Number of PK 
observations 
Percentage of total 
observations [%] 
Pre-dose values  
set to 0 
0 0 9 0.1 
0.5 58 12.55 541 7.8 
1 74 16.02 988 14.3 
2.5 92 19.91 1,736 25.1 
5 145 31.39 1,989 28.8 
10 93 20.13 1,644 23.8 
Total 462 100 6,907 99.9 
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Table 10  Parameter estimates of the base pharmacokinetic model of Project 3a 
 Unit Estimate 
Typical parameter   
F % 100 fix 
Fstudy IV % 151 
Ka h-1 0.549 
VC/F L 713 
QP/F  L/h 412 fix 
VP/F  L 1,650 fix 
CL/F L/h 243 
Bmax,C nM 4.82 
Kd nM 0.0652 fix 
Amax,P/F  nmol 1,650 fix 
Inter- and intraindividual variability 
ωF CV% 44.2 
Correlation ωF/ ωCL  -0.704 
ωCL  CV% 23.9 
ωKa  CV% 87.6 
ωVC CV% 22.6 
ωBmax,C CV% 29.6 
piF CV% 39.2 
Residual variability   
σprop,phase IIa
1)
 % 13.6 
σprop,phase IIb
1)
 % 38.1 
1)
 Estimated based on log-transformed data 
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Table 11  Covariates selected during the different steps of the covariate analysis in Project 3a 
 Covariate tested within 
NONMEM 
Explora-
tory 
analysis 
GAM Covariate 
Selection 
(Project 1) 
Special 
interest 
Selected 
within 
NONMEM 
Age  X  X  
Dose group  X    
Height1)  X    
Weight    X X 
Sex    X  
ηF 
Study IV (metformin 
comedication)2) 
    X 
Age  X  X  
Dose group  X    
Alanine transaminase  X X X  
Triglycerides  X    
Creatinine clearance  X  X  
Metformin comedication      
Gamma-glutamyl 
transferase 
 X  X X 
C-reactive protein  X    
Alkaline phosphatase  X    
Weight    X  
ηCL/F 
Sex    X  
Formulation X    X 
Dose group  X X  X 
Body surface area  X    
Age    X  
Weight    X  
ηKa 
Sex    X  
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Table 11  Covariates selected during the different steps of the covariate analysis in Project 3a 
(cont.) 
 Covariate tested within 
NONMEM 
Explora-
tory 
analysis 
GAM Covariate 
Selection 
(Project 1) 
Special 
interest 
Selected 
within 
NONMEM 
Pre-dose DPP-4 activity X X   X 
Dose group  X   X 
Age  X  X X 
Aspartate transaminase  X X   
Triglycerides  X    
Alkaline phosphatase  X    
C-reactive protein  X    
Metformin comedication  X    
Serum creatinine  X    
Weight    X  
ηBmax,C 
Sex    X X 
Creatinine clearance  X    
Age    X  
Weight3)    X X 
ηVC/F 
Sex    X  
1)
 Not further tested, highly correlated to weight, weight resulted in a higher drop in OBJF and was 
physiologically more plausible 
2)
 Selected during base model development 
3)
 When testing the remaining covariates together in one run, the effect of weight on volume was no longer 
significant. Thus, only the effect of weight on the bioavailability was retained in the final model, not the 
effect of weight on VC. 
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Table 12  Distribution of categorical covariates in Project 3b 
Covariate Categories Number of patients 
(percentage) 
No alcohol 251 (41.35%) 
Average consumption 353 (58.15%) 
Alcohol status 
Above-average consumption 3 (0.49%) 
I 47 (7.74%) 
II 77 (12.69%) 
III 216 (35.58%) 
Study 
IV 267 (43.99%) 
Caucasian 559 (92.09%) 
Black 15 (2.47%) 
Asian 11 (1.81%) 
Ethnic origin 
Hispanic 22 (3.62%) 
Male 401 (66.06%) Sex 
Female 206 (33.94%) 
Never smoker 336 (55.35%) 
Ex-smoker 195 (32.13%) 
Smoking status 
Current smoker 76 (12.52%) 
No 340 (56.01%) Add-on to metformin 
Yes 267 (43.99%) 
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Table 13  Distribution of continuous covariates using the baseline values in Project 3b 
Covariate Unit Num-
ber 
Mean Median Range 5th 
Percentile 
95th 
Percentile 
Age years 607 59.2 60 30-78 43 72 
Weight  kg 607 90.4 89 55-138 67 117 
Height  cm 607 170.7 172 142-198 155 185 
Body mass index kg/m2 607 31.0 30.6 20.4-42.2 25.0 38.7 
Body surface 
area 
m2 607 2.02 2.02 1.54-2.63 1.69 2.37 
Serum creatinine mg/dL 607 0.86 0.85 0.45-1.69 0.60 1.11 
Creatinine 
clearance 
mL/min 607 117.9 112.9 47.9-318.1 67.9 191.8 
Urea mM 607 3.09 3.06 1.42-5.74 2.27 4.06 
Alanine 
transaminase 
U/L 607 35.7 29.4 0-232 10.6 81.7 
Aspartate 
transaminase  
U/L 607 26.9 20.8 -1.9-236.5 5.8 63.2 
Alkaline 
phosphatase  
U/L 607 150.7 143.1 14.6-513.5 68.9 251.8 
Gamma-glutamyl 
transferase  
U/L 607 57.4 35.1 -1.9-1,048.2 9.5 161.8 
Bilirubin  mg/dL 607 0.41 0.35 0.01-2.15 0.13 0.88 
Creatine kinase U/L 607 207.6 183.0 51.3-924.7 86.2 430.7 
Cholesterol  mg/dL 607 179.3 177.5 14.5-507.2 91.7 273.9 
C-reactive protein mg/dL 607 0.30 0.17 0-3.94 0.10 0.94 
Triglycerides mg/dL 607 207.7 167.7 8.9-4,363.1 56.4 473.6 
Fasting plasma 
glucose 
mM 607 9.99 9.88 5.11-20 6.66 13.7 
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Table 14  Distribution of the number of subjects as well as pharmacokinetic and pharmacodynamic 
observations per dose group in Project 3b 
Linagliptin dose 
group [mg] 
Number of 
subjects 
Percentage of 
total subjects [%] 
Number of PK and 
PD observations 
Percentage of total 
observations [%] 
Placebo 160 26.4 2,4101) 24.9 
0.5 53 8.7 545 5.6 
1 74 12.2 1,055 10.9 
2.5 87 14.3 1,803 18.6 
5 140 23.1 2,108 21.8 
10 93 15.3 1,753 18.1 
Total 607 100 9,674 100 
1)
 The linagliptin plasma concentrations were set to zero for all placebo patients. 
 
Table 15  Parameter estimates of the base pharmacokinetic/pharmacodynamic model of Project 3b 
 Unit Estimate RSE [%] 
Typical Parameter    
BSL RFU 11,600 1.03 
Emax % 92.5 0.12 
EC50 nM 2.97 1.69 
Hill  3.21 1.90 
BSL_EC501) % 6.96·10-3 7.31 
Interindividual variability   
ωBSL  CV% 21.6 8.84 
ωEC50  CV% 18.4 13.8 
Residual variability    
σprop % 15.7 7.22 
1)
 EC50i = EC50·(1+BSL_EC50)·(BSLi-BSL))·exp(ηEC50) 
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Table 16  Covariates selected during the different steps of the covariate analysis in Project 3b 
 Covariate tested within 
NONMEM 
Exploratory 
analysis 
GAM Selected within 
NONMEM 
Fasting plasma glucose X X X 
Alanine transaminase X X X 
Aspartate transaminase X X X 
Gamma-glutamyl transferase X X X 
Cholesterol X X X 
Creatine kinase  X  
C-reactive protein  X  
Triglycerides  X X 
Sex X X X 
Alcohol status X   
Study X X X (study II) 
Dose group  X  
ηBSL 
Ethnic origin X X X (Asian) 
Fasting plasma glucose X X  
Alanine transaminase X X  
Aspartate transaminase X X  
Alkaline phosphatase X   
Gamma-glutamyl transferase X X  
Dose group X X  
Study X X X 
Age  X  
Serum creatinine  X  
ηEC50 
Triglycerides  X X 
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Table 17  Distribution of the number of subjects and pharmacokinetic observations per dose group 
in Project 4 
Linagliptin dose 
group [mg] 
Number of 
Subjects 
Percentage of total 
subjects [%] 
Number of PK 
observations 
Percentage of total PK 
observations [%] 
0.5 i.v. 6 21.4 144 16.7 
2.5 i.v. 6 21.4 144 16.7 
5 i.v. 245 28.4 
10 p.o. 
10 35.7 
185 21.5 
10 i.v. 6 21.4 144 16.7 
Total 28 100 862 100 
 
Table 18  Mean (±SD) animal weights per dose group and rat strain in Project 5 
Animal weight (±SD) [g] Dose group linagliptin 
[mg/kg] 
DPP-4-deficient rats Wildtype rats 
0.01 NA 249 (12.2) 
0.1 250 (12.0) 258 (3.7) 
0.3 255 (8.8) 266 (9.0) 
1 224 (3.1) 233 (5.4) 
NA, not applicable 
 
Table 19  Distribution of pharmacokinetic observations per dose group and rat strain in Project 5 
DPP-4-deficient rats Wildtype rats Dose group 
linagliptin [mg/kg] 
Number of 
observations 
Percentage of total 
observations [%] 
Number of 
observations 
Percentage of total 
observations [%] 
0.01 NA NA 26 21.5 
0.1 20 32.8 32 26.45 
0.3 20 32.8 32 26.45 
1 21 34.4 31 25.6 
Total 61 100 121 100 
NA, not applicable 
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A-2 Figures 
 
Figure 1  Scatter plots and distributions of the continuous demographic covariates in Project 1. 
AGE, age (years); WT, weight (kg); HGT, height (cm); BMI, body mass index (kg/m2); BSA, body 
surface area (m2).  
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Figure 2  Scatter plots and distributions of the continuous laboratory covariates in Project 1. SCR, 
serum creatinine (mg/dL); CRCL, creatinine clearance (ml/min); UREA, urea (mM); ALT, alanine 
transaminase (U/L); AST, aspartate transaminase (U/L); AP, alkaline phosphatase (U/L); GGT, 
gamma-glutamyl transferase (U/L); BIL, total bilirubin (mg/dL); CK, creatine kinase (U/L); CHOL, 
cholesterol (mg/dL); CRP, C-reactive protein (mg/dL); TRIG, triglycerides (mg/dL); FPG, fasting 
plasma glucose (mM); DPP, pre-dose DPP-4 activity (RFU). 
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Figure 3  Plasma concentration-time profiles per dose group of studies I (left panels) and II (right 
panels). 
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Figure 4  Plasma DPP-4 activity-time profiles per dose group of studies I (left panels) and II (right 
panels). 
   178 Appendix 
Bmax,C [nM]
3.5 4.0 4.5 5.0 5.5
Ch
a
n
ge
 
in
 
o
bje
ct
ive
 
fu
n
ct
io
n
0.00
3.84
5.00
10.00
15.00
20.00
Amax,P [nmol]
1000 1500 2000 2500
Ch
a
n
ge
 
in
 
o
bje
ct
ive
 
fu
n
ct
io
n
0.00
3.84
5.00
10.00
15.00
20.00
 
Figure 5  Log-likelihood profiles of the model parameters accounting for the concentration of central 
binding partner (Bmax,C) and the amount of peripheral binding partner (Amax,P). The solid horizontal 
line indicates the cut-off at which the change in the OBJF becomes statistically significant, 3.84 in 
this case. The 95% confidence intervals for Bmax,C and Amax,P are represented by the points of 
intersection of the solid horizontal lines and the log-likelihood profiles.  
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Figure 6  Standard goodness-of-fit plots for the pharmacokinetic part of the final population 
pharmacokinetic/pharmacodynamic model in Project 1. 
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Figure 7  Standard goodness-of-fit plots for the pharmacodynamic part of the final population 
pharmacokinetic/pharmacodynamic model in Project 1. 
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Figure 8  Visual predictive checks. The concentration-time profiles of 1,000 patients per dose group 
and study were simulated based on the final population pharmacokinetic/pharmacodynamic model 
of Project 1. The solid lines show the 90% confidence intervals and the median of the simulated 
concentration-time profiles. The observed linagliptin plasma concentrations are displayed as dots. 
Only the steady-state profiles are shown. 
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Figure 9  Visual predictive checks. The plasma DPP-4 activity-time profiles of 1,000 patients per 
dose group and study were simulated based on the final population pharmacoki-
netic/pharmacodynamic model of Project 1. The solid lines show the 90% confidence intervals and 
the median of the simulated concentration-time profiles. The observed plasma DPP-4 activities are 
displayed as dots. Only the steady-state plasma DPP-4 activity-time profiles are shown. 
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Figure 10  Standard goodness-of-fit plots for the final pharmacokinetic model of Project 2d. 
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Figure 11  Visual predictive checks. 1,000 patients per treatment group were simulated based on 
the final population pharmacokinetic model of Project 2d. The solid lines show the 90% confidence 
interval and the median of the simulated concentration-time profiles. The observed linagliptin 
plasma concentrations are displayed as dots. 
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Figure 12  Posterior predictive checks. Distribution of the gMean AUC0-inf values of 1,000 simulated 
datasets per treatment group. The dashed lines show the 90% confidence interval and the median 
of the simulated gMean AUC0-inf values per treatment group. The observed gMean AUC0-inf per 
treatment group is displayed as a straight line. 
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Figure 13  Posterior predictive checks. Distribution of the gMean Cmax values of 1,000 simulated 
datasets per treatment group. The dashed lines show the 90% confidence interval and the median 
of the simulated gMean Cmax values per treatment group. The observed gMean Cmax per treatment 
group is displayed as a straight line. 
 
Figure 14  Scatter plots and distributions of the continuous demographic covariates in Project 3a. 
AGE, age (years); WT, weight (kg); HGT, height (cm); BMI, body mass index (kg/m2); BSA, body 
surface area (m2). 
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Figure 15 Scatter plots and distributions of the continuous laboratory covariates in Project 3a. 
SCR, serum creatinine (mg/dL); CRCL, creatinine clearance (ml/min); UREA, urea (mM); ALT, 
alanine transaminase (U/L); AST, aspartate transaminase (U/L); AP, alkaline phosphatase (U/L); 
GGT, gamma glutamyl transferase (U/L); BIL, total bilirubin (mg/dL); CK, creatine kinase (U/L); 
CHOL, cholesterol (mg/dL); CRP, C-reactive protein (mg/dL); TRIG, triglycerides (mg/dL); FPG, 
fasting plasma glucose (mM); DPP, pre-dose DPP-4 activity (RFU). 
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Figure 16  Linagliptin plasma concentrations at steady-state per dose group, time interval, and 
study (Project 3a). 
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Figure 17  Standard goodness-of-fit plots of the post-hoc estimates of study III derived by applying 
the base model of Project 1. 
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Figure 18  Standard goodness-of-fit plots of the post-hoc estimates of study IV derived by applying 
the base model of Project 1. 
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Figure 19  Histograms of the η-distribution of the post-hoc estimates of study III (upper panels) and 
study IV (lower panels) around the population mean. The solid lines show the assumed means of 
each distribution (0). The dashed lines show the observed means of each distribution. 
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Figure 20   Standard goodness-of-fit plots of the final model of Project 3a. 
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Figure 21  Visual predictive checks. 1,000 linagliptin plasma concentration-time profiles were 
simulated per dose group and study based on the base population pharmacokinetic model of 
Project 3a. The solid lines show the 90% confidence intervals and the median of the simulated 
concentration-time profiles. The observed linagliptin plasma concentrations are displayed as dots. 
Only steady-state profiles are shown. 
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Figure 22  Posterior predictive checks of Project 3a. Distribution of the median Ctrough levels of 
1,000 simulated datasets per dose group. The dashed lines show the 90% confidence intervals and 
the median of the simulated median Ctrough levels per dose group. The observed median Ctrough level 
per dose group is displayed as a straight line. 
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Figure 23  Posterior predictive checks of Project 3a. Distribution of the median Cmax levels of 1,000 
simulated datasets per dose group. The dashed lines show the 90% confidence intervals and the 
median of the simulated median Cmax levels per dose group. The observed median Cmax levels per 
dose group is displayed as a straight line. 
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Figure 24  Scatter plots and distributions of the continuous demographic covariates in Project 3b. 
AGE, age (years); WT, weight (kg); HGT, height (cm); BMI, body mass index (kg/m2); BSA, body 
surface area (m2). 
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Figure 25  Scatter plots and distributions of the continuous laboratory covariates in Project 3b. 
SCR, serum creatinine (mg/dL); CRCL, creatinine clearance (ml/min); UREA, urea (mM); ALT, 
alanine transaminase (U/L); AST, aspartate transaminase (U/L); AP, alkaline phosphatase (U/L); 
GGT, gamma-glutamyl transferase (U/L); BIL, total bilirubin (mg/dL); CK, creatine kinase (U/L); 
CHOL, cholesterol (mg/dL); CRP, C-reactive protein (mg/dL); TRIG, triglycerides (mg/dL); FPG, 
fasting plasma glucose (mM); DPP, pre-dose DPP-4 activity (RFU). 
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Figure 26  Standard goodness-of-fit plots for the final pharmacokinetic/pharmacodynamic model of 
Project 3b. 
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Figure 27  Standard goodness-of-fit plots for the final pharmacokinetic model of Project 4. 
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Figure 28  Visual predictive checks. 1,000 patients per dose group were simulated based on the 
final population pharmacokinetic model of Project 4. The solid lines show the 90% confidence 
intervals and the median of the simulated concentration-time profiles. The observed linagliptin 
plasma concentrations are displayed as dots. The visual predictive checks are depicted in semi-
logarithmic scale for all dose groups. In addition, the visual predictive check for the oral 10 mg dose 
is displayed for the first 24 h in linear scale. 
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Figure 29  Standard goodness-of-fit plots for the final pharmacokinetic model of Project 5. 
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Figure 30  Comparison of the amount of linagliptin in the peripheral compartments 72 h after 
administration per dose group between wildtype rats (closed circles) and DPP-4 deficient rats 
(open circles) based on the final model of Project 5. 
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A-3 Model derivation and code of  the target-mediated drug 
disposition model of  linagliptin 
A-3.1 Model derivation 
The target-mediated drug disposition model of linagliptin assuming quasi-equilibrium 
conditions for the binding of linagliptin to DPP-4 was derived as exemplified in the 
following using a one-compartment model with concentration-dependent binding in the 
central compartment. A one-compartment model with concentration-dependent binding 
can be described by equations 1 and 2 according to the law of mass. 
( )
unboundboundOFF
boundCunboundON
unbound
AKAK
ABAKinput
dt
dA
⋅−⋅+
−⋅⋅−=
20
max,
                  
   (Equation 1) 
( ) boundOFFboundCunboundONbound AKABAKdt
dA
⋅−−⋅⋅= max,      (Equation 2) 
dAunbound/dt can also be expressed as: 
dt
dAAKinput
dt
dA bound
unbound
unbound
−⋅−= 20       (Equation 3) 
dtdA
dAdA
AKinput
dt
dA
unbound
unboundbound
unbound
unbound
⋅
⋅
−⋅−= 20      (Equation 4) 
Equation 4 can be rearranged to:  
unbound
unbound
unboundboundunbound AKinput
dtdA
dAdA
dt
dA
⋅−=
⋅
⋅
+ 20      (Equation 5) 
unbound
unbound
boundunbound AKinput
dA
dA
dt
dA
⋅−=





+⋅ 201         (Equation 6) 
By assuming equilibrium conditions (dAbound/dt = 0) equation 2 simplifies to equation 7, 
with Kd = KOFF/KON. 
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Cunbound
bound KA
BA
A
+
⋅
=
max,
         (Equation 7) 
Equation 7 can be differentiated with respect to Aunbound yielding equation 8. 
( )
( ) ( )2
max,
2
max,max,
dunbound
dC
dunbound
CunbounddunboundC
unbound
bound
KA
KB
KA
BAKAB
dA
dA
+
⋅
=
+
⋅−+⋅
=   (Equation 8) 
Substituting dAbound/dAunbound in equation 6 by equation 8 results in equation 9, which was 
the basis for the target-mediated drug disposition model of linagliptin. 
( )2
max,
20
1
dunbound
dC
unboundunbound
KA
KB
AKinput
dt
dA
+
⋅
+
⋅−
=        (Equation 9) 
A-3.2 Model code 
The target-mediated drug disposition model of linagliptin as developed in Project 1 is 
constituted by the equations 10-13. To be used in the differential equations, the model 
parameters need to be transformed as follows:  
P
32
C
23
C
20Pd2Cd1Cmax.CCmax, V
QK and ,
V
QK ,
V
CLK ,VKK ,VKK ,VBA ===⋅=⋅=⋅=  
The linagliptin amount A in the depot compartment (1), the central compartment (2) and 
the peripheral compartment (3) is described by differential equations 10, 11, and 12, 
respectively. 
( ) ( )11 AK
dt
dA
a ⋅−=       (Equation 10) 
( ) ( ) ( ) ( ) ( )
( )( )21
1max,
202332
2
1
22312
KA
KA
AKAKAKAK
dt
dA
C
a
+
⋅
+
⋅−⋅−⋅+⋅
=    (Equation 11) 
( ) ( ) ( )
( )( )22
2max,
3223
3
1
323
KA
KA
AKAK
dt
dA
P
+
⋅
+
⋅−⋅
=        (Equation 12) 
From this the total linagliptin plasma concentration Ctot is calculated as presented in 
equation 13. 
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